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ABSTRACT 
This manuscript examines three separate but inter-related research questions. After 
reviewing scientifically relevant literature in the first chapter, the second chapter compares the 
prevalence of carotid plaque among the three major race-ethnic groups in the Electron-beam 
computed tomography, Risk factor Assessment among Japanese and U.S. Men in the Post-World 
War II birth cohort (ERA JUMP Study). This study shows that prevalence of carotid plaque, a 
biomarker of subclinical atherosclerosis, is significantly lower among men in Japan and South 
Korea than in the US. This difference is independent of traditional risk factors of coronary heart 
disease (CHD). Further, it shows that only age, hypertension and diabetes are cross-sectionally 
associated with the prevalence of carotid plaque. 
The third chapter examines the association between brachial-ankle pulse wave velocity 
(baPWV) and coronary artery calcification (CAC), an established biomarker of coronary 
atherosclerosis and a strong predictor of future CHD risk. baPWV is a non-invasive and convenient 
measure of arterial stiffness and is clinically used in eastern Asia as a tool for assessing future 
cardiovascular risk. This study found that higher baPWV is cross-sectionally associated with 
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higher prevalence of CAC among middle-aged men in the ERA JUMP study, including White men 
in the US.  
The final and fourth chapter of the manuscript examines the association of serum levels of 
soy isoflavones and equol, with CAC among Japanese men in Japan. Japanese consume soy and 
soy products regularly. Isoflavones are a component in soy and are known to have anti-
atherosclerotic properties. Equol is a potent isoflavone produced from the dietary isoflavone 
daidzein by action of intestinal bacteria. This study shows that individuals who have bacteria to 
convert daidzein to equol, i.e. equol producers, have lower CAC than equol non-producers. 
These three studies, individually and as a whole, contribute significantly to public health 
knowledge. Japan has significantly lower atherosclerosis than the US in spite of a similar level of 
risk factors. Several lessons, including change in diet, may be learned from Japan in an effort to 
reduce CHD mortality in the US. baPWV may potentially provide similar information to clinicians 
as CAC without exposing the patient to radiation. 
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PREFACE 
Coronary heart disease (CHD), although declining, still remains the leading cause of 
mortality in the US. Although risk scores exist for predicting future CHD among individuals based 
on their risk factor profile, these risk scores fail to identify many individuals at low to intermediate 
risk of CHD and who would be candidates for targeted interventions. Thus, several subclinical 
disease biomarkers have received attention in the past two decades; these biomarkers can further 
identify individuals who have high risk of CHD and who may benefit most from these preventive 
interventions. Examples of such biomarkers are – coronary artery calcification (CAC), carotid 
intima-media thickness, carotid plaque, pulse wave velocity, aortic calcification and ankle brachial 
index. 
Although CAC has emerged with highest potential for translating into clinical practice, it 
exposes the patient to harmful radiations. In contrast, brachial-ankle pulse wave velocity (baPWV) 
is a non-invasive and convenient measure of arterial stiffness and is widely used by clinically in 
eastern Asia as a predictor of CHD. baPWV carries the potential to be accepted clinically in the 
US, and deserves thorough examination. 
In contrast to the US, CHD rates are low in Japan – this is paradoxical given similar or 
higher burden of some CHD risk factors exist in Japan as in US e.g. smoking and hypertension 
prevalence is higher in Japan. A comparison of prevalence of carotid plaque between US and Japan 
may provide an estimate of their relative atherosclerotic burden. Further, reasons for paradoxically 
low rates of CHD in Japan are not well-understood. The lower rate of CHD may be due to a 
xv 
lifestyle factor such as the Japanese diet that is rich in marine derived n-3 fatty acids and soy 
isoflavones, both known to have anti-atherosclerotic properties. 
The following research questions were examined in this manuscript –  
1. What is the prevalence and risk factors of carotid plaque among Whites in the US, 
Japanese in Japan and Koreans in S Korea? 
2. Is baPWV significantly associated with coronary atherosclerosis assessed by CAC? and 
3. Are serum levels of equol, a soy isoflavones product, associated with coronary 
calcification among Japanese men in Japan?  
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and you start to work on your dissertation. This work is also dedicated to my friend and my guru, 
Sameer Sharma, who is the source of inspiration for everything good that I try to do. I treasure you 
being a part of my life. Whenever I have had a doubt, I tried to imagine what you would have done 
in that situation, and tried to follow your path. I hope I have not disappointed you as a disciple.     
I am grateful to my advisor Dr Akira Sekikawa for all I have got from him over the past 
three years. Akira, you have been a wonderful person and I’m sure I’ll appreciate all that I’ve 
learned from you over the coming years. Thank you for requesting and meticulously going over 
multiple revisions of my drafts – I write much better now than I ever did. I look forward to keep 
working together in the future. 
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1.0  INTRODUCTION 
1.1 EPIDEMIOLOGY OF CORONARY HEART DISEASE 
Even after continuous and significant decline in Coronary Heart Disease (CHD) mortality 
achieved in the past five decades, CHD remains the leading cause of mortality in the United States.1 
The deaths attributable to cardiovascular diseases (CVD) declined by 31% between 2000 and 
2010, however, CVD still accounts for 1 of every 3 deaths in the US, out of which every other 
death was due to CHD. One American gets a potentially lethal CHD event every 34 seconds, and 
one dies of a CHD event every 1 minute and 23 seconds.1 Thus, reducing the burden of CHD still 
remains a public health priority.  
With the significant decline in CHD achieved over the decades, the American Heart 
Association (AHA) has started to shift the focus from cardiovascular disease to cardiovascular 
health to continue this declining trend. In this regard, the AHA has identified 7 components of 
ideal cardiovascular health as targets for intervention: smoking, body weight, physical activity, 
healthy diet, total cholesterol, blood pressure, and fasting plasma glucose.2 (Table 1-1) Together, 
these are attributable risk factors for a large majority of the cardiovascular disease events in the 
US.1  
1 
Table 1-1 Components of Ideal Cardiovascular health among adults 
Smoking Never or quit > 12 months ago 
BMI <25 kg/m2 
Physical activity ≥150 min/week moderate intensity or ≥75 min/week vigorous intensity or combination 
Healthy diet score** 4-5 components 
Total cholesterol <200 mg/dl 
Blood pressure <120/<80 mmHg 
Fasting plasma glucose <100 mg/dl 
*Adapted from Lloyd-Jones, 20102 
** Based on 2006 nutritional guidelines3 
 
A majority of the deaths among patients with acute coronary event occur before reaching 
the hospital. Clearly, therapeutic advancements in clinical care of CHD cannot be relied upon to 
reduce mortality among those who die before reaching the hospital. Thus, in addition to improving 
the medical care for patients with CHD, it is prudent to identify individuals who have high-risk for 
future CHD, and to provide aggressive prevention strategies to reduce the CHD risk. One common 
strategy to identify such individuals is to screen them for traditional risk factors of CHD. Many 
guidelines and scores exist that take into account risk factors such as gender, smoking, and 
cholesterol have been established to predict individual’s future risk of CHD – most commonly 
used among those is the Framingham Risk Score which predicts individual’s 10-year risk of 
CHD/CVD.4 Although such guidelines and risk scores have helped clinicians identify patients with 
high CHD risk, their prediction can be further improved among individuals at intermediate risk of 
CHD.5 This can be especially important given the changing demographics in the US as well with 
the sustained decline in the total cholesterol levels in the past few decades – both of these being 
important determinants of the calculated CHD risk. To prevent any reversal of the declining trend 
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of CHD in US, it is important to further improve strategy to identify and prevent CHD in 
individuals at risk of CHD. An important strategy to identify such individuals is to examine for 
the presence of subclinical cardiovascular disease. 
In the past two decades, many subclinical CVD markers have been examined for their 
validity in prediction of future CVD. In general, these subclinical CVD markers identify structural 
or functional changes that are said to be a result of atherosclerosis or one of the pathophysiological 
processes associated with atherosclerosis.  
 
1.2 ATHEROSCLEROSIS AND ITS ASSESSMENT  
1.2.1 Introduction 
Atherosclerosis is the complex pathological process that leads to the development of 
lesions in the arterial wall. The symptoms and consequences of an atherosclerotic lesion depends 
on the extent, location, and stability of the lesion, with large unstable lesions in the coronary 
arteries accounting for a majority of CHD deaths. Because atherosclerosis is the major underlying 
cause of CHD, a significant effort has been made to understand and characterize the steps that lead 
to atherosclerosis, to assess the presence of atherosclerosis in the arteries, and to find treatment 
options to prevent and delay atherosclerosis and its complications.   
 3 
1.2.2 Pathophysiology of Atherosclerosis 
Atherosclerosis is a systemic disease process that begins early, usually by the second 
decade of life. Even though it is a systemic process, certain regions of the arterial tree are known 
to be more susceptible to the development of atherosclerosis such as the proximal portion of the 
left anterior descending artery where it progresses to become one of the most common cause of 
death in the world, and the bifurcation of the carotid artery i.e. the region around the carotid bulb. 
The pathogenesis of atherosclerosis involves multiple steps that have been studied in detail6,7 – (1) 
deposition of low-density lipoprotein cholesterol (LDL-c) particles in the arterial wall with 
subsequent oxidation of these particles, (2) recruitment of leucocytes, particularly monocytes and 
lymphocytes,  and the formation of early atherosclerotic lesions, (3) accumulation of LDL-c in the 
monocyte-derived macrophage and formation of lipid-laden foam cell, and (4) evolution of 
atheroma with death of macrophage, fibrosis and smooth muscle proliferation. As these 
atherosclerotic lesions advance, they also accumulate calcium with a process that is similar to bone 
formation (Figure 1-1)  
Along with the process of lesion formation as briefed above, arterial remodeling takes place 
for much of lesion growth. E.g. until at a late stage of atherosclerosis, the lesion grows outwards 
with increasing diameter of the arterial trunk, without much compromise of the arterial lumen.8,9  
The most catastrophic event in relation to atherosclerosis occurs when the fibrous cap of 
the atherosclerotic lesion ruptures, allowing the blood to come in contact with highly thrombogenic 
contents of the coronary plaque, and the formation of a thrombus. If the thrombus formation that 
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ensues is enough to occlude the victim artery, blood flow to the downstream myocardium may 
completely occlude, thus causing myocardial infarction.10    
 
Figure 1-1 Pathogenesis of Atherosclerosis 
_____________________________________________ 
Reprinted with permission from Libby P, Circulation 2001; 104:365-372. Copyright American heart Association  
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1.2.3 Biomarkers of Atherosclerosis as Predictors of CHD 
A biomarker or a biological marker is a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention.11 
While atherosclerosis can be seen in many arterial beds, it is the presence of atherosclerosis 
in the coronary and carotid artery that is known to have disastrous consequences, given the relative 
importance of the organs to which they supply blood. Thus, significant efforts have been made in 
the last few decades to examine atherosclerosis in the coronary and carotid arteries at the 
subclinical stage i.e. before the occurrence of a CVD event. This strategy allows identification of 
individuals who would be candidates for intervention in the form of primary and secondary 
prevention of the CVD event. 
1.2.3.1 Coronary Artery Calcification 
Of all the subclinical measures of CVD that have been examined in different research 
studies for their prediction of CVD event, Coronary Artery Calcification (CAC) appears to be the 
most promising as a clinical tool for identification of asymptomatic patients at high risk for 
CVD.12,13 The American College of Cardiology Foundation (ACCF)/AHA task force concluded 
in 2010 that there was some evidence that benefits from use of CAC outweigh the risk it poses 
among patients with intermediate (10-20%) and low-intermediate (6-10%) 10-year risk of CVD, 
but not among individuals with low (<6%) 10-year risk.14 The United States Preventive Services 
Task Force concluded in 2009 that there is fair evidence that use of CAC predict CVD outcome.15 
These reports also point the limitations with the use of CAC – (1) Exposure to radiation, (2) validity 
 6 
of repeated measurements of CAC as evidence for progression, and whether it adds anything to 
the risk-factor based Framingham Risk Score prediction model for CVD.16-18 Table 1-1 
Components of Ideal Cardiovascular health among adults reports important longitudinal studies 
examining CAC as a predictor of cardiovascular event. In the Multi-ethnic study of 
Atherosclerosis, participants with significant (AU≥100) and intermediate coronary atherosclerosis 
(0<AU≤100) respectively had 7 to 10 times and 4 times higher risk of experiencing a coronary 
event as compared to participants with no atherosclerosis.19  Other studies, such as Rotterdam 
study20 and Heinz Nixdorf Recall Study,21 have also shown a similar association of CAC with 
future coronary event. In contrast, asymptomatic individuals with no CAC are shown to have 
extremely low risk for occurrence of a coronary event.22 
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 Table 1-2 Important Prospective Studies reporting CAC as a predictor of cardiovascular disease event 
Author-Year-
Location 
Population Follow-
Up 
CAC definition/categories Outcome Results 
Greenland 
2004 USA 23 
Population-based, 
predominantly 
men, >45 years 
(mean age ~ 65 
years), South Bay 
Heart Watch study 
FU: 8.5 
years 
0, 1-100, 101-300, ≥301 AU Non-fatal MI and CHD death Across categories of FRS, CAC 
score improved risk prediction 
among patients at intermediate and 
high risk (>10% 10-year risk), but 
not at low risk (<10% 10-year risk).  
Vliegenthart 
2005 
Netherlands 20 
Population-based, 
42.5% male, 
71.1±5.7 years, 
N=1795. The 
Rotterdam Study 
FU: 3.3 
years 
0 – 100, 101 – 400, 401 – 1000, 
>1000 
PTCA, CABG, MI, Stroke, 
CHD mortality, CVD 
mortality  
CAC further improves CHD 
prediction from the FRS model, even 
in the elderly 
Taylor 2005 
USA 24 
Healthy army 
personnel, 82% 
male, ~43 years, 
N=1983. The 
Prospective Army 
Coronary Calcium 
Project (PACC) 
FU: 3 
years 
0, 1 – 9, 10 – 44, ≥45; Tertiles of 
CAC 
CHD Presence of CAC associated with 
11.8 fold higher risk of CHD. Risk 
increased with tertiles of CAC, 
among those with CAC 
Becker 2008 
Germany 25 
Preventive 
cardiology clinic 
patients, 59% 
male, 57.7 ± 13.3 
years, N=1726 
FU: 
40.3 
months 
Log-transformed CAC; 0, >0 to 75th 
percentile, >75th percentile of CAC 
Non-fatal MI or CHD death Higher CAC score predicted higher 
MI and CHD mortality, no cardiac 
events observed among those with 
CAC=0 
Detrano 2008 
USA 19 
Population-based, 
47.2% male, 
62.2±10.2 years, 
N=6722. The 
MESA Study 
FU: 3.8 
years 
0, 1 – 100, 101 – 300, >300 CHD including MI, angina 
followed by 
revascularization, definite 
angina not followed by 
revascularization, and 
probable angina followed by 
revascularization  
Doubling of calcium score increased 
the risk of major coronary event by 
15 to 35%. 
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 1.2.3.2 Intima-Media Thickness 
Intima-media thickness (IMT), commonly measured in the carotid artery, has been 
extensively examined as the predictor of CVD and as a measure of atherosclerosis in clinical 
trials.26-28 IMT is measured using B-mode ultrasound scan of the carotid artery – the technique is 
reproducible, sensitive, and non-invasive. The ACCF/AHA guidelines recommends against 
routine use of carotid IMT testing among patients at risk of first CVD event.29 This is because 
conflicting reports have emerged regarding the usefulness of IMT as a predictor of CVD, with 
recent meta-analysis published in the Journal of American Medical Association reporting no 
significant improvement in risk prediction with the use of carotid IMT.27,28,30  
1.2.3.3 Carotid Plaque 
Similar to carotid IMT, B-mode ultrasound scan can be used to examine the presence of 
atherosclerotic plaque in the carotid arteries. Presence of carotid plaque is also associated with 
incident CHD. 27 In the carotid arteries, presence of plaque is most common around the site of 
bifurcation of the carotid artery i.e. the carotid bulb and the proximal internal carotid artery, while 
plaque is rare in the common carotid artery. In the MESA study, plaque (when defined as any 
stenosis of the carotid artery) increased the hazards of CVD by 45% over a 8 year follow-up 
period.31 Other large epidemiological studies have also reported association of carotid plaque with 
increased rates of cardiovascular disease. 32-34 
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Many recent epidemiological studies in the US and Europe have examined carotid arteries 
for the presence of plaque.32-36 In general, age, sex, hypertension, diabetes, and smoking are said 
to be strongest predictors of plaque. The prevalence of carotid plaque increases with age as well 
as with increases in the traditional CVD risk factors among all populations. (Table A-1)  
Use of different methodologies to examine and define carotid plaque renders it difficult to 
compare the prevalence of plaque across studies. While many recent epidemiological studies have 
defined carotid plaque in relation to the thickness of the nearby IMT,35,37,38 several others have 
defined carotid plaque with an absolute value of the carotid IMT e.g. >1.0 mm or >1.2 mm. (Table 
A-1 and Table B-1) 
While recent meta-analyses have raised questions on the utility of IMT as a predictor of 
CHD, carotid plaque has emerged as a strong CHD predictor.27 In this meta-analysis comprising 
of 11 population-based and 27 diagnostic-cohort studies were included. Using a meta-regression 
approach, the authors found that both in population-based as well as diagnostic cohort studies, the 
relative diagnostic odds ratio for carotid plaque was 35% higher than that for carotid IMT 
(p=0.046).27 
1.2.3.4 Other Biomarkers of Atherosclerosis 
 
Ankle-Brachial Index 
Ankle-Brachial Index (ABI) is a non-invasive technique for screening patients for 
peripheral arterial disease. ABI is the ratio of the systolic blood pressure measured in the ankle 
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region to the systolic blood pressure measured in the arm over the brachial artery. In a healthy 
patient, ABI values in the range of 0.9 to 1.3 are considered normal. ABI value less than 0.9 
indicate presence of peripheral arterial disease, and are strongly associated with all-cause and 
cardiovascular mortality.39,40 The prevalence of PAD, and thus abnormal ABI, increases with age 
and is associated with traditional CVD risk factors. In contrast, a high ABI (>1.3) indicates 
incompressible arteries in the leg, which is also associated with worse cardiovascular outcomes. 
Several epidemiological studies have reported that an abnormal ABI in asymptomatic individuals 
predicts worse cardiovascular outcomes.41-44 A recent review of the evidence by the United States 
Preventive Services Task Force found insufficient evidence to recommend screening the patients 
with ABI. However, the review noted that ABI and peripheral arterial disease is an active field of 
research, and that recommendations are likely to be updated again soon.45 
Flow-mediated Dilatation 
Brachial flow-mediated dilatation (FMD) is a non-invasive measure of endothelial 
dysfunction. In this measurement, first the brachial artery is compressed for sustained 4-5 minutes 
by inflating pressure cuff and then the vascular occlusion is released. In a healthy artery, increased 
flow of blood causes dilatation of the arterial lumen by release of nitric oxide. Using ultrasound of 
the brachial artery, the dilatation of the artery can be examined. A healthy arterial endothelium 
releases more nitric oxide and thus leads to a greater dilatation of the arterial lumen. Although this 
measure predicts future CVD, it requires high sonographer skill, and may not have high 
reproducibility even in the same participant.  
Many epidemiological studies have documented the relationship between FMD, traditional 
CVD risk factors,46 and CVD events.47-49 However, the American College of Cardiology 
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Foundation (ACCF)/AHA task force (2010) gave class III recommendation (i.e. no benefit) to 
FMD as a tool for assessing future CVD risk, noting that the evidence for its utility in insufficient 
and there remained challenges in technical standardization of the measurement.  
1.3 ARTERIAL STIFFNESS AS PREDICTOR OF CVD 
1.3.1 Introduction 
Arterial stiffness is a hallmark of aging, with contributions from co-morbidities such as 
diabetes, hypertension, atherosclerosis, and chronic renal disease.50 It is considered as one of the 
earliest manifestation of structural and functional changes within the vessel wall.51 With increasing 
age, there is an imbalance between the two core structural components of the arterial wall – elastin 
and collagen, with elastin progressively replaced by abnormal collagen, eventually leading to 
arterial stiffness.50 The 2007 European Society of Hypertension guidelines recommend using 
arterial stiffness among patients with high blood pressure. Arterial stiffness is generally assessed 
in epidemiological studies with the measurement of Pulse Wave Velocity (PWV) which, as the 
name implies, is the velocity at which the pulse transits between two points on the arterial tree. 
Other measures for arterial stiffness, esp. the large artery stiffness such as tissue Doppler and strain 
imaging employ advanced echocardiography techniques; however, these are not commonly used 
in epidemiological studies. 52,53 
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1.3.2 Pathophysiology of Arterial Stiffness 
The vascular wall is held stable, resilient, and compliant through a slow, dynamic process 
of production and degradation of two major scaffolding proteins: collagen and elastin. A 
dysregulation of process with a subsequent overproduction of collagen and underproduction of 
elastin leads to vascular stiffness. On histological examination of the intima, a stiffened vascular 
wall would reveal disarrayed collagen, broken elastin molecules, abnormal endothelial cells, 
vascular smooth muscle cells, macrophages and mononuclear cells. In addition, increased amounts 
of matrix metalloproteinases, transforming growth factor (TGF)-β, intracellular cell adhesion 
molecules, and cytokines are present.   
 
Figure 1-2 Summary of multiple causes and locations of arterial stiffness 
_______________________________ 
Reprinted with permission from Zieman SJ, et al Arterioscler Thromb Vasc Biol 2005;25:932-943 
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Collagen molecules are rendered insoluble to hydrolytic enzymes by cross-linking; thus, 
collagen provides tensile strength to the vessel wall. Further, collagen is susceptible to glycation 
cross-linking which renders it structurally inadequate. 50,54,55 Similarly, cross-links between elastin 
molecules are also disrupted in the process of arterial stiffness, thus rendering it weak. The weak 
and dysfunctional elastin is susceptible to mineralization by calcium and phosphorus. These 
structural changes, altered molecular repair mechanisms, together with the catabolic activities of 
matrix metalloproteinases (MMP’s) lead to arterial stiffness.50 
Endothelial cells as well as vascular smooth muscle cells play an active role in the 
pathogenesis of arterial stiffness. Vascular smooth muscle tone is regulated by cell stretch and 
calcium signaling, as well as by paracrine effects of the endothelium i.e. by secretion of mediators 
such as angiotensin II,56 endothelin,57 oxidative stress,58 and nitric oxide. A positive feedback loop 
is suggested to exist between arterial stiffness and endothelial dysfunction. Other factors that are 
said to play a significant role in arterial stiffness are – angiotensin II, 56 dietary salt,59 chronic 
hyperglycemia, chronic hyperinsulinemia, 60,61 and chronic renal disease.62 
1.3.3 Biomarkers of Arterial Stiffness 
While multiple markers of arterial stiffness are available, it is important to make a 
distinction between their ability to assess stiffness in central vs. peripheral arteries. This is 
particularly important as the mechanism for arterial stiffness differs between large and small 
arteries. While the increase in disarrayed collagen is the primary mechanism in the central conduit 
arteries, the vascular smooth muscle cells and endothelial function play a more prominent role in 
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the medium-sized muscular arteries. In contrast, stiffness in the microcirculation is critically 
dependent on the smooth muscle tone.63   
1.3.3.1 Pulse Wave Velocity 
Many epidemiological studies have used Pulse Wave Velocity (PWV) measurement as a 
marker of arterial stiffness. Although aortic or carotid-femoral pulse wave velocity (cfPWV) is 
considered by many as the gold standard marker of arterial stiffness, PWV measures from brachial-
ankle arterial segment is fast emerging as a marker of arterial stiffness and a predictor of CVD.  
1.3.3.2 Carotid-femoral pulse wave velocity (cfPWV) 
cfPWV primarily assesses the stiffness in the large aortic trunk and, thus, is also referred 
to as a measure of aortic stiffness or central arterial stiffness. cfPWV has been reported as a 
predictor of future cardiovascular events and all-cause mortality.64 European Society of 
Hypertension has recommended the use of cfPWV in assessing target end-organ damage among 
hypertensive patients, especially in patients in whom the target organ damage is not discovered by 
routine investigations. 65 However, cfPWV measurement suffers from limitations – (1) exposure 
of the inguinal region, and (2) difficulty in recording femoral waveform in patients with metabolic 
syndrome, obesity, diabetes, and peripheral arterial disease.66 In contrast to cfPWV, another 
combined measure of central and peripheral arterial stiffness i.e. brachial-ankle pulse wave 
velocity (baPWV) is fast emerging as a marker of arterial stiffness.  
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Figure 1-3 Measurement of carotid-femoral PWV with the foot to foot method 
___________________________ 
Reprinted with permission from Laurent S et al. Eur Heart J 2006;27:2588-2605. © The European Society of Cardiology 
1.3.3.3 Brachial-ankle Pulse Wave Velocity (baPWV) 
baPWV is an index of arterial stiffness assessed by measuring the difference between the 
time at which the pulse wave reaches the brachial artery and the posterior tibial artery. The arterial 
distance between the two sites (derived automatically by the machine, based on height of the 
participant) is then divided by this difference to obtain the baPWV. In contrast to the cfPWV that 
requires direct interrogation of the carotid and femoral arteries, baPWV is conveniently measured 
by placing blood pressure cuffs over arms and ankles and thus has less potential for human error 
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in measurement. baPWV is a popular clinical tool used in the east Asian countries such as Japan 
and South Korea to assess risk of CVD among patients. Most of the research studies examining 
baPWV as a tool for CVD prediction also originate from these countries. 
A meta-analysis was conducted to examine the prediction of cardiovascular disease events 
and all-cause mortality with baPWV (referred to as brachial-ankle Elasticity Index, baEI in the 
paper). A total of 18 longitudinal studies were included in the meta-analysis, reporting on a total 
of 8169 participants. Out of these, 15 studies reported results on CVD events (5544 participants), 
7 reported on CVD mortality (2274 participants), and 9 reported on all-cause mortality (5097 
participants). The risk for CV event was significantly higher among individuals with high baPWV 
than among individuals with low baPWV (relative risk 2.89, 95% CI: 1.99, 4.20) Additionally, the 
relative risk for total CVD events was 1.12 (95% CI: 1.05, 1.19) with every 100 cm/s increase in 
baPWV. (Figure 1-4) Out of 18, only 1 study was conducted in the Europe while the rest were 
conducted in Asia.67 
Studies reporting baPWV as a predictor of CVD events after the publication of this meta-
analysis are presented in Table D-1. 
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 Figure 1-4 Results of the meta-analysis reporting prediction of CVD events with baPWV  
___________________________ 
Reprinted with permission from Vlachopoulos, C. et al. Hypertension 2012;60:556-562. © The American Heart Association 
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 1.3.3.4 Other Regional Pulse Wave Velocity measurements 
The pulse wave velocity can also be measured regionally, i.e. on any given arterial 
segment. The nomenclature of these measures is also derived from the segment of the arterial that 
it covers for measurement of PWV, e.g. heart-femoral PWV (hfPWV) measures velocity of the 
pulse wave when one sensor is placed over the heart, and the other is placed over the femoral 
artery. Techniques are available to simultaneously measure the PWVs at many sites by placing 
multiple sensors over the body – the machine then analyzes data from various sensors and provides 
estimates of the different measurements PWVs.68  
Depending on the segment of the arterial tree they measure the PWV on, some of these 
measurements may be regarded as true measures of arterial stiffness, depending on the direction 
of travel of the pulse wave. 
heart-femoral PWV(hfPWV) 
 Several studies, including ours, have measured hfPWV as a marker of arterial stiffness.69-
73 It has been shown to have stronger association with CVD than other measures of arterial stiffness 
than other markers of regional arterial stiffness such as femoral-ankle pulse wave velocity or heart-
carotid pulse wave velocity.74 Some regard this as a more precise measure of central arterial 
stiffness as the pulse travels only in one direction between the heart and the femoral artery.  
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heart-brachial PWV (hbPWV) 
Similar to hfPWV, this also measures the velocity of pulse wave as it moves in one 
direction, i.e. from the heart to the brachial artery. Few studies have measured and reported 
hbPWV and its association with smoking,75 FMD,76 and advanced glycation end products.77  
femoral-ankle PWV (faPWV) 
The faPWV measures PWV in the leg, i.e. between the femoral and the posterior tibial 
artery at the ankle. Similar to hbPWV, this segment represents the muscular portion of the arterial 
tree that is more susceptible to the process of atherosclerosis than the aortic trunk which in contrast 
is more susceptible to arteriosclerosis.78 The faPWV value reported in the ERA JUMP study is 
higher than cfPWV but lower than baPWV.73 Further, faPWV was associated with target end-
organ damage among patients with essential hypertension.79 
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 Figure 1-5 Various arterial segments for measurement of PWVs 
1.3.3.5 Other Measures of Arterial Stiffness 
Pulse Wave Contour Analysis  
The structure and function of the arteries influence the shape of the pressure wave as it 
travels from the heart to the peripheral arterial tree. As it originates from the heart, the shape of 
the pulse wave is influenced by the mechanics of ventricular systole and the ejection of blood from 
the left ventricle. The shape changes as the pulse moves from the heart to the peripheral arterial 
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tree. A well-recognized change that occurs as the pulse move from the heart is the augmentation 
of the systolic pressure wave and decay of the diastolic wave. 80,81 One of the effects of ageing and 
vascular disease is the augmentation of the systolic central pressure. This augmentation, if 
evaluated clinically using pulse wave contour analysis, can provide a measure of arterial 
stiffness.63 
Pulse Pressure 
The pulse pressure i.e. the systolic-diastolic blood pressure difference provides a crude 
estimate of the large artery stiffness.82,83 Elevated pulse pressure is reported to be associated with 
worse cardiovascular outcomes, such as heart failure,84,85 and myocardial infarction.84,86 Pulse 
pressure has also been used as a surrogate end-point for evaluating therapies for hypertension and 
CVD.85 
1.3.3.6 Comparison between PWV measurements as a tool for measuring arterial stiffness  
While cfPWV is established as a marker of arterial stiffness, baPWV is a new measure of 
arterial stiffness that covers both central as well as peripheral arterial stiffness. While cfPWV spans 
mostly over the aortic truck and, only some portion of the peripheral arterial tree i.e. carotid artery, 
the baPWV spans significant length of the peripheral arterial tree. As peripheral arterial wall has 
more smooth muscle component as compared to the aortic trunk, it is possible that the mechanism 
of stiffness may differ between the two types of arterial walls. It is likely that peripheral arterial 
wall is more affected by atherosclerosis than the aortic trunk.78 Although the process of arterial 
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stiffness in the aorta has been studied in detail, similar scrutiny has not been done for the peripheral 
arterial tree.  
In a meta-analysis of longitudinal studies examining prediction of CVD events and all-cause 
mortality with aortic stiffness or cfPWV, it was found that relative risk of clinical events 
increased with increasing tertiles of arterial stiffness.64 All of the 15 studies that reported total 
CVD events reported a significant increase in total CVD events with PWV, and all except one 
studies reported a significant increase in CVD mortality and all-cause mortality with higher 
PWV. Many of the studies were conducted in the Europe 87-89 and the US. 90,91 Thus, similar to 
baPWV, cfPWV also predicts CVD events. 
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Relative risk (RR) and 95% confidence interval (CI) for high aortic pulse wave velocity (PWV) and total cardiovascular (CV) events (A), CV mortality (B), and 
all-cause mortality (C). (Vlachopoulos, 2010, JACC; 55:1318-1327) © American College of Cardiology Foundation 
 
Figure 1-6 RR and 95% CI for High Aortic PWV and Clinical Events 
___________________________ 
Reprinted with permission from Vlachopoulos, C. et al. JACC 2010;55:1318-1327. © The American College of Cardiology 
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1.3.3.7 Pulse Wave Velocity measurements: Advantages and Challenges 
While cfPWV is considered the gold-standard measure of arterial stiffness, and predicts 
future CVD,  certain methodological factors limit its wider application. cfPWV measurement 
requires some expertise from the technician. The skin sensor for the femoral artery has to be placed 
over the femoral artery in the inguinal region, thus requiring exposure to the inguinal region. 
Although this may not be an issue among symptomatic patients, asymptomatic patients and 
participants in epidemiological studies may be reluctant to undergo this procedure. The operator 
dependence and inguinal exposure may limit its utility in a busy physician’s office.  
In comparison, baPWV measurement faces few such challenges. It is easy to perform, 
requires minimal operator or technical expertise, and requires only placement of cuffs over the 
arms and the ankles. Also, baPWV is shown to predict future CVD events. 
However, baPWV measurement itself faces certain challenges before it can gain wider 
acceptability in epidemiological and clinical research as well in a physician’s office.  
a. Standardization and validation of the path length of baPWV, 
b. Measurement and validation data among non-Asian populations, 
c. Establishing normal and disease reference values for the healthy as well as clinical 
population, and 
d. Improved understanding of the disease pathogenesis, esp. in the peripheral arteries. 
 
25 
1.4 EPIDEMIOLOGY OF CHD – COMPARISON BETWEEN THE US AND JAPAN 
1.4.1 Introduction 
Coronary heart disease (CHD) remains the leading cause of mortality in the US, even after 
witnessing decades of declining trend in its age-adjusted mortality.92,93 About 50% of all CHD 
deaths are estimated to be out of hospital and sudden.94-98 Moreover, during the next 20 years, 
prevalence of CHD will rise by 16% just because of demographic changes and the costs 
attributable to CHD will triple from $35.7 to $106.4 billion.99 Thus, prevention of CHD, especially 
its primary prevention, is of critical importance to bring down healthcare and economic burden of 
CHD in the US. 
In contrast to the US and much of the western world, Japan has much lower rates of CHD, 
and has much higher longevity. This is in spite of having worse risk profile for many 
cardiovascular disease risk factors as compared to the United States. For example, hypertension 
and smoking rates are much higher in Japan as compared to the US, while total cholesterol levels 
are similar. However, average BMI is much lower in Japan than the US. Thus, comparison between 
the US and Japan might provide us with new insights into lower CHD in the US.  
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1.4.2 Epidemiological Studies in the 20th Century 
The Seven Countries Study 
The Seven Countries Study is an epidemiological study that systematically examined the 
effect of lifestyle and diet on CHD and stroke in different populations. A total of 12,763 men, aged 
40-59 years, were recruited in USA, Europe, and Japan, and followed for more than 50 years. This 
was the first international study to report that Japanese men had much lower rates of CHD than 
others population groups.100 
The Seven Countries Study in the 1960’s revealed that CHD mortality in Japan is uniquely 
low, which was attributed to low serum levels of total cholesterol in Japan, i.e., 165 vs. 240 mg/dl 
in the US.100 Because studies of Japanese migrants to the US show a dramatic rise in CHD,101 CHD 
mortality in Japan was expected to increase as Japanese adopt more Westernized lifestyle: In fact, 
levels of total cholesterol in Japan have continuously increased from 165 mg/dL in the1960’s to 
210 mg/dl in 2000.102 Very paradoxically, however, CHD mortality in Japan has constantly 
declined since the 1970’s  similar to the other developed countries where population levels of total 
cholesterol have been continuously declining, e.g., from 240 to 200 mg/dl in the US between the 
1960’s and 2008.103,104 These epidemiological observations indicate some protective factors 
against CHD in Japanese in Japan. 
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Ni-Hon-San Study  
The Ni-Hon-San (Nippon (Japan), Honolulu, and San Francisco) study was started in 1965 
as a large epidemiological study to examine environmental factors and their association with 
ischemic heart disease and stroke. Only male residents of Japanese descent were recruited from 
the population in the US (Honolulu and San Francisco). In Japan, participants were recruited from 
the cities of Hiroshima and Nagasaki. Age at recruitment was 41 to 70 years in Japan, 46 to 65 
years in Honolulu, and 30 to 69 years in San Francisco. The study allowed for examination of 
environment and lifestyle as a risk factor for CVD. A total of about 11,900 men were recruited. In 
addition to detailed self-administered questionnaire, participant examination was done including 
anthropometry, BP, vital capacity, and detailed dietary assessment. Blood measures included 
glucose, hematocrit, cholesterol, and uric acid analysis. The study found an increasing trend of 
CHD from Japan to Honolulu to San Francisco, while there was an increasing trend for stroke in 
the opposite direction i.e. Japan > Honolulu > San Francisco.101,105-109 
Honolulu Heart Program 
The Honolulu Heart Program was started in 1965 to examine differences in cardiovascular 
disease mortality between Japanese living in Japan and individuals of Japanese origin living in 
Hawaii, US.  It was started in Oahu, Hawaii and included 8006 men of Japanese descent who were 
born between 1900 and 1919. The study found that Japanese in Japan had much lower CHD 
mortality than those in Hawaii. Age, SBP, serum cholesterol, serum glucose, cigarette smoking, 
and alcohol consumption were predictors of CHD incidence. The initial examination was 
performed from 1965 to 1968. Follow-ups were done 2 and 6 years later. Questionnaire, 
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anthropometric data, lifestyle, dietary, and risk factor information were collected. Twelve-lead 
electrocardiogram were recorded. The Honolulu Heart Program found higher rates of 
cerebrovascular disease among Japanese Americans living in the US than Japanese living in Japan. 
In addition, the study found higher rates of type 2 diabetes among Japanese Americans than 
Japanese in Japan. Also, there was an increase in CHD and its risk factors with acculturation among 
Japanese Americans.110,111  
INTERMAP Study 
The International study of Macronutrients and Blood Pressure (INTERMAP) study was a 
large population-based epidemiological study to specifically examine dietary factors that are 
responsible for high blood pressure in US, United Kingdom, China and Japan. Between 1995 and 
1999, a total of 4,680 men and women, aged 40-59 years gave 24-hour dietary history and 24-hour 
urine samples, which were examined in a standardized manner. Various nutrients were examined 
esp. with respect to energy intake, minerals, vitamins, cholesterol, dietary fiber, and caffeine.112,113 
This study reported significant differences in intake of dietary factors that partly explain 
differences in prevalence of cardiovascular diseases between these world regions. A significant 
finding from this study was the inverse association between omega-3 fatty acid intake, 114 and 
vegetable protein intake and BP,115 and a positive association between cholesterol and BP. 116 
Among the Japanese participants in Japan and Japanese Americans in Hawaii (The 
INTERLIPID study), it was found that serum omega-3 fatty acids were positively associated with 
HDL-cholesterol among men. Also, traditional CHD risk factors were lower among Japanese in 
Japan than Japanese Americans in Hawaii.117 
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1.4.3 The ERA JUMP Study 
The Electron-beam computed tomography, Risk factor Assessment among Japanese 
and U.S. Men in the Post-World War II birth cohort (ERA JUMP Study) was started as an 
investigator-initiated study sponsored by the National Institute of Health (HL68200), to examine 
and compare the extent of atherosclerosis among 300 White and 100 Black men in Pittsburgh, US, 
300 Japanese American men in Honolulu, US who were offspring of members of the Honolulu 
Heart Program, and 300 Japanese men in Kusatsu, Japan. Men, 40-49 year old and free of CVD or 
other severe diseases, were recruited from the population between 2002 and 2006. Using a similar 
protocol, about 300 South Korean men were also recruited from the population in Ansan, South 
Korea. Along with participant questionnaires and measurement of traditional cardiovascular risk 
factors, serum samples were collected, and subclinical atherosclerosis in the form of Carotid IMT 
and CAC was examined in a standardized fashion.118 
 
Figure 1-7 The ERA JUMP Study logo 
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1.4.3.1 N-3 fatty acids and subclinical atherosclerosis in the ERA JUMP study 
The ERA JUMP study reported higher subclinical atherosclerosis among White men in the 
US than Japanese men in Japan.118,119 Also, consistent with the findings previously reported from 
the Honolulu Heart Program and other epidemiological studies from the 20th century, it reported 
higher atherosclerosis i.e. higher carotid IMT and higher prevalence of CAC (≥10 AU) among 
Japanese Americans men than Japanese men in Japan.  
One factor that was found to be associated with lower subclinical atherosclerosis among 
Japanese in Japan was serum levels of marine n-3 fatty acids. In fact, the significant difference in 
subclinical atherosclerosis found between Japanese men in Japan and White men became non-
significant after adjusting for serum levels of n-3 fatty acids, thus highlighting the important role 
they may play in protection from atherosclerosis. Notably, serum levels of n-3 fatty acids were 
significantly higher among Japanese in Japan, consistent with their higher dietary intake.120 
A 4 to 6 year follow-up of the ERA JUMP visit 1 has recently been completed across the 
study sites, and shows that incidence of CAC is inversely associated with baseline serum n-3 fatty 
acids,121 thus providing further evidence that n-3 fatty acids are protective against atherosclerosis. 
Other prospective epidemiological studies in the US have also reported similar inverse association 
of higher n-3 fatty acids with atherosclerosis and CHD.122-128 
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1.4.4 Other anti-atherogenic Dietary Factors in Japan 
1.4.4.1 Soy Isoflavones 
One strategy to examine reasons for differences in CHD and subclinical atherosclerosis 
between US and Japan is to identify dietary factors having pro- or anti-atherosclerotic properties, 
of which consumption is strikingly different between the US and Japan, and to examine whether 
such nutrients have significant associations with atherosclerosis independent of traditional risk 
factors. In addition to n-3 fatty acids described in the earlier section, one nutrient with anti-
atherosclerotic properties, of which intake is substantially higher among Japanese in Japan as 
compared to US, is soy isoflavones.113,129  
In recent years, soy isoflavones, specifically its aglycone components, daidzein and 
genistein, have been examined for their potential protective effects on atherosclerosis,130 CHD131-
133 and other conditions such as cognition134, cancers,135 osteoporosis,136 and menopausal 
symptoms.137 A randomized clinical trial in the US has reported lower intima-media thickness 
progression among those who has isoflavone supplementation than those in the placebo group; 
however, the difference was not statistically significant. Nevertheless, the difference was 
significant among early postmenopausal women.130  Several laboratory and animal studies have 
also reported that soy isoflavones have anti-atherosclerotic properties.138-141  
Although classified as phytoestrogens due to their structural similarity to estrogens and 
their estrogen receptor-binding capability, unlike estrogens, soy isoflavones preferentially bind to 
estrogen β receptors (ER-β) expressed in the vascular endothelium over estrogen α receptors (ER-
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α) expressed in the reproductive tissue.142,143 Thus, at concentrations present in the human, the 
primary effects of soy isoflavones are on the vasculature. In addition to its estrogenic properties, 
soy isoflavones act as antioxidants by reducing lipid peroxidation and exhibit anti-inflammatory 
activity by reducing nitric oxide production.144 Mean consumption of isoflavones in Japan is 25-
50 mg/day145 whereas it is negligible in the US, i.e., <2 mg/day.145,146  
Soy isoflavones, especially genistein, preferentially bind with ER-β but only weakly with 
ER-α. The binding activity of genistein on ER-β is 87% of the binding activity of estradiol, albeit 
at much higher concentrations. In contrast, its binding activity on ER-α is only 4% in comparison 
to estradiol. Daidzein, the other major isoflavone, has much lower affinity to these receptors as 
compared to genistein i.e. its binding activity at ER-α and ER-β is only 0.1% and 0.5% as compared 
to estradiol.147 
Animal studies have reported anti-atherosclerotic effects of soy isoflavones.138-141,148,149 In 
an important clinical trial of soy isoflavones among female cynomologus monkey, atherosclerosis 
progression was lower among the group that was fed diet rich in soy isoflavones as compared to 
the group that was fed control diet, although the difference was only marginally significant. The 
progression was lowest among the group fed conjugated equine estrogen. In this study, monkeys 
were fed atherogenic diet for 26 months, at which time surgical menopause was induced, and 
subjects were followed for another 10 months.140 Other studies from the same research group have 
reported improvement in cardiovascular risk factors such as LDL-c, VLDL-c, HDL-c, and total 
cholesterol:HDL-cholesterol ratio,150 and vascular reactivity149 among monkeys.  
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 Figure 1-8 Distribution of the two subtypes of estrogen receptors 
____________________________________________________________ 
Reprinted with permission from S Nilsson and J-Å Gustafsson Nature 2011;89:44-55. © Macmillan Publishers Ltd 2011  
ER-β is known to play an atheroprotective role. In a study of mice, it was found that heat-
shock protein 27 (HSP27), an atheroprotective protein that acts to prevent atherogenic lesion 
formation, works in an estrogen-dependent manner. In vitro, HSP27 works strongly in the presence 
of an ER-β agonist but only modestly in the presence of an ER-α agonist.151 In contrast, other 
studies have reported similar or higher atherosclerotic properties of ER-α than ER-β.152 However, 
the uterotrophic and mammotrophic effects of ER-α stimulation limits the usefulness of any 
agonists to target these receptors. In contrast, ER-β has no such potentially harmful characteristics 
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and, thus, is safer to target. In spite of the continues interest in the biological roles of estrogens and 
its receptors, the exact pathophysiological role that these receptors play with regards to 
development of various disease process is not completely understood.152 
Several epidemiological studies in the past have examined the protective effects of soy 
isoflavones on CHD.131-133 Two of these three studies are from countries where consumption of  
Figure 1-9 Comparison of serum levels of Soy Isoflavones between US and Japanese men in the ERA 
JUMP Study 
soy is significantly higher than that in the US – both shown a protective effect of soy on 
CHD. In contrast, in Europe, where the average consumption of soy isoflavones is low, no 
protective effect of soy isoflavones was found.132  
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Soybeans are the almost exclusive dietary source of isoflavones. However, the average 
intakes of isoflavones differ markedly between the US and Japan: <2 mg/day in US vs. 25-50 
mg/day in Japan. In the ERA JUMP study, median (interquartile range) levels of serum isoflavones 
Figure 1-10 Chemical structure of Isoflavones and Equol 
 (nmol/L) in Japan and the US were 517 (195, 1147) and 7 (3, 58) respectively (Fig 1-7). 
While genistein and daidzein are the two major isoflavones in dietary sources, equol is produced 
from daidzein in the gut by intestinal bacteria. These isoflavones are structurally similar to 
estradiol (Fig 1-8). However, unlike estradiol which binds to the ER-α present in the reproductive 
tissue as well as with ER-β,141,153 isoflavones bind preferentially to the ER-β expressed in the 
vasculature.141 As their serum concentration is 1000-fold higher than estradiol,154 isoflavones are 
able to exert anti-atherosclerotic effects through estrogenic properties on ER-β in spite of their 
relatively minuscule potency.153 Observational studies from Japan131 and China,133 where intake 
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of isoflavones is much higher than the US, support the hypothesis of anti-atherosclerotic effects of 
isoflavones. 
1.4.4.2 Equol – a soy derivative 
 
Figure 1-11 Conversion of Daidzein into Equol by intestinal bacteria 
__________________________________________________________________ 
Reprinted with permission from Yuan, J. et al. Molecular nutrition and Food Research 2007;51:765-781. © 2007 WILEY-VCH Verlag 
GmbH & Co. KGaA, Weinheim 
Equol [7-hydroxy-3-(4'-hydroxyphenyl)-chroman] is an isoflavone derived from daidzein. 
Equol was first isolated in 1932 from pregnant mare's urine,155  and was found in human urine in 
1984.156 Similar to genistein and daidzein, equol is classified as a non-steroidal 
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estrogen.157 However, equol does not occur freely in nature - daidzein is acted upon by intestinal 
bacteria to produce equol (Figure 1-11).158 Equol can now also be artificially produced from 
daidzein.159  160 It exists in two forms - an active S-(-)equol and an inactive R-(+) equol form.  
Equol has several pharmacokinetic properties that differ from those of its precursor, 
daidzein. After being absorbed from the intestine, equol undergoes first-pass metabolism - 
glucuronidation and sulfur-conjugation in the alimentary tract. Once formed, it has longer half-
life, and higher bioavailability than daidzein – a study examining pharmacokinetics of daidzein 
and equol found that while daidzein had a plasma clearance of 17.5 L/h, the clearance of equol 
was much slower at 6.85 L/h.161 Equol has much higher free and unbound form (49.7%) than 
daidzein (18.7%) and estradiol (4.6%) in the blood.162 Almost all of it is excreted in the urine.163,164  
Although equol is derived from daidzein through a series of steps in the intestine, (Figure 
1-11) it retains many of the important properties of daidzein. E.g. equol retains structural similarity 
to estradiol and has affinity for the ER-β.157 Between genistein, daidzein and equol, daidzein has 
lowest affinity for estrogen receptor. While the affinity for estrogen receptor is similar between 
equol and genistein, equol induces more transcription than genistein through activation of the 
intracellular mechanisms, and thus results in more biologic effect.165  In fact, equol has the highest 
biological potency of all isoflavones.161 Equol has higher anti-oxidant properties, higher 
bioavailability, and slower clearance rate compared to other isoflavones.161,166-169 Thus, equol may 
provide an exciting opportunity to bring down atherosclerotic burden in the US.  
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Equol Producer status 
Given that equol is produced from daidzein by the action of intestinal bacteria, both 
presence of daidzein in diet as well as equol-producing bacteria in the intestine are necessary to 
produce and absorb equol from the intestine. It is estimated that 10-50% of Japanese 170-174 and 25-
40% of Americans have intestinal bacteria to convert daidzein to equol.158,174,175 Although 25-40% 
of Americans are equol producers, the proportion of the Americans consuming daidzein on a 
regular basis is much lower. Thus, estimation of equol producer status among Americans cannot 
be performed without giving a daidzein challenge to the individual.  Equol producing status is 
reported to be stable and is determined by intestinal bacteria.158,176,177 It is unlikely that genetics 
has any role to play in production of equol.173-175,178 Given that only some individuals have the 
bacteria to produce equol, a terminology of “equol producer” and “equol non-producer” is 
frequently used to distinguish between these two groups in the scientific literature. 
Setchell et al. have examined dietary factors that may be associated with equol producer 
status in a study comprising of Caucasians who were followed for 2 years. In their study, 30.3% 
of Americans, and 28.6% of Australians were equol producers [defined as log10(urinary 
equol/daidzein) > -1.75]. The study investigators found that as compared to equol-producers, equol 
non-producers had lower polyunsaturated fat intake as well as lower polyunsaturated fat/saturated 
fat intake ratio.177 Of the 20 participants among which the equol producer status was followed, 
producer/non-producer status remained stable among 18 participants (90%) which were followed 
for 2 years. Additionally, administration of an anaerobic antibiotic (i.e. metronidazole) did not 
have effect on equol producer status among 4 of the 5 participants.177     
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 Criteria for determining Equol producer status 
 Several clinical studies have been conducted to determine the prevalence of equol 
producing status in the population. These studies used varied definitions to determine equol 
producer status. The WISH trial which is the largest clinical trial to date of soy isoflavones in the 
US, used plasma level of ≥20 nmol/L as the cut-off point to determine equol producer status.130 
Setchell et. al. recommended use of ≥83 nmol/L in plasma as the cut-off point for determining 
equol producer status in 2002, while updated their recommendation and prescribed log10(urinary 
equol/urinary daidzein) > -1.75 as the criterion in 2006.179 Following this, a majority of studies 
have used log-transformation formula for determining equol producer status. Although the log-
transformation formula is accepted by several studies, it is recommended only when equol and 
daidzein levels are measured in the urine.179 When the equol and daidzein levels are measured in 
the plasma, Setchell et al. have found that this formula did not correctly determine equol producer 
status.179  
Although several studies have examined equol producer status by assessing equol 
concentration in the urine, few have measured equol in the plasma. 130,179,180 Further, these studies 
have used different criteria to determine equol producer status. Thus, the definition to assess equol 
producer status by measuring equol in the plasma is unclear from the scientific literature. Further, 
all the previous studies have been conducted by measuring equol after giving a challenge with soy 
isoflavones or soy containing food. However, none of these studies have examined equol producer 
status in the general population without administration of isoflavones. Although Setchell et al. 
updated their definition of equol producer in 2006 when measuring equol in urine, their definition 
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for measuring equol producer status when measuring equol in the plasma (i.e. ≥83 nmol/L) still 
holds. 
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 Table 1-3 Studies using varying criteria to determine equol producer status 
Author-Year, Type 
of Study Study Population Equol assessment Soy challenge? 
Equol producer 
definition 
Prevalence of Equol 
producers 
Setchell-1997, 
clinical trial, US181 
N=25, all infants Urine Soy-based infant 
formula 
Any detectable equol 
in plasma 
57.1% 
Watanabe-1998, soy 
pharmacokinetic 
study, Japan182 
N=7, all males, Age 
range: 23 to 54 years 
Urine Soy challenge Any measurable 
equol in urine 
28.1% 
Rowland-2000, 
crossover clinical 
trial, UK183 
N=24, 79.1% female, 
Age range: 19-40 
years 
Both serum and 
urine 
High and low 
isoflavones 
containing diet 
Definition not 
provided 
36% 
Setchell-2002, soy 
pharmacokinetic 
study, US161 
N=16, all 
premenopausal 
females 
Urine Soy food for 7 days Any measureable 
equol in urine 
37.5% 
Wiseman-2004, 
clinical trial, UK184 
N=76, 50% female, 
Age ~ 24 years 
Urine Soy supplements for 
10 weeks 
> 1000 nmol/24 hr 34% 
Setchell-2006, 
clinical trial, US179 
N=41, 44% female, 
71% vegetarians, 
Age range: 26-64 
years 
Both serum and 
urine 
500 ml/day of soy 
milk for 3 days 
Log10(equol/daidzein) 
> - 1.75 
Vegetarians: 59% 
Non-vegetarians: 
25% 
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Vedrine-2006, 
clinical trial, 
France180 
N=12, all white 
postmenopausal 
females 
Both urine and 
plasma 
soy supplements Plasma: >40 nmol/L 
Urine: >1000 nmol/ 
36 h 
41.6% 
Maskarinec-2007, 
clinical trial, US175 
N=43, all Japanese 
American females, 
Age range: 18-78 
years 
Urine Soy challenge with 
soymilk 
Any measurable 
equol in urine 
33% 
Atkinson-2008, 
clinical trial, US185 
N=200, all female, 
Age range: 40-45 
years 
Urine 3 soy bars or bag of 
soy nuts 
Any detectable equol 
in urine 
27.5% 
Thorp-2008, 
crossover clinical 
trial, Australia186 
N=91, 63.7% female, 
Age range: 18-80 
years 
Urine Isoflavones 
containing diet 
Log10(equol/daidzein) 
> - 1.75 
32.9% 
Hodis-2011, clinical 
trial, US 
N=350, all female, 
Age range: 45 to 92 
years 
Plasma Soy protein diet Plasma equol ≥20 
nmol/L 
Consistent 
producers: 26%  
Intermittent 
producers: 23.3% 
Sen-2012, clinical 
trial, USA187 
N=82, all female, 
Age: 39.2 ± 6.1 years 
Urine High and low soy 
diet 
(i) daidzein > 2 
nmol/g creatinine, or 
(ii) equol/daidzein > 
0.018 
52.4% 
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Wong-2012, clinical 
trial, Canada188 
N=85, 50.6% female, 
Age 59.9 ± 9.9 years 
Urine Soy food 
supplements 
(i) >1000 nmol/day, 
or 
(ii) 
Log10(equol/daidzein) 
> - 1.75 
35.3% 
Setchell-2013, 
clinical trial, US 
and Australia177 
N= 159, 57.2% 
female, Age range: 
21-61 years 
Urine 480 ml/day of soy 
milk for 3.5 days 
Log10(equol/daidzein) 
> - 1.75 
US: 30.3% 
Australia: 28.6% 
Tseng-2013, clinical 
trial, US189 
N=224, all Chinese 
American female, 
Age range: 36 to 58 
years 
Urine Soy challenge Urine: ≥30 nmol/L 30% 
Van der Velpen-
2014, crossover 
clinical trial, 
Netherlands190 
N=58, all female, 
Age ~ 63 years 
Urine Isoflavones 
supplement 
Log10(equol/daidzein) 
> - 1.75 
27.3% 
Nakatsu-2014, 
clinical trial, US191 
N=17, all female, 
Age: 60.2±7.3 years 
Urine Soy bar Log10(equol/daidzein) 
> - 1.75 
23.5% 
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Equol: possible mechanisms of action 
Of all metabolites of daidzein, equol has the most potent action on the ER-β,192 and most 
potent anti-oxidant effects.161  Given these effects, it is possible that equol producers have less 
atherosclerosis and lower CHD than non-equol producers. Although many studies from East Asian 
countries have examined this hypothesis, its assessment among US populations in an observational 
setting is limited by the fact that consumption of daidzein is negligible in the US. Due to this 
limitation, it is unlikely that even those US individuals having intestinal bacteria to produce equol 
would have been exposed to appropriately high concentration of equol over their lifetime. In 
contrast to the US, soy is a part of daily diet in Japan with foods such as tofu and miso providing 
a bulk of the isoflavones. Thus, it is safe to assume that anyone with low equol level in the blood 
in Japan does not have intestinal bacteria to convert daidzein into equol. 
To date, only one pilot clinical trial of equol has been conducted.178 This 12-week 
randomized double-blinded crossover trial was conducted on 54 overweight or obese individuals 
(age: 59.4 ± 1.3 years, 70.4% female) in Japan; efficacy of daily intake of 10 mg equol supplement 
was tested against placebo. Equol supplementation led to significant reduction in waist 
circumference, HbA1c, LDL-c, and cardio-ankle vascular index, a measure of arterial stiffness.193 
Further analysis showed that findings were stronger among women than men. Also, findings were 
significant only among those who were determined equol non-producers at baseline with almost 
no effect seen among equol producers. Although this small trial resulted in significant 
improvement on a variety of cardiovascular risk factors, little is known about the mechanism of 
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action of equol in humans. Larger studies are needed to assess true potential of equol as an anti-
atherosclerotic supplement. 
In addition to the clinical trial of equol, several clinical trials of soy/ soy protein/ 
isoflavones have determined equol-producer status and reported the effects of isoflavones by equol 
producer status. In the Women’s Isoflavones Soy Health (WISH) trial comprising of 350 
postmenopausal women in the US, equol producers had non-significantly lower IMT progression 
than non-producers.130 In a case-control study within the original Shanghai Men’s Health and 
Shanghai Women’s heath cohorts, increasing urinary equol quartiles were associated with lower 
CHD among women but not in men.194 In a small clinical trial of soy isoflavones, those consuming 
high-dose isoflavones had similar reductions in LDL-c in both equol producers and non-producers, 
however, HDL-c and apoA-1 were preserved only among equol producers.188 Finally, a recent 8-
week clinical trial in Netherlands (n=57) examining effects of isoflavones supplementation on 
biopsy-derived adipose tissue showed down-regulation of energy metabolism-related genes with 
high-dose isoflavones supplementation but an inverse effect with low-dose isoflavones 
supplementation.190 
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1.5 SPECIFIC AIMS 
This manuscript examines the following specific research questions 
• What is the prevalence of carotid plaque among middle-aged Caucasian men in US, 
Japanese men in Japan and Korean men in South Korea in the ERA JUMP study? 
Which risk factors are significantly associated with carotid plaque in these 
populations? 
•  Is brachial-ankle pulse wave velocity associated with presence of coronary artery 
calcification among middle-aged men in the ERA JUMP study? 
• Are serum levels of soy isoflavones and equol producer status inversely associated 
with presence of coronary artery calcification among Japanese men in Japan in the 
ERA JUMP study? 
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2.0  CAROTID PLAQUE: COMPARISON AMONG MIDDLE-AGED MEN LIVING 
IN US, JAPAN, AND KOREA 
2.1 ABSTRACT 
Background: Carotid plaque has emerged as a strong predictor of coronary heart disease 
(CHD) risk. Comparison of carotid plaque burden between race/ethnicities may provide a relative 
estimate of their future CHD risk.  
Methods: A population-based international study was conducted among apparently 
healthy middle-aged men aged 40-49 years (ERA JUMP study (n=924)): 310 Whites in Pittsburgh, 
US, 313 Japanese in Otsu, Japan, and 301 Koreans in Ansan, S Korea. Carotid plaque and CHD 
risk factors were assessed using a standardized protocol across all centers. Prevalence of carotid 
plaque was compared between race/ethnicities after age-BMI, and after multivariable adjustment 
for other CHD risk factors. Cross-sectional associations of risk factors with carotid plaque were 
examined. 
Results: Whites (22.8%) had about five-fold higher prevalence (p<0.01) of carotid plaque 
than Japanese men (4.8%) while the prevalence among Koreans was 10.6%. These differences 
remained significant after age, BMI as well as after multivariable adjustment – odds ratio (95% 
confidence-interval) for plaque prevalence was 0.18 (0.09, 0.32) for Japanese and 0.43 (0.26, 0.74) 
for Koreans. Further, these differences remained significant even after adjusting for carotid intima-
media thickness (IMT). Age, hypertension and diabetes were significantly associated with 
presence of carotid plaque in the overall population. 
48 
Conclusion: Whites had significantly higher carotid plaque than men in Japan and S Korea. 
Lower carotid plaque burden among Japanese and Koreans was independent of traditional CHD 
risk factors and IMT.  
2.2 INTRODUCTION 
Presence of plaque in the carotid artery has emerged as a strong predictor of coronary heart 
disease (CHD). A recent meta-analysis reported carotid plaque as a stronger predictor of CHD than 
the carotid intima-media thickness (IMT)27,195 which is commonly used as a measure of subclinical 
atherosclerosis. Thus, comparison of carotid plaque prevalence between race/ethnicities may 
provide an estimate of their relative burden of atherosclerosis, which is the major underlying cause 
of CHD.  
CHD remains the leading cause of mortality in the United States (US), with more than 
three-fold higher CHD mortality rates in the US than in Japan.1 Although being industrialized for 
several decades with westernization of diet and lifestyle, Japan continues to have extremely low 
CHD rates. The author’s research group has also reported lower coronary atherosclerosis and lower 
IMT among Japanese men than US Whites.118 While several studies have examined race/ethnic 
differences in CHD as well as subclinical disease markers such as carotid IMT,196,197 few studies 
have compared prevalence of carotid plaque across various race/ethnicities.198 Further, previous 
studies used varying methodology to examine and define carotid plaque,27 thus limiting validity 
of any post-hoc comparison of plaque prevalence between different studies. With the emergence 
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of carotid plaque as a predictor of CHD, it is now important to systematically examine the 
differences in the prevalence of carotid plaque between the US and Japan. 
Although many population-based studies have assessed the prevalence of carotid 
plaque,198,199 no study has compared the prevalence of carotid plaque between the US and Japan. 
Thus, a standardized protocol was used to compare the prevalence of carotid plaque among Whites 
in the US, Japanese in Japan, and Koreans in Korea in the ERA JUMP study, an international 
population-based study for assessing subclinical atherosclerosis in 40-49 year-old men. The 
hypothesis for the present study was that the prevalence of carotid plaque would be highest among 
Whites in Pittsburgh. Further analysis was performed to examine which CHD risk factors were 
associated with the presence of carotid plaque in this sample population. 
2.3 METHODS 
2.3.1 Participants 
During 2002–2006, a population-based sample of 925 men aged 40–49 years, with no 
clinical cardiovascular disease (CVD) or other severe diseases was obtained from 4 centers: 310 
Whites from Pittsburgh, Pennsylvania; 313 Japanese from Kusatsu city, Shiga, Japan; and 302 
Koreans from Ansan, Gyeonggi-do, South Korea as previously described.118 The final sample for 
this study consisted of 924 men (310 Whites, 313 Japanese men in Japan, and 301 Koreans) with 
complete data. Written informed consent was obtained from all participants. The study was 
approved by the Institutional Review Boards of the following institutions: the University of 
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Pittsburgh, Pittsburgh, Pennsylvania; Shiga University of Medical Science, Otsu, Japan; and Korea 
University, Seoul, South Korea. 
2.3.2 B-Mode Carotid Ultrasound Scanning 
Presence and extent of plaque were evaluated in each of 5 segments of the left and right 
carotid arteries i.e. distal and proximal common carotid artery (CCA), carotid bulb, proximal 
internal carotid artery (ICA) and external carotid artery, and summarized as the presence or 
absence of any plaque.  Plaque was defined as a distinct area of the vessel wall protruding into the 
vessel lumen that was at least 50% thicker than the adjacent IMT.  Number of distinct plaques was 
counted in the abovementioned carotid segments on both sides.200 
Before the start of the study, sonographers at all centers received training for carotid 
scanning provided by the Ultrasound Research Laboratory at the University of Pittsburgh. 
Continuous-quality assessment programs developed by the Ultrasound Research Laboratory to 
assure scanning quality were applied across all study sites throughout the study.200 Pittsburgh and 
Kusatsu sites used a Toshiba 140A scanner (Tokyo, Japan) equipped with a 7.5-MHz-linear-array 
imaging probe while the Ansan site used a Titan high-resolution ultrasound system with a 10.5 
MHz linear array. Readers were blinded to participant’s characteristics and the study centers. 
Under continuous-quality assessment programs, there was excellent agreement between 
sonographers for carotid plaque assessment (kappa statistic, κ=0.78).  
For the purpose of measurement of IMT, digitized images of the carotid artery were sent 
to the University of Pittsburgh from other centers, and were read by a trained reader using 
standardized protocol.118 The sonographer measured the average IMT across 1-cm segments of 
near and far walls of the common carotid arteries and the far wall of the carotid bulb and internal 
51 
carotid arteries on both sides. Average IMT was calculated by taking a mean of the IMT 
measurements. 
2.3.3 Risk Factor Assessment 
All participants underwent a physical examination, completed a lifestyle questionnaire and 
a laboratory assessment as described previously.118,201,202 Body weight and height were measured 
while the participant was wearing light clothing without shoes. Body-mass index (BMI) was 
calculated as weight in kilograms divided by the square of the height in meters. Blood pressure 
was measured - after the participant emptied his bladder and sat quietly for 5 min- twice on right 
arm with an automated sphygmomanometer (BP-8800, Colin Medical Technology, Komaki, 
Japan) using an appropriate sized cuff with; the average of the two measurements was used. 
Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood 
pressure (DBP) ≥90 mmHg or use of anti-hypertensive medications. 203 Venipuncture was 
performed early in the clinic visit after a 12-hour fast. Blood samples were stored at −80°C and 
shipped on dry ice to the University of Pittsburgh. Serum lipids were determined using the protocol 
standardized by the Centers for Disease Control and Prevention. 204 Hyperlipidemia was defined 
as LDL-c ≥ 160 mg/dl or use of lipid-lowering medications.205 Serum glucose was determined by 
using hexokinase–glucose-6-phosphate-dehydrogenase enzymatic assay. Diabetes was defined as 
individuals with fasting glucose ≥126 mg/dl or use of medications for diabetes. 206 Alcohol 
drinking was defined as intake ≥ twice/week. Ever smoking was defined as current or past cigarette 
smoking. Use of blood pressure-lowering, diabetes, and lipid-lowering medication was ascertained 
through questionnaire. Data collection procedures were standardized across all centers. 
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2.3.4 Statistical Methods 
Descriptive characteristics, as well as segment-wise presence of carotid plaque, were 
assessed after stratification by race. To compare the prevalence of carotid plaque between these 
population groups, crude, age-BMI adjusted, and multivariable-adjusted prevalence ratios were 
calculated through log-binomial regression using GENMOD procedure in SAS. When any of the 
above models failed to converge, the prevalence ratio was calculated using log-poisson regression 
with robust variance estimator.207 
To examine which CVD risk factors were associated with the presence of carotid plaque, 
forward-selection logistic regression analysis was performed in a combined sample of the four 
racial groups. Carotid plaque presence was kept as the outcome variable and following variables 
as the predictor variables in the regression model – age, BMI, SBP, glucose, ever smoking, 
alcohol drinking status, HDL-c, LDL-c, and triglycerides (log-transformed). Alpha was set at 
0.05 for determining statistical significance. As a confirmatory analysis, the above analyses was 
performed using traditional logistic regression model forcing all the above variables in the 
regression equation. All analyses were performed using SAS/STAT software v9.3 of the SAS 
System, Cary, NC, USA. 
2.4 RESULTS 
2.4.1 Comparison of Risk Factors 
The mean age was about 45 years in all the three population groups. Whites had 
significantly higher BMI than that of Japanese in Japan and Koreans, although Whites had much 
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lower smoking rates than Japanese in Japan and Koreans. Whites had LDL-c similar to Japanese 
men in Japan, while LDL-c was lowest among Korean men. Whites had higher HDL-c than 
Koreans but less than Japanese in Japan. Whites and Koreans had lower hypertension rates than 
Japanese in Japan. Whites had the lowest prevalence of diabetes in the three groups although the 
differences were not statistically significant. (Table 2-1) 
When comparing population characteristics by presence of carotid plaque in the combined 
population of four groups, those with plaque (n=117) were older (46.1±2.8 years vs. 44.8±2.8 
years, p=<0.01), had higher BMI (26.9±4.4 kg/m2 vs. 25.2±3.7 kg/m2, p=<0.01), SBP (125.5±14.6 
mmHg vs. 122.7±13.9 mmHg, p=0.04), glucose (105.4±17.9 mg/dl vs. 103.2±16.4 mg/dl, p=ns), 
diabetes (12.8% vs. 5.2%, p=<0.01), and hypertension (29.9% vs. 17.4%, p=<0.01), while they 
had similar rates of alcohol drinking (50.4% vs. 52.2%, p=ns) and smoking (53.8% vs. 62.3%, 
p=ns). (Table 2-3) 
2.4.2 Carotid Plaque Prevalence 
White men (22.8%) had significantly higher prevalence of carotid plaque as compared to 
Japanese men in Japan (4.8%) and Koreans (10.6%). A majority of participants with prevalent 
carotid plaque had only one plaque in the carotid arteries. In all three race/ethnicities, more plaque 
was present in the carotid bulb than in common carotid or internal carotid artery. (Table 2-2)  
The differences in plaque prevalence were independent of age and BMI (Model I). (Figure 
2-1) The differences remained significant even after further adjusting for other risk factors such as 
hypertension and diabetes (Model II). As compared to Whites, the multivariable adjusted 
prevalence ratio for carotid plaque was 0.18 (95% CI: 0.10, 0.30) for Japanese in Japan, and 0.44 
(95% CI: 0.30, 0.65) for Koreans. The differences remained significant even after further adjusting 
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for carotid IMT (Model III). (Figure 2-1) Similar results were seen after removing participants 
with hypertension, diabetes, and hyperlipidemia from the analysis. 
2.4.3 Risk Factors for Carotid Plaque 
In a race-adjusted logistic regression model created using forward-selection strategy 
(Model A), age, hypertension, diabetes, and ever smoking were significantly associated with the 
presence of carotid plaque. (Table 2-4) These risk factors together explained 18% of the total 
variance (R2) in carotid plaque. When other cardiovascular risk factors were force-entered in the 
model (Model B), the results were similar, and the R2 increased marginally to 19%. (Table 2-4) 
When IMT was further included in the model, the R2 increased from 19% to 33% (Model 
C). In this regression model, IMT had the strong association with the presence of carotid plaque 
with a βstd of 0.56. 
2.5 DISCUSSION 
In this population-based international study among middle-aged men without CVD, wide 
variations in the prevalence of carotid plaque were found, with Whites having about five-fold 
higher prevalence of carotid plaque as compared to Japanese in Japan. Further analysis showed 
that age, hypertension, diabetes, and smoking were independently associated with carotid plaque 
while other cardiovascular risk factors added little to the prediction model. This is the first 
population-based international study to compare the prevalence of carotid atherosclerotic plaque 
among different population groups living in different countries. 
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The prevalence of carotid plaque among Whites was 22.8%, which was significantly higher 
than that in Japanese and Korean men. Similar prevalence (26.6%) of carotid plaque among Whites 
has been reported from the Atherosclerosis Risk in Communities study among 45-49 year old 
men.208 In the Multi-Ethnic Study of Atherosclerosis, 46% of the White men and women aged 
between 45-84 years had carotid artery plaque.199 In Japan, previous studies among older 
populations have reported much higher prevalence than in the present study. In the Suita Study, 
i.e. among 1,694 Japanese in Japan, men (n=814) in age groups of 50-59 years, 60-69 years and 
70-79 years had 79%, 91% and 98% prevalence of carotid plaque respectively. In a smaller 
Japanese study consisting of 100 CVD patients (age: 61±14 years, 76% male) and 132 participants 
with no CVD (age: 58±14 years, 67% male), prevalence of carotid plaque was 59% and 41% 
respectively. However, carotid plaque was defined as IMT > 1.1 mm and IMT > 1.0 mm in these 
Japanese studies, respectively. It is likely that the increased prevalence in previous studies was due 
to older sample population and use of a different definition for carotid plaque. In Korea, a 
population-based study reported approximately 31% prevalence of carotid plaque in a rural 
population free of CVD. This study included both men and women 40-91 years of age (mean ~ 61 
years).209  Another population-based study in a similar age group reported 37% prevalence of 
plaque among men.210 The prevalence of plaque reported in these studies is higher likely due to 
the older population than that in the present study.  
2.5.1 Eastern Asia vs. the US 
Whites had more than four times higher prevalence of carotid plaque than Japanese in Japan 
although Japanese in Japan had higher rates of hypertension, diabetes and smoking, and similar 
levels of LDL-c. The difference remained after adjustment for BMI, smoking, and other CVD risk 
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factors. This author’s group have also reported significantly more coronary atherosclerosis and 
higher IMT among Whites than Japanese in Japan.118 The differences in the prevalence of carotid 
plaque were independent of the differences in carotid IMT. These differences in subclinical 
atherosclerosis are probably due to one or more protective lifestyle factors prevalent among 
Japanese in Japan but absent in the US.   
Koreans had about half the prevalence of carotid plaque than Whites even after adjusting 
for traditional risk factors. Although Koreans share many biologic and lifestyle characteristics with 
Japanese in Japan, Koreans had twice their carotid plaque prevalence. This is in spite of similarities 
in BMI and smoking prevalence, and lower SBP, glucose, LDL-c than Japanese in Japan, although 
Koreans had lower HDL-c and lower prevalence of alcohol drinking. In this sample population, 
Koreans also had higher carotid IMT than Japanese in Japan.211  Further, previous reports have 
identified CHD mortality among South Koreans that is lower than the US but higher than Japanese 
in Japan.212  Thus, similar to Japan, there may be one or more protective factors in the South 
Korean lifestyle that leads to lower atherosclerotic burden in these populations. 
Several studies have tried to assess reasons for lower CHD in Japan.213,214 While higher 
fish intake is consistently shown to be protective against CHD by several observational 
studies120,215,216 and also a clinical trial in Japan,217 low-to-medium dose trials of omega-3 fatty 
acids have failed to show significant benefit in western populations. It is possible that the absence 
of significant benefit in clinical trials in the West was due to omega-3 fatty acid supplementation 
that was less than their average daily intake in Japan over lifetime. Further, it is possible that the 
lower CHD in Japan is due to some other lifestyle/dietary factors or their combination such as very 
high intake of soy products in eastern Asia including Japan. 
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2.5.2 Risk Factors for Plaque 
Of all traditional CVD risk factors, only age, hypertension, and diabetes were significant 
predictors of carotid plaque after adjusting for race in this cross-sectional study. Even in this 
relatively homogenous population of men aged 40-49 years, age was the strongest predictor of 
carotid plaque. In the NOMAS study, i.e. an older population-based cohort in the US comprising 
of 60% Hispanics, age, smoking, SBP, DBP, diabetes, and blood pressure medication use were 
significant predictors of carotid plaque.36 Similarly, Klein et al have reported that in a sample of 
876 clinical patients (mean age: 53.4±12.0 years; 47% female), age, sex, SBP, smoking, diabetes, 
and lipid medication were significant predictors of carotid plaque.35 The present study found lesser 
number of significant predictors than these previous studies, possibly because these studies had 
older populations, and included clinical patients.  
In the present study, 18.16% of the variance in the prevalence of carotid plaque was 
explained by the four significant predictors in the model. Forcing other variables in the model did 
not result in an increase in the R2. Previous studies have reported similar results – in the NOMAS 
study, risk factors explained 19.5% of the carotid plaque variance.36 Similar to the present study, 
age, was the single largest contributor to that R2. Klein et al reported from a clinical population 
the R2 of 48.6% for total carotid plaque area, and R2 of 13.9% for total carotid stenosis.35 
In this study, the differences in plaque prevalence remained even after adjusting for carotid 
IMT. This was somewhat expected as the definition used to identify plaque had a measure of IMT 
in it, i.e. plaque was defined as focal protrusion at least 50% thicker than the surrounding IMT. 
Thus, assessment of plaque in an individual was based on his IMT. Further, while IMT is strongly 
associated with age and blood pressure,218 carotid plaque are atherosclerotic in nature and have a 
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lipid core.219 Thus, it is likely that IMT and carotid plaque have different pathophysiological 
origins. In another study in France, carotid IMT is shown to be a significant predictor of carotid 
plaque occurrence in a 59 to 71 year old population followed over 4 years.220 In the present study 
as well, IMT was the strongest determinant of plaque among all risk factors. Thus, it seems that 
IMT is an important, but not the only, determinant of plaque.   
Results of this study should be interpreted in light of certain limitations. Results of this 
study are based on analysis of cross-sectional data, thus the temporality of association is not 
established. Use of non-invasive assessment limits examination differences in carotid plaque 
characteristics such as presence of intraplaque calcification and hemorrhage. However, 
ultrasonographic carotid artery examination was performed given the population-based design of 
this study. All the participants in this study were males 40-49 years of age, thus limiting the 
generalizability of the findings. Assessing atherosclerosis in this middle-aged sample gives the 
opportunity for potential intervention to prevent the development of future clinical disease. This 
study cannot perform analysis to examine risk factors of carotid plaque in individual races as there 
are few men with carotid plaque among Japanese in Japan and Koreans. A majority of participants 
with prevalent carotid plaque had only one plaque in the carotid arteries; thus presence of carotid 
plaque was used as an indicator for carotid atherosclerotic burden. However, this is the first 
population-based epidemiological study to use a standardized protocol for risk factor and carotid 
plaque assessments across the geographic regions.  
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2.6 CONCLUSION 
Whites have significantly higher carotid atherosclerotic plaque than Japanese in Japan and 
Koreans despite having more desirable profile on several CVD risk factors. These differences are 
not explained by traditional cardiovascular risk factors, and were independent of the carotid IMT. 
2.7  TABLES AND FIGURES
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Table 2-1 Prevalence of carotid plaque and other cardiovascular risk factors among 40-49 year old men in the ERA JUMP Study 
Characteristic Whites (n=310) 
Japanese in Japan 
(n=313) 
Koreans 
(n=301) 
Differences 
(p<0.05) 
1 2 3 
Age (years) 45.0 ± 2.8 45.1 ± 2.8 44.8 ± 2.8 2=1=3 
BMI (kg/m2) 28.0 ± 4.4 23.7 ± 3.1 24.7 ± 2.7 1>3=2 
Systolic Blood Pressure 
(mmHg) 
122.6 ± 11.2 125.0 ± 16.1 121.6 ± 14.1 2>1=3 
Hypertension (%)* 15.2 26.5 15.6 2>3=1 
Glucose (mmol/l) 5.65 ± 0.86 5.93 ± 1.04 5.71 ± 1.0 2>3=1 
Diabetes (%)† 3.6 6.1 9.6 3=2=1 
Ever Smoking (%) 27.1 82.8 74.1 2>3>1 
Current alcohol drinker 
(%)‡ 
44.3 67.3 44.0 2>1=3 
LDL-cholesterol 
(mmol/l) 
3.48 ± 0.86 3.42 ± 0.93 3.00 ± 0.82 1=2>3 
HDL-cholesterol 
(mmol/l) 
1.23 ± 0.33 1.40 ± 0.35 1.18 ± 0.30 2>1>3 
Total cholesterol: HDL-
cholesterol ratio 
4.7 ± 1.3 4.2 ± 1.3 4.4 ± 1.2 1> 3=2 
Triglycerides, mmol/l 
median (IQR) § 
1.46 (1.04, 2.08) 1.55 (1.16, 2.05) 1.51 (1.08, 2.27) 2=3=1 
Medications (%) 
Hypertension 
Diabetes 
Lipid 
8.7 
1.0 
12.3 
5.4 
1.9 
3.5 
4.6 
0.3 
1.3 
1=2=3 
2=1=3 
1>2=3 
Intima-Media thickness 0.68 ± 0.10 0.61 ± 0.07 0.66 ± 0.09 1>3>2 
Values are mean ± SD unless otherwise mentioned. 
* - Hypertension was defined as presence of one or more of following – i) Systolic blood pressure (BP) ≥140 mmHg, ii) Diastolic
BP ≥90 mmHg, or iii) use of antihypertensive medication 
† - Diabetes was defined as either glucose ≥7 mmol/L or use of diabetic medication, or both   
‡ - Alcohol drinking was defined as 2 or more drinks per week; § - IQR  - Interquartile range 
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Table 2-2. Site-specific prevalence of carotid plaque in the four population groups 
White 
(n=310) 
Japanese in 
Japan 
(n=313) 
Koreans 
(n=301) Difference 
Plaque 
prevalence (%) 
22.8 4.8 10.6 1>3>2 
Plaque in CCA 
(%) 
0.6 0.3 0.3 1=3=2 
Plaque in bulb 
(%) 
16.9 3.5 9.3 1>3>2 
Plaque in ICA 
(%) 
10.1 1.6 2.3 1>3=2 
CCA: common carotid artery; ICA: internal carotid artery 
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Table 2-3 Prevalence of carotid plaque and other cardiovascular risk factors among 40-49 year old men in the 
ERA JUMP Study 
Plaque present 
(n=117) 
No Plaque 
(n=803) 
p-value 
Age (years) 46.1 ± 2.8 44.8 ± 2.8 <0.01 
BMI (kg/m2) 26.9 ± 4.4 25.2 ± 3.7 <0.01 
Systolic Blood Pressure 
(mmHg) 
125.5 ± 14.6 122.7 ± 13.9 0.04 
Hypertension (%)* 29.9 17.4 <0.01 
Glucose (mg/dl) 105.4 ± 17.9 103.2 ± 16.4 ns 
Diabetes (%)† 12.8 5.2 <0.01 
Ever Smoking (%) 53.8 62.3 Ns 
Current alcohol drinker 
(%)‡ 
50.4 52.2 ns 
LDL-cholesterol (mg/dl) 133.7 ± 35.3 127.0 ± 34.7 0.05 
HDL-cholesterol (mg/dl) 47.5 ± 13.6 49.5 ± 13.1 0.12 
Total cholesterol: HDL-
cholesterol ratio 
4.7 ± 1.3 4.4 ± 1.3 0.02 
Triglycerides, mg/dl  
median (IQR) § 
131 (95, 201) 132 (97, 183) ns 
Medications (%) 
Hypertension 
Diabetes 
Lipid 
13.7 
3.4 
8.6 
5.0 
0.6 
5.4 
<0.01 
<0.01 
ns 
Intima-Media thickness 0.75 ± 0.12 0.63 ± 0.08 <0.01 
Values are mean ± SD unless otherwise mentioned. 
* - Hypertension was defined as presence of one or more of following – i) Systolic blood
pressure (BP) ≥140 mmHg, ii) Diastolic BP ≥90 mmHg, or iii) use of antihypertensive 
medication 
† - Diabetes was defined as either glucose ≥126 mg/dl or use of diabetic medication, or both  
‡ - Alcohol drinking was defined as 2 or more drinks per week 
§ - IQR  - Interquartile range
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Figure 2-1 Prevalence Ratio of Carotid plaque among the three races in the ERA JUMP study 
0
0.2
0.4
0.6
0.8
1
1.2
Crude Model Model I Model II Model III
Japanese in Japan
Koreans
White (ref)
White was treated as the referent category in the analyses 
All prevalence ratios in the analyses were significant at p-value <0.01 
Crude Model: Unadjusted model 
Model I: Age, BMI- adjusted  
Model II: Model I + SBP, total cholesterol: HDL-cholesterol ratio, diabetes, hypertension, 
smoking, and alcohol drinking 
Model III: Model II + carotid intima-media thickness 
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Table 2-4 Regression models for prediction of Plaque in the ERA JUMP study 
Model Variable Standardized β 
(βstd) 
β SEM p-value R2 
M
od
el
 A
*,
†  Age 0.2899 0.1870 0.0403 <0.0001 
18% Hypertension 0.3392 0.1277 0.0079 
Diabetes 0.5040 0.1855 0.0066 
M
od
el
 B
*,
‡  
Age 0.2844 0.1834 0.0407 <0.0001 
19% 
Hypertension 0.3313 0.1331 0.0128 
Total 
cholesterol: 
HDL-
cholesterol ratio 
0.0945 0.1361 0.1046 0.1933 
Diabetes 0.4876 0.1883 0.0096 
BMI 0.0173 0.0082 0.0313 0.7926 
Ever Smoking 0.1497 0.1249 0.2305 
Drinking 
frequency 
0.0591 0.1137 0.6034 
Triglyceride 
(log) 
0.0111 0.0404 0.2404 0.8665 
M
od
el
 C
 
Age 0.2277 0.1467 0.0445 0.0010 
33% 
Hypertension 0.2095 0.1440 0.1456 
Total 
cholesterol: 
HDL-
cholesterol ratio 
-0.0113 -0.0163 0.1152 0.8878 
Diabetes 0.2305 0.2088 0.2696 
BMI -0.0803 -0.0382 0.0347 0.2712 
65 
Ever Smoking 0.2709 0.2686 0.3131 
Drinking 
frequency 
0.0144 0.1230 0.9070 
Triglyceride 
(log) 
0.0117 0.0428 0.2913 0.8832 
Carotid IMT 0.5596 10.9479 1.3497 <0.0001 
* Models were additionally adjusted for Race
† Model A was developed using forward-selection strategy in logistic regression with p-value for 
significance at 0.05 
‡ Model B was traditional model with risk factors forced into the logistic regression  
Model C: Model B + Carotid IMT 
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Table 2-4 contd.
3.0  BRACHIAL-ANKLE PULSE WAVE VELOCITY IS ASSOCIATED WITH CORONARY 
ATHEROSCLEROSIS AMONG 1,171 HEALTHY MIDDLE-AGED MEN 
3.1 ABSTRACT 
Background: Brachial-ankle pulse wave velocity (baPWV) is a simple and reproducible 
measure of arterial stiffness, and is extensively used to assess cardiovascular disease risk in eastern 
Asia. This study examined whether baPWV is associated with coronary atherosclerosis in an 
international cohort of apparently healthy middle-aged men.  
Methods: A population-based sample of 1,171 men aged 40-49 years was recruited – 281 
White and 83 Black men in Pittsburgh, US, 235 Japanese-Americans in Honolulu, US, 292 
Japanese in Otsu, Japan, and 280 Koreans in Ansan, Korea. baPWV was measured with an 
automated waveform analyzer (VP2000, Omron) and atherosclerosis was examined as coronary 
artery calcification (CAC) by computed-tomography (GE-Imatron EBT scanner). Association of 
the presence of CAC (defined as ≥10 Agatston unit) was examined with continuous measure as 
well as with increasing quartiles of baPWV. 
Results: As compared to quartile 1 of baPWV, the multivariable-adjusted odds ratio (95% 
confidence-interval [CI]) for presence of CAC in the combined sample was 1.72 (1.00, 2.96) for 
2nd quartile, 1.92 (1.10, 3.34) for 3rd quartile, and 2.25 (1.24, 4.09) for 4th quartile (p-trend = 0.01). 
The odds for CAC were higher by 20% per 100 cm/s increase (p<0.01), or by 38% per standard-
deviation increase (p<0.01) in baPWV. There was no difference in this association by race. 
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Conclusion: baPWV is cross-sectionally associated with CAC among healthy middle-aged 
men. The association is consistent among different races. Longitudinal studies are needed in the 
West to determine its CVD predictive ability. 
3.2 INTRODUCTION 
Coronary heart disease (CHD) remains the leading cause of mortality in the United States 
(US) in spite of a significant decline in age-adjusted CHD over the past 5 decades.1 The burden of 
CHD is likely to increase by 16% over the next 20 years due to an aging population and increased 
survival after suffering from a coronary event.99 One of the current strategies for further reducing 
CHD is to identify and implement prevention strategies among individuals who are at an 
intermediate CHD risk according to the current risk prediction tools, and who would benefit most 
from CHD prevention therapy.29 
Coronary artery calcification (CAC), assessed by computed-tomography scan (CT), is a 
strong independent predictor of future CHD events among asymptomatic individuals. Use of CAC 
imaging is currently recommended among individuals who are at low to intermediate risk i.e.10-
year risk of cardiovascular disease (CVD) risk between 6%-20%.14 However, CAC imaging 
exposes an individual to ionizing radiation, which may limit its wider applicability as a screening 
tool. Also, the cost-effectiveness of routine CT imaging among asymptomatic individuals is not 
yet established.18 
Brachial-ankle pulse wave velocity (baPWV) is a highly reproducible measure of arterial 
stiffness that has shown promise as a predictor of future CVD among east Asian populations.67 
Unlike carotid-femoral pulse wave velocity (cfPWV), which is a measure of central arterial 
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stiffness, baPWV likely is a combined measure of central and peripheral arterial stiffness.221 
Although cfPWV is considered as gold standard marker for central arterial stiffness and a predictor 
of future CHD, despite much work, it has not gained acceptance into clinical practice in the US222 
– possibly due to operator training and expertise, and also patient’s discomfort with groin 
exposure. In contrast, baPWV is currently used routinely in Japan and South Korea to assess CVD 
risk. baPWV is convenient to measure in a clinic, requires little technical expertise, and, unlike 
cfPWV, does not require exposure to the inguinal region. The author’s research group has 
previously reported a significant association between baPWV and the presence of CAC among 
obese post-menopausal women in the US.223 However, the utility of baPWV in the US remains to 
be thoroughly examined.224,225 
Therefore, the association between baPWV and presence of CAC was examined in the 
Electron beam computed tomography and Risk factor Assessment among Japanese and U.S. Men 
in the Post-World War II birth cohort (ERA JUMP Study), an international study of subclinical 
atherosclerosis among 40-49 year old men. The hypothesis was that baPWV is significantly 
associated with presence of CAC in this healthy sample of middle-aged men. 
3.3 METHODS 
3.3.1 Participants 
During 2002–2006, a population-based sample of 1,335 men aged 40–49 years, with no 
clinical CVD or other severe diseases, was obtained from 4 centers: 310 Whites and 107 Blacks 
from Pittsburgh, Pennsylvania, US; 303 Japanese Americans from Honolulu, Hawaii, US; 313 
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Japanese from Kusatsu city, Shiga, Japan; and 302 Koreans from Ansan, Gyeonggi-do, South 
Korea as previously described.118 Written informed consent was obtained from all participants. 
The study was approved by the Institutional Review Boards of the following institutions: the 
University of Pittsburgh, Pittsburgh, Pennsylvania, US; the Kuakini Medical Center, Honolulu, 
Hawaii, US; Shiga University of Medical Science, Otsu, Japan; and Korea University, Seoul, 
South Korea. 
3.3.2 Pulse Wave Velocity Assessment 
At the start of the study, staff from the University of Pittsburgh’s Ultrasound Research 
Laboratory visited the Honolulu site to train the sonographers in Honolulu and from South Korea 
for PWV measurements. In addition, continuous quality control measures were implemented for 
all the sites, including Japan. PWV measurements were automatically generated using a 
noninvasive and automated waveform analyzer (VP2000, Omron, Japan). This device provides 
automated measures of baPWV on both right and left sides – average of the two sides was used. 
Following 10 min of rest in a supine position, occlusion and monitoring cuffs were placed around 
both arms and both ankles of the participant. The arm cuffs were placed on the skin or over light 
clothing, and the ankle cuffs were directly placed over the skin. ECG electrodes were placed on 
both wrists and a phonocardiogram i.e. a microphone for detecting heart sounds was placed on the 
left edge of the sternum. The path length for baPWV was calculated using height-based formulae.71 
PWV was calculated as the distance between arterial sites divided by the time between the feet of 
the respective waveforms. Intra-class correlations (ICC) for re-examination of baPWV was 0.97 
within technician, and 0.91 between technicians.73 
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3.3.3 Coronary Artery Calcification 
CAC scanning was performed with a GE-Imatron C150 EBT scanner (GE Medical 
Systems, South San Francisco, California) at all centers as published elsewhere in detail.121 Briefly, 
a standardized protocol was used to perform CAC scanning; 30–40 contiguous, 3-mm-thick 
transverse images from the level of the aortic root to the apex of the heart were obtained during 
maximal breath holding by using electrocardiogram triggering (60 percent of the R-R interval) so 
that each 100 millisecond exposure was obtained during the same phase of the cardiac cycle.121 
One trained reader at the University of Pittsburgh read the images using a DICOM (Digital 
Imaging and Communications in Medicine) workstation and software by AccuImage (AccuImage 
Diagnostic Corporation, San Francisco, California). The software program implements the widely 
accepted Agatston scoring method.226 Coronary artery calcification was considered to be present 
when 3 contiguous pixels (area = 1 mm2) greater than 130 Hounsfield Unit (HU) were detected 
overlying the vessels of interest.  A coronary calcium score (CCS) was then calculated for each 
region of interest by multiplying the area of all significant pixels by a grade number (1, 2, 3, 4) 
indicative of the peak computed tomography number (HU). The individual region of interest scores 
was then summed for a total CCS. The reader was blinded to the participant’s characteristics and 
the study centers. ICC for re-examination of electron-beam computed tomography scans was 0.98. 
Presence of CAC was defined as ≥ 10 Agatston Unit (AU) as a score between 0-10 is likely to be 
noise;121 a cut-off value of 10 AU maximizes the positive predictive value of CAC for underlying 
plaque disease by minimizing any contribution from beam hardening or motion artifact.  
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3.3.4 Risk Factor Assessment 
All participants underwent a physical examination, completed a lifestyle questionnaire, and 
a laboratory assessment as described previously.118,201,202 Body weight and height were measured 
while the participant was wearing light clothing without shoes. Body-mass index (BMI) was 
calculated as weight in kilograms divided by the square of the height in meters. Blood pressure 
was measured – after the participant emptied his bladder and sat quietly for 5 min – twice on right 
arm with an automated sphygmomanometer (BP-8800, Colin Medical Technology, Komaki, 
Japan) using an appropriate sized cuff; average of the two measurements was used. Hypertension 
was defined as systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) 
≥90 mmHg or use of anti-hypertensive medications.203 Venipuncture was performed early in the 
clinic visit after a 12-hour fast. Blood samples were stored at −80°C and shipped on dry ice from 
all centers to the University of Pittsburgh. Serum lipids were determined using the protocol 
standardized by the Centers for Disease Control and Prevention.204 Serum glucose was determined 
by using hexokinase–glucose-6-phosphate-dehydrogenase enzymatic assay. Diabetes was defined 
as individuals with fasting glucose ≥126 mg/dl or use of medications for diabetes.206 Alcohol 
drinking was defined drinking two or more times per week. Smoking was measured as history of 
ever smoking. Use of blood pressure-lowering, diabetes, and lipid-lowering medication were 
ascertained through questionnaire. Data collection procedures were standardized across all centers. 
Following participants were excluded: those taking antihypertensive medications (n=140), 
those with extreme outliers i.e. CAC >1,000 AU (n=3), and those with extremely high baPWV i.e. 
baPWV >2,000 cm/s (n=4). The final sample for this study consisted of 1,171 men (281 Whites, 
83 Blacks, 235 Japanese Americans, 292 Japanese in Japan, and 280 Koreans) with complete data. 
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3.3.5 Statistical Methods 
Descriptive characteristics of the sample population were examined, including 
demographics, CVD risk factors, baPWV, and CAC. Comparisons of population characteristics 
were made using t-tests for continuous variables, and chi-square tests for categorical variables. 
Non-parametric tests were used for skewed variables. Logistic regression was used to examine the 
association between baPWV (per 100 cm/s increase, per 1 SD increase) and presence of CAC (≥ 
10 AU) – in an unadjusted model (crude model), in an age-race adjusted model (Model I), as well 
as in multivariable models adjusted for CVD risk factors including race, age, SBP, LDL-c, ever 
smoking, and diabetes (Model II), and further adjusting for HDL-c, BMI and alcohol drinking 
(Model III). Unadjusted analysis was also performed after stratification by race-ethnicity. Further, 
baPWV was categorized into quartiles and its association with the presence of CAC was examined 
keeping lowest quartile of baPWV as the reference category. Similar to the previous analysis, the 
association was examined using unadjusted model, race-adjusted, and multivariable-adjusted 
models in logistic regression. Interaction analysis was performed to examine the differences in the 
association of baPWV with CAC; further, unadjusted analyses was performed after stratification 
by race. All data analysis was performed using SAS/STAT software, version 9.3 of the SAS 
System, Cary, NC, USA.     
3.4 RESULTS 
Participants with CAC (n=207) were slightly older (46.0 vs. 44.9 years, p<0.001), had 
higher BMI (27.6 vs. 25.5 kg/m2, p<0.001), SBP (126.4 vs. 122.7 mmHg, p<0.001), LDL-c (136.0 
vs. 126.4 mg/dl, p<0.001), and triglycerides (148 vs. 129 mg/dl, p<0.01) than those with no CAC 
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(n=964). Prevalence of diabetes was also higher among those with CAC (9.7% vs. 5.6%, p=0.03). 
Further, baPWV was significantly higher among those with CAC (1392.6 vs 1317.0 cm/s among 
those with no CAC, p<0.001). (Table 3-1) The mean (SD) of baPWV (cm/s) among individual 
races was: Whites 1313.9(151.3), Blacks 1374.2(164.0), Japanese Americans 1414.4(160.5), 
Japanese in Japan 1296.1(175.6), and Koreans 1294.8(138.1). The prevalence of CAC increased 
successively with increasing baPWV. (Figure 3-1) With every 100 cm/s increase in baPWV, the 
odds for presence of CAC increased by 30% (p<0.001) in the crude model, 27% (p<0.001) after 
adjustment for age and race (Model I), and 19%-20% (p<0.01) in multivariable-adjusted models 
(model II and model III). Similarly, with every 1 SD increase in baPWV, the odds for CAC 
increased by 61% (p<0.001), 52% (p<0.001), and 38% (p<0.01) in crude, age-race adjusted and 
multivariable adjusted models respectively. (Table 3-2) When examining baPWV by quartiles, a 
significant trend was seen for increasing prevalence of CAC with increasing baPWV quartiles in 
unadjusted and age-race adjusted models, as well as after multivariable-adjustment. 
Among individual race-ethnicities, the prevalence of CAC was: Whites (24.9%), Blacks 
(15.7%), Japanese Americans (28.1%), Japanese in Japan (10.3%), and Koreans (10.0%). There 
was no significant interaction between race and baPWV in the model for the presence of CAC 
(p=0.28). When analysis was performed after stratifying by race, in unadjusted model, the 
association between baPWV and CAC prevalence was significant among Whites (OR: 1.30 per 
100 cm/s increase; p<0.01), Blacks (OR: 1.63 per 100 cm/s increase, p<0.01), and Koreans (OR: 
1.36 per 100 cm/s increase; p=0.03); the association was not significant among Japanese 
Americans and Japanese in Japan although the odds for presence of CAC were higher with higher 
baPWV. (Table 3-2) When examining baPWV by quartiles in individual races, the analysis could 
not be performed among Blacks due to sample size limitations. Among other races, the p-trend for 
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higher presence of CAC with higher quartiles of baPWV was significant among Whites in 
unadjusted models. (Table 3-3)    
3.5 DISCUSSION  
This study reports that baPWV iss associated with coronary atherosclerosis among middle-
aged men without CVD. This association was independent of traditional CVD risk factor and did 
not differ by race. This is the first international study to examine the association between baPWV 
and coronary atherosclerosis among healthy middle-aged men.  
Previous studies have reported similar association of baPWV with CAC among 504 obese 
postmenopausal women in the US,223 and among 654 patients without CVD in Taiwan.227 In the 
US, the author’s group has previously shown that among 504 obese postmenopausal women, the 
multivariable-adjusted odds ratio for presence of any CAC (>0 AU) were 1.94 (95% CI 1.01, 3.70), 
2.90 (95% CI 1.50, 5.58), and 2.21 (95% CI 1.11, 4.42) for quartiles 2, 3, and 4 respectively as 
compared to quartile 1 of baPWV; the strength of association was stronger for baPWV than for 
cfPWV.223 Similarly, in the Taiwanese study, the mean (±SD) CAC score increased (35.7 ± 173.6, 
100.2 ± 249.7, and 227.6 ± 412.5, p-trend<0.001) with increasing baPWV (<1400 cm/s, 1400 
cm/s-1800 cm/s, and >1800 cm/s). Further, addition of baPWV to Framingham Risk Score (FRS) 
improved the area under curve (AUC) for prediction of CHD from 0.676 to 0.728.227  Several 
clinical studies in eastern Asia have shown an association of baPWV with other intermediate CVD 
outcomes. For example, baPWV is reported to be positively associated with coronary stenosis in 
Korea,228-230 Japan,231  Taiwan227, and China.232 The present study’s sample population was 
healthier than these previous studies i.e. the present sample was younger and population-based. 
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Additionally, the mean baPWV in the present sample population was less than the baPWV 
reported from these studies. Examining this association among healthy men allowed the 
assessment of the utility of baPWV as an early marker of CVD in an asymptomatic population.  
baPWV likely measures arterial stiffness over the central and peripheral arterial tree. In 
contrast, cfPWV – a widely accepted marker of arterial stiffness – primarily measures stiffness in 
the central aortic trunk. Increased smooth muscle in the peripheral arteries, as compared to aorta, 
may lead to increased velocity of transmission of the pulse wave in the peripheral vasculature. 
This at least partly explains the increased PWV seen in the brachial-ankle region as compared to 
the cfPWV. However, given that aorta forms a large portion of the brachial-ankle region, 58% of 
the variation in baPWV can be explained by aortic PWV.233 Further research is needed to examine 
pathogenesis of arterial stiffness especially within the peripheral muscular arteries. 
Several factors may account for the association between baPWV and coronary 
atherosclerosis. Firstly, the pathogenesis of arterial stiffness possibly shares some common risk 
factors with atherosclerosis234,235 – this is more likely in the peripheral muscular arteries than in 
the central aortic trunk. This author has previously shown that atherogenic lipoprotein particles are 
associated with baPWV and femoral-ankle pulse wave velocity, but not cfPWV.78 Secondly, 
arterial stiffness increases the mechanical stress on the arterial wall. This triggers molecular 
cascades that further triggers the growth of microvasculature within the vessel walls, and 
ultimately leads to microvasculature remodeling and damage.236 These microscopic changes may 
be a fertile ground for the formation of atherosclerotic lesions. Finally, arterial stiffening reduces 
the cushioning effect of the aortic trunk that helps in maintaining coronary blood flow during the 
diastole. It increases cardiac afterload, thus increasing left-ventricular mass and requirement for 
coronary blood flow.237   
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baPWV has a potential for wide clinical application. A recent meta-analysis reported that 
baPWV is an independent predictor of total cardiovascular events, cardiovascular mortality, and 
all-cause mortality. However, 17 out of 18 studies used in this meta-analysis were conducted in 
eastern Asia. baPWV measurement is inexpensive, can be performed in a physician’s office, 
requires little operator’s expertise, and does not require exposure to the inguinal area. Currently, 
it is widely used in clinics in Japan and South Korea to assess the risk of future CVD. However, 
several concerns need to be addressed before it can be used as a clinical tool in the US, most 
important of which are determination of normal reference values and applicability among Western 
populations.  
These results should be interpreted in light of certain study limitations. As the present study 
is cross-sectional, temporality of the association between baPWV and CAC cannot be determined; 
a scenario in which CAC leads to increase in baPWV, however, seems unreasonable. Results of 
this study are not generalizable to older populations as the sample consisted of middle-aged men 
within a relatively narrow age range. However, use of this sample population allows examination 
of the study hypothesis in the age-group in which baPWV is most likely to be useful as an early 
screening tool. Presence of CAC was defined as ≥ 10 AU as CAC score between 0 and 10 is likely 
to be noise. Few participants in the present study had clinically significant CAC (≥400 AU) 
(n=19),238 and thus, association of baPWV with clinically significant CAC could not be tested. 
The limited sample size within each race/ethnicity limits the ability to perform multivariable 
adjustment in race-specific analysis in this study. 
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3.6 CONCLUSION  
In conclusion, in a population-based sample of healthy middle-aged men without CVD, 
baPWV is independently associated with coronary atherosclerosis measured by CAC imaging. 
This association was consistent among Whites and Blacks in the US. Longitudinal studies to 
examine ability of baPWV to predict coronary atherosclerosis and CVD events in the US 
population are needed. 
3.7 TABLES AND FIGURES 
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Table 3-1 Presence of cardiovascular risk factors among 40-49 year old men in the ERA JUMP Study, by 
presence of CAC (≥10 AU) 
Population characteristic CAC (n=207) No CAC (n=964) p-value 
Age (years) 46.0 (2.6) 44.9 (2.9) <0.001 
BMI (kg/m2) 27.6 (4.5) 25.5 (3.8) <0.001 
Race/ethnicity (%) 
Whites 
Blacks 
Japanese Americans 
Japanese in Japan 
Koreans 
24.9 
15.7 
28.1 
10.3 
10.0 
75.1 
84.3 
71.9 
89.7 
90.0 
<0.001 
Systolic Blood Pressure 
(mmHg) 
126.4 (12.6) 122.7 (13.3) <0.001 
Hypertension (%)$ 16.4 13.6 ns 
Glucose (mmol/l) 5.9 (0.8) 5.8 (1.0) ns 
Diabetes (%)‡ 9.7 5.6 0.03 
Pack years of smoking† 0.8 (0.0, 21) 1.1 (0.0, 18.9) ns 
Ever Smoking (%) 53.6 54.0 ns 
Ethanol intake (g/day)† 8.2 (0.4, 28.4) 7.5 (0.2, 24.7) ns 
Alcohol drinker (%) 49.3 47.3 ns 
LDL-cholesterol (mmol/l) 3.5 (0.9) 3.3 (0.9) <0.001 
HDL-cholesterol (mmol/l) 1.3 (0.4) 1.3 (0.3) ns 
Triglycerides, mmol/l† 1.7 (1.1, 2.4) 1.5 (1.0, 2.1) <0.01 
baPWV (cm/s) 1392.6 (162.3) 1317.0 (160.7) <0.001 
CAC Score† 42.3 (20.1, 96.5) NA 
CAC Score ≥ 100 AU (%) 23.7 NA 
Values are mean ± SD unless otherwise mentioned. 
$ - Hypertension was defined as presence of one or more of following – i) Systolic blood 
pressure (BP) ≥140 mmHg, ii) Diastolic BP ≥90 mmHg, or iii) use of antihypertensive 
medication 
‡ - Diabetes was defined as either glucose ≥7 mmol/l or use of diabetic medication, or both  
† -Median (IQR) 
ns = not significant 
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CAC = Coronary Artery Calcification, AU = Agatston unit, LDL = low-density lipoprotein 
cholesterol, HDL = high-density lipoprotein cholesterol, baPWV = brachial-ankle pulse wave 
velocity, BMI = body-mass index, IQR = inter-quartile range 
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Table 3-1 contd.
CAC = coronary artery calcification, AU = Agatston unit, baPWV = brachial-ankle pulse 
wave velocity 
Figure 3-1 Prevalence of CAC (10- <100 AU and ≥100 AU) with baPWV 
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Model I: Age, Race-adjusted. 
Model II: Model I + systolic blood pressure, low-density lipoprotein cholesterol, 
ever smoking and diabetes 
Model III: Model II + high-density lipoprotein cholesterol, alcohol drinking and 
body-mass index 
Figure 3-2 Association between baPWV and CAC: odds ratios for presence of CAC (≥10 AU) 
with increasing quartiles of baPWV (n=1,171) 
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Table 3-2 Association between baPWV and CAC: odds ratio for presence of CAC (≥ 10 AU) using continuous 
variables of baPWV 
baPWV 
 (per 100 cm/s) 
baPWV  
(per SD change) P-value 
Crude 1.31 (1.20, 1.44); 1.61 (1.37, 1.90); p<0.001 
Model I 1.24 (1.12, 1.37); 1.46 (1.22, 1.74); p<0.001 
Model II 1.19 (1.06, 1.34); 1.36 (1.10, 1.67); p=0.004 
Model III 1.20 (1.06, 1.35); 1.38 (1.12, 1.70); p=0.003 
Race-Specific Analysis** 
baPWV (per 100 cm/s) baPWV (per SD change) P-value 
Caucasian 
(n=281) 1.30 (1.07, 1.58); 1.49 (1.11, 2.01); p=0.009 
African American 
(n=83) 1.83 (1.22, 2.73); 3.03 (1.45, 6.33); p=0.003 
Japanese American 
(n=235) 1.17 (0.98, 1.40); 1.32 (0.97, 1.81); p=0.078 
Japanese in Japan 
(n=292) 1.15 (0.94, 1.41); 1.31 (0.88, 1.93); p=0.183 
Koreans 
(n=280) 1.36 (1.03, 1.79); 1.55 (1.04, 2.31); p=0.030 
Model I: Age, Race-adjusted. 
Model II: Model I + systolic blood pressure, low-density lipoprotein-cholesterol, ever smoking, alcohol 
drinking, and diabetes 
Model III: Model II + high density lipoprotein cholesterol, body-mass index 
CAC = coronary artery calcification, baPWV = brachial-ankle pulse wave velocity, AU = Agatston 
unit, SD = standard deviation  
** Race-specific analysis was unadjusted for confounders. No significant interaction was present by 
race 
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Table 3-3 Odds ratio for presence of CAC (≥ 10 AU) with increasing quartiles of baPWV 
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trend 
Caucasian 
(n=251) 1 3.13 (1.22, 8.04) 4.00 (1.54, 10.39) 4.22 (1.57, 11.33) 0.02 
Japanese American 
(n=202) 1 0.69 (0.20, 2.44) 1.24 (0.40, 3.86) 1.58 (0.53, 4.69) 0.31 
Japanese in Japan 
(n=281) 1 2.38 (0.84, 6.73) 1.84 (0.56, 6.00) 2.19 (0.70, 6.88) 0.41 
Korean 
(n=277) 1 1.11 (0.34, 3.59) 2.69 (0.96, 7.56) 1.61 (0.43, 6.06) 0.20 
* Unadjusted models
** Analysis could not be performed due to small sample size among Blacks  
CAC = Coronary Artery Calcification, baPWV = brachial-ankle pulse wave velocity, SD = Standard deviation 
Analysis could not be performed among African-Americans due to limited sample size 
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4.0  EQUOL PRODUCER STATUS, BUT NOT SERUM ISOFLAVONES, IS ASSOCIATED 
WITH LOWER CORONARY ATHEROSCLEROSIS AMONG HEALTHY JAPANESE MEN  
4.1 ABSTRACT  
Objective: Epidemiological studies in Asia, where consumption of soy isoflavones is 
regular, implicate that isoflavones are protective against coronary heart disease (CHD), especially 
among post-menopausal women. Equol is a derivative of daidzein, a common soy isoflavone, and 
is said to have stronger anti-atherosclerotic properties than other isoflavones. Individuals who have 
intestinal bacteria to convert daidzein to equol are commonly termed as “equol producers”. The 
aim of this study was to examine a cross-sectional association of serum levels of soy isoflavones 
and equol producer status with the presence of coronary artery calcification (CAC) among men in 
Japan. 
Materials and Methods: A population-based sample of 303 men aged 40-49 years in 
Japan was recruited in 2002-06. Risk factors of coronary heart disease were measured. Coronary 
calcium score (CCS) was calculated with the Agatston’s method; the presence of CAC was defined 
as a CCS ≥ 10. Stored samples at -80°C were analyzed to determine serum levels of isoflavones 
and equol. Serum level of equol ≥83 nM was used as the criterion to determine equol producer 
status. The association of tertiles of isoflavones and equol producer status with the prevalence of 
CAC was analyzed using multiple logistic regression model. Further analyses was performed after 
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excluding very heavy drinkers of alcohol (≥69 grams/day) as these men are previously reported to 
have much burden of coronary atherosclerosis. 
 Results: The median (interquartile range) of isoflavones and equol were 482 (192, 1,082) 
nM and 10 (0, 33) nM, respectively. A median (75th, 90th and 95th percentile) of CCS was 0 (1.5, 
15.4, and 40.9). About 16% of the participants were equol producers. These was no significant 
association between tertiles of soy isoflavones and CAC. After excluding very heavy alcohol 
drinkers (n=31), the prevalence of CAC was much lower among equol producers (2.3%) than 
among non-producers (10.9%). After multivariable adjustment, the odds for presence of CAC were 
significantly lower among equol producers (OR=0.10, 95% CI: 0.01, 0.96) than among equol non-
producers. 
Conclusions: Among men in Japan, there was no association between serum isoflavones 
and CAC. However, equol producers had a significantly lower CAC than equol non-producers, 
suggesting that the anti-atherosclerotic properties of isoflavones in Japanese in Japan may be 
mediated through equol.   
4.2 INTRODUCTION 
While several dietary nutrients have been examined for their anti-atherosclerotic 
properties,239 the contribution of soy isoflavones in preventing CHD is not completely understood. 
Soy isoflavones such as daidzein and genistein are regular components of diet in east Asian 
countries such as Japan due to regular consumption of soy products such as tofu and miso. While 
daidzein and genistein are obtained directly from plant sources, equol is a structurally similar 
isoflavone derivative produced by the action of intestinal bacteria on daidzein.158 CHD rates are 
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much lower in Japan as compared to the US, despite having very high smoking prevalence, higher 
blood pressure, and similar levels of serum total cholesterol and diabetes prevalence, which are all 
independent risk factors of CHD.240 It is thus possible that soy isoflavones and equol contribute to 
the lower CHD rates in Japan.  
Anti-atherogenic properties of soy isoflavones are reported in animal and in vitro 
studies.140,141,148,241 The association of dietary intake of soy isoflavones with incident CHD is 
reported in several large prospective cohort studies.131,132,242 These studies in Asian countries 
where dietary intake of soy and isoflavones is regular and high reported a significant inverse 
association, especially among post-menopausal women.131,242 In contrast, a study in western 
countries, where the dietary intake of soy isoflavones is negligible compared to the dietary intake 
in Asia, reported no significant association.132 It is, therefore, possible that soy isoflavones exert 
their anti-atherogenic properties only at levels currently consumed in east Asian countries. 
Soy isoflavones are a class of compounds derived mostly from soybeans and classified as 
phytoestrogens because of their structural similarity to estrogen. Common isoflavones found in 
nature are genistin, daidzin, and glycitin, i.e. glucoside forms of genistein, daidzein and glycitein 
respectively. While dietary isoflavones i.e. genistein and daidzein are traditionally examined by 
most studies for their anti-atherosclerotic effects, 130,131 equol – a daidzein derivative – is said to 
have the most potent anti-atherosclerotic effect of all isoflavones. 161 Equol has higher anti-oxidant 
properties, higher bioavailability, and slower clearance rate compared to other isoflavones.161,166-
169 However, only some individuals have the intestinal bacteria to produce equol from daidzein. 
Individuals with regular intake of soy isoflavones and with the capability to produce equol are 
likely to benefit most from the anti-atherosclerotic properties of equol. These individuals, 
commonly termed as “equol producers” in the scientific literature, may have lower atherosclerosis 
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than equol “non-producers.” It is reported that 10-50% of Japanese are equol producers,170-174,178 
while 25-30% of Americans can produce equol. 174,243  However, consumption of soy and soy 
products is low in the US i.e. the mean consumption of isoflavones in the US is <2mg/day.145,146 
In contrast, their average consumption in Japan is 25-50 mg/day.145 Thus, it is unlikely that soy 
isoflavones have any clinically significant anti-atherosclerotic effects at the levels currently 
consumed in the US. In contrast, equol producers in east Asian countries including Japan may have 
clinically significant lower atherosclerosis than non equol-producers. 
Although only a fraction of the population can convert daidzein into equol, equol is now 
available as a dietary supplement.244 The first randomized controlled trial of equol supplement was 
conducted in Japan. In this crossover trial among 54 overweight or obese Japanese men (n=16) 
and women (n=38) conducted over 12 weeks, investigators found that equol supplementation 
resulted in a significant reduction in glycosylated hemoglobin (HbA1c), LDL-c and cardio-ankle 
vascular index, a measure of arterial stiffness.178 Given the effects of equol on CVD risk factors, 
equol can potentially provide an exciting opportunity to further reduce CHD in the US. 
Coronary artery calcification (CAC) on computed tomography scanning is a strong 
independent predictor of CHD.19 No previous studies, however, have examined if the presence of 
CAC is associated with soy isoflavones or equol. The hypothesis for the current study is that among 
apparently healthy men in Japan, the presence of CAC has a significant inverse association with 
serum levels of dietary isoflavones, a reliable biomarker of their dietary intake in a population 
where soy isoflavone consumption is high and regular.245 Further hypothesis was that the presence 
of CAC would be lower among equol producers than equol non-producers in Japan. The 
hypotheses were tested by examining serum levels of isoflavones and equol in a population-based 
sample of 303 men in Japan from the ERA JUMP Study.120 
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4.3 METHODS 
4.3.1 Study Population 
During 2002 to 2006, 303 men aged 40-49 years were randomly selected from Kusatsu, 
Shiga, Japan, as previously reported. 120 All participants were without clinical cardiovascular 
disease or other severe diseases. Informed consent was obtained from all participants. The study 
was approved by the Institutional Review Boards of Shiga University of Medical Science, Otsu, 
Japan and University of Pittsburgh, Pittsburgh, US. 
All participants underwent a physical examination, lifestyle questionnaire, and laboratory 
assessment as described earlier.120 Body weight and height were measured while the participant 
was wearing light clothing without shoes. Body-mass index (BMI) was calculated as weight in 
kilograms divided by the square of the height in meters. Blood pressure was measured – after the 
participant emptied his bladder and sat quietly for 5 min – twice on right arm with an automated 
sphygmomanometer (BP-8800, Colin Medical Technology, Komaki, Japan) using an appropriate 
sized cuff; average of the two measurements was used. Hypertension was defined as systolic blood 
pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg or use of anti-
hypertensive medications.203 Exercise habit was assessed as at least 1 hour of exercise/week. 
Education was ascertained as years of schooling. Venipuncture was performed early in the clinic 
visit after a 12-hour fast. Blood samples were stored at −80°C and shipped on dry ice from all 
centers to the University of Pittsburgh. Serum lipids were determined using the protocol 
standardized by the Centers for Disease Control and Prevention.204 Serum glucose was determined 
by using hexokinase–glucose-6-phosphate-dehydrogenase enzymatic assay. Diabetes was defined 
as individuals with fasting glucose ≥126 mg/dl or use of medications for diabetes.206 Alcohol 
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intake was categorized as nil, 1-23 grams/day, 24-46 grams/day, 46-69 grams/day and >69 
grams/day. Heavy alcohol drinking was defined as > 69 grams/day of alcohol intake. Use of blood 
pressure-lowering, diabetes, and lipid-lowering medication were ascertained through 
questionnaire.  
4.3.2 Measurements of serum isoflavones 
The serum levels of two major forms of dietary isoflavones: daidzein and genistein, were 
measured using the serum samples stored at -80°C at University of Pittsburgh in 2009-12 with a 
modified method of Pumford.246 In brief, daidzein-d4 and genistein-d4(Cambridge Isotope 
Laboratories, Andover, MA) and equol-d4 (Medical Isotopes Inc., Pelham, NH) were added to 
samples and the samples incubated with β-glucuronidase Type H-1(Sigma – Aldrich; St. Louis, 
MO) at 37˚C, overnight. The samples were extracted twice with diethylether and the pooled 
extracts dried under nitrogen. MTBSTFA + 1% TBDMCS, (Thermo-Fisher Scientific, Inc; 
Waltham, MA) was added and the samples heated at 70˚C for 4 hours. The samples were cooled 
and heptane added. The samples were analyzed by GC-MS in the SIM mode: Trace Ultra GC/DSQ 
II (Thermo-Fisher). Column: TR-5MS, 30 m x 0.25 mm; 0.25 µm film (Thermo-Fisher). Injection 
port: 280˚C; column: 200˚C for 1 minute; 25˚C/minute; 320˚C for 8 minutes; transfer line: 320˚C. 
Carrier gas helium at 1.5 mL/min. Ions monitored (m/z): 425/482; 234/470 and 555 for daidzein, 
equol and genistein, respectively; 428/485, 236/474 and 559 for daidzein-d4, equol-d4 and 
genistein-d4, respectively. Coefficients of variation: 6.2% and 7.5% for daidzein (m/z 428 and m/z 
485 and 6.7% for genistein (m/z 555). 
90 
4.3.3 Measurement of CAC 
As described in the previous chapter, the scanning for CAC was done using a GE-Imatron 
C150 Electron Beam Tomography scanner (GE Medical Systems, South San Francisco, US). 
Images were recorded over a disc in Japan and shipped to the University of Pittsburgh to be read 
by a trained reader using a DICOM (Digital Imaging and Communications in Medicine) 
workstation and software by AccuImage (AccuImage Diagnostic Corp., San Francisco, US). The 
software program implements the widely accepted Agatston scoring method. The reproducibility 
of non-zero CCS from this laboratory had an intraclass correlation of 0.98. 
4.3.4 Statistical analyses  
Total serum levels of isoflavones defined as the sum of daidzein and genistein were used 
because serum levels of these two isoflavones were highly correlated, i.e., a Spearman correlation 
coefficient of 0.90 (p<0.01). Tertiles of total serum isoflavones were used as the main independent 
variables in the model because their distribution was highly skewed to the right. To examine the 
trend association of tertiles of total isoflavones with risk and other factors, general linear model 
for the continuous variables and Cochran-Armitage trend test for binary variables was used.   
As described in the previous chapter, a cutoff point of CCS of 10 Agatston unit (AU) was 
used to define the presence of CAC. To analyze the association of CAC with tertiles of serum 
isoflavones, logistic regression to examine the association of prevalence of CAC with tertiles of 
total isoflavones was used. For the analysis, the following models were used - (i) an unadjusted 
analysis, (ii) after adjustment for age, exercise, education, smoking status and alcohol intake 
(Model I), (iii) Model I + further adjustment for BMI, LDL-c, HDL-c, diabetes and hypertension 
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(Model II), and (iv) Model II + further adjusted for serum levels of omega-3 fatty acids (Model 
III).  
In a previous report from this sample population, it has been reported that heavy alcohol 
drinkers, i.e. those consuming ≥69 grams/day of alcohol, had more than ten times higher risk of 
CAC presence than moderate drinkers (23-45 grams/day of alcohol), and about four times higher 
risk of CAC presence than never drinkers. This alcohol intake is equivalent to about 4.5 shots of 
alcohol/day. This level of consumption is extremely high and not commonly seen in the US. For 
example, in the ERA JUMP study, the prevalence of heavy alcohol drinking was about 10% among 
Japanese in Japan as compared to less than 1% among Whites in Pittsburgh and less than 6% 
among Japanese Americans in Honolulu.  Due to very high prevalence of CAC among heavy 
alcohol drinkers (≥69 grams/day or ~4.5 shots of alcohol),247 this association was examined after 
excluding very heavy alcohol drinkers (n=31) in a subsequent analysis. 
To examine the association of equol producer status with the presence of CAC, a criteria 
recommended by Setchell et al.,161 i.e. a serum level of ≥83 nM, was used as a cut-off point for 
defining equol producer status. Examination of the association between equol producer status and 
presence of CAC was performed by using multiple logistic regression and adjusting for (i) age, 
BMI and alcohol intake (Model I) (ii) hypertension, diabetes, LDL-c, and HDL-c (Model II), (iii) 
Model II + log-transformed serum levels of soy isoflavones (Model III), and (iv) Model II + serum 
levels of omega-3 fatty acids (Model IV). Similar to the exclusion done in the previous analysis, 
this analysis was further performed after excluding very heavy alcohol drinkers. As a sensitivity 
analysis, different cut-off points of ≥20 nM and ≥40 nM for defining equol producer status were 
used.130,180A two-sided p-value <0.05 was considered significant. All the analyses were performed 
using SAS/STAT software version 9.3 of the SAS System, Cary, NC.  
92 
4.4 RESULTS 
Descriptive characteristics of the study population by tertiles of soy isoflavones are 
presented in Table 4-1. With increasing tertiles of soy isoflavones, no significant trend existed for 
BMI, SBP, DBP, hypertension, diabetes, education, alcohol drinking or exercise. With increasing 
tertiles of soy isoflavones, there was a significant increase in glucose, and a marginally significant 
increase in age and serum triglycerides. CAC was present in 10.6% of the individuals in tertile 1, 
15.4% in tertile 2 and 8.7% in tertile 3 of isoflavones (p-trend = ns).    
Table 4-2 presents the descriptive characteristics of the study population by equol producer 
status. About 16% of the individuals (n=49) were equol producers (≥83 nM). There were no 
significant differences in traditional cardiovascular risk factors such as age, BMI, SBP, LDL-c, 
HDL-c, diabetes, hypertension, exercise or education by equol producer status. While 12.0% of 
equol producers were heavy alcohol drinkers (≥69 grams/day), the prevalence was 9.9% among 
non-producers (p=ns). The prevalence of CAC was lower among equol producers (8.0%) than non-
producers (12.3%), but the difference was not statistically significant (p=0.39). When heavy 
drinkers of alcohol were excluded from the analysis (n=24), there was a marginally significant 
lower prevalence of CAC among equol producers (2.3%) than non-producers (10.6%) (p=0.08).  
Table 4-3 presents results of multiple logistic regression analysis to examine association 
between serum levels of soy isoflavones and presence of CAC. Independent of other risk factors, 
the odds for CAC were higher, although not statistically significant, among those in tertile 2 of soy 
isoflavones, while the odds were non-significantly lower among those in tertile 3, as compared to 
tertile 1 of soy isoflavones. The results did not materially change when heavy alcohol drinkers 
were excluded from the analyses (Table 4-4). 
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In an unadjusted analysis, equol producers had 38% lower odds for presence of CAC than 
equol non-producers (OR=0.62, 95% CI: 0.21, 1.84). After multivariable adjustment (Model II), 
the association became stronger, although still was not statistically significant (p=0.21). This 
association remained similar after adjustment for log-transformed serum levels of soy isoflavones 
(log-transformed) (Model III) or after adjustment for serum omega-3 fatty acids (Model IV). 
(Table 4-6) 
When heavy alcohol drinkers were excluded, the odds for presence of CAC were 80% 
lower among equol producers than among non-producers in an unadjusted analysis. (Table 4-7) 
After multivariable adjustment for cardiovascular risk factors, the association strengthened and 
became marginally significant (Model II) (OR=0.14, 95% CI: 0.02, 1.17). When further 
adjustment was done for log-transformed serum levels of soy isoflavones (Model III) or with 
serum levels of omega-3 fatty acids (Model IV), the association became significant with odds of 
CAC presence as much as 90% lower (OR=0.10, 95% CI: 0.01, 0.97) among equol producers than 
among non-producers. 
In a supplementary analysis, alternate cutoff points of ≥20 nM and ≥40 nM were used to 
define equol producer status. The prevalence of those with equol ≥20nM was 40.3% and those 
with equol ≥40 nM was 22.4%. There was no statistically significant association between equol 
producer status and presence of CAC using these alternate definitions of equol producers, although 
the odds for CAC presence were about 50% lower among equol producers than among equol non-
producers when using a cut-off value of 40 nM to define equol producer status. (Table 4-8 and 
Table 4-9) 
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4.5 DISCUSSION 
In a population-based study among healthy middle-aged Japanese men in Japan, serum 
levels of soy isoflavones were not associated with presence of coronary atherosclerosis. In contrast, 
equol producers had much lower prevalence of CAC than equol non-producers – the association 
was marginally significant in the whole sample population, and became statistically significant 
after excluding very heavy alcohol drinkers. These results indicate that while soy isoflavones 
might not have anti-atherosclerosis properties, equol provides significant benefit against 
atherosclerosis. This is the first study to report significant inverse association of serum levels of 
equol with coronary atherosclerosis among men. 
There was no significant association between serum levels of soy isoflavones and CHD 
risk factors. Several systematic reviews and meta-analyses have found similar observations that 
the effect of isoflavones on risk factors, if present, is modest.248-251 Although there was a significant 
positive association between serum isoflavones and glucose seen in the present study, no such 
trend was seen with diabetes. Further, no association of other traditional risk factors was seen with 
equol producer status. 
A nested case-control study having 377 cases and 753 controls in China had similar 
findings as this present study. In this study on Shanghai Women Health study and Shanghai Men 
Health Study cohorts, although urinary levels of isoflavones were not associated with CHD 
outcomes, urinary equol was inversely associated with CHD in women but not in men. As 
compared to quartile 1 of equol, participants in quartile 4 of equol had 54% lower odds of CHD, 
and there was a significant linear trend towards lower CHD with increasing quartiles of equol 
(p=0.02). Reasons for not replicating similar association among men might be shorter duration of 
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follow-up and lower prevalence of equol producers among men as compared to women.194 Further, 
equol supplementation significantly reduced HbA1c, LDL-c and CAVI in a small 12-week 
randomized crossover trial in Japan.178 Findings of this trial as well as the current study need to be 
validated through well-powered epidemiological studies and trials.  
Although no previous study has examined the association between soy isoflavones and 
CAC, previous studies have also reported no significant association between soy isoflavones and 
another measure of atherosclerosis i.e. carotid IMT.130,252-254 In the Women’s Isoflavones Soy 
Health (WISH) trial among 350 postmenopausal women, isoflavones supplementation 
significantly reduced IMT progression only among women who were within 5 years of menopause 
(n=68).  Also, there was no statistically significant difference in IMT progression by equol 
producer status, although the study was not statistically powered to examine this hypothesis.130    
Setchell et al. have recommended using 83 nM as the cut-off point in the serum while 
defining equol producer status.161 Alternate definitions of 20 nM and 40 nM were used in 
sensitivity analyses to define equol producer status. Although there were substantially lower odds 
for CAC among equol producers using the cut-off at 40 nM, the finding was not statistically 
significant. In contrast, no association was seen when the cut-off was kept at 20 nM. It is likely 
that several equol non-producers are misclassified as equol producers using these alternate 
definitions, and thus the lack of association between equol producer status and coronary 
calcification.  
Participants with very high alcohol intake were excluded from the analysis in this study. A 
J-shaped association between alcohol intake and coronary calcification has previously been 
reported in this study sample.247 As is also reported in the previous chapter of this manuscript, 
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Japanese in Japan have higher prevalence of alcohol drinking than other population groups. An 
intake of ≥69 grams/day is extremely high and is equivalent to about 4.5 shots of whiskey per day. 
Such heavy alcohol drinking increases the risk for CHD which is unlikely to be completely 
attenuated by anti-atherosclerotic properties of any single known dietary component including soy 
isoflavones or equol. When the analyses was performed after including heavy drinkers but 
adjusting for alcohol intake in the statistical models, the odds for presence of CAC were lower 
among equol producers than among equol non-producers, but not statistically significant. 
Results of this study should be interpreted in light of the relevant study limitations. Serum 
levels of isoflavones and equol may not provide a true estimate of their past exposure. This is 
cross-sectional study among healthy middle-aged men in Japan, thus, temporality and 
generalizability cannot be inferred. The criteria to define equol producer is not clear especially 
when measuring equol in the serum. Also, previous studies have determined equol producer status 
after giving a daidzein challenge to the participants. As this study is among Japanese men living 
in Japan, an assumption is made that they were consuming isoflavones in the past, and that 
absence/low equol in the serum is due to absence of intestinal bacteria that convert daidzein to 
equol.  
4.6 CONCLUSION 
To conclude, this is the first population-based study to report lower coronary 
atherosclerosis among equol producers than among non-producers, with significant differences 
seen among those who were not very heavy alcohol drinkers. This inverse association was not seen 
with soy isoflavones, thus indicating independent anti-atherosclerotic properties of equol.  
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4.7 TABLES AND FIGURES
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Table 4-1 Characteristics of the participants according to tertiles of serum isoflavones 
Tertile 1 
(n=102) 
Tertile 2 
(n=99) 
Tertile 3 
(n=102) 
P for trend 
Range of isoflavones (nM) 0–257 258-837 838–7,640 
Age (years) 44.8 (2.9) 45.0 (2.6) 45.5 (2.8) 0.077 
Body-mass index (kg/m2) 23.5 (3.3) 23.9 (3.1) 23.7 (2.8) 0.668 
Systolic BP (mmHg) 124.6 (15.2) 124.2 (17.6) 126.1 (15.5) 0.508 
Diastolic BP (mmHg) 76.2 (11.2) 76.5 (13.2) 76.9 (11.3) 0.658 
Hypertension (%) 23.1 31.1 25.2 0.721 
Total cholesterol (mg/dl) 215.4 (40.7) 219.8 (33.8) 216.2 (33.2) 0.871 
LDL-cholesterol (mg/dl) 134.4 (39.6) 133.5 (34.4) 128.7 (33.5) 0.253 
HDL-cholesterol (mg/dl) 53.2 (13.2) 55.4 (13.7) 53.6 (13.9) 0.842 
Triglycerides (mg/dl) 132.5 (92.5, 169) 136.5 (106, 180) 147 (110, 203) 0.085 
Glucose (mg/dl) 104.6 (11.3) 105.7 (15.0) 110.3 (26.2) 0.028 
Diabetes (%) 5.8 4.7 7.8 0.549 
Current smokers (%) 55.8 44.3 47.8 0.129 
Pack years of smoking (years) 18.0 (1.8, 30.0) 16.8 (4.9, 28.0) 21.8 (5.5, 29.0) 0.813 
Education (years) 14.0 (2.2) 14.4 (2.0) 14.4 (1.9) 0.159 
Current drinkers (%) 66.4 64.2 70.9 0.490 
Heavy Alcohol drinkers (%) 11.5 12.3 6.8 0.261 
Medication for 
Hypertension (%) 1.9 7.6 6.8 0.121 
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Lipids (%) 2.9 3.8 3.9 0.696 
Exercise (%) 23.1 30.2 26.2 0.607 
Coronary calcium score (50th,  75th, 
90th and 95th percentile) (0, 1.8, 20.8, 37.8) (0, 1.7, 18.0, 43.1) (0, 1.5, 8.0, 31.3) 
Prevalence of coronary calcium 
score ≥10 (%) 10.6 15.4 8.7 0.682 
Current drinkers were defined as individuals who drank alcohol ≥2 times a week. Heavy drinkers were defined as alcohol intake ≥ 69 
grams/day. Exercise was defined as exercise ≥ 1 hour a week. 
BP: blood pressure, LDL: low-density lipoprotein cholesterol, HDL: high-density lipoprotein  
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Table 4-1 contd.
Table 4-2  Characteristics of the participants by Equol producer status (≥83 nmol/L) (n=303) 
 Equol Producer 
(n=49) 
Equol non-producer 
(n=254) 
P-value 
Soy Isoflavones 794.4 (286.9, 1326.3) 422.4 (180.5, 942.0) 0.005 
Age (years) 45.7 (2.6) 45.0 (2.8) 0.107 
Body-mass index (kg/m2) 23.9 (2.8) 23.7 (3.2) 0.697 
Systolic BP (mmHg) 123.0 (16.1) 125.2 (15.8) 0.368 
Diastolic BP (mmHg) 76.0 (11.5) 76.5 (11.9) 0.798 
Hypertension (%) 20.4 27.7 0.287 
Total cholesterol ( mg/dl ) 218.7 (40.4) 216.8 (36.5) 0.741 
LDL-cholesterol (mg/dl) 136.1 (33.2) 131.9 (35.9) 0.406 
HDL-cholesterol ( mg/dl ) 53.4 (10.8) 54.1 (14.2) 0.682 
Triglycerides (mg/dl) 132 (110, 167) 139 (102, 183) 0.452 
Glucose ( mg/dl) 107.3 (16.2) 106.9 (19.4) 0.911 
Diabetes (%) 2.0 7.0 0.185 
Current smokers (%) 42.9 50.8 0.120 
Pack years of smoking 18 (4, 28) 18 (3, 29) 1.000 
Current drinkers (%) 75.5 65.2 0.257 
Heavy alcohol drinkers (%) 12.0 9.9 0.615 
Medication for    
Hypertension (%) 6.1 5.5 0.855 
Lipids (%) 4.1 3.5 0.846 
Education (years) 14.5 (2.3) 14.2 (2.0) 0.535 
Exercise (≥1 hr/wk) (%) 30.6 26.2 0.521 
Coronary calcium score (50th,  
75th, 90th and 95th percentile) 
(0, 2.6, 6.7, 17.5) (0, 1.5, 23.7, 43.1) 0.945 
Prevalence of coronary 
calcium score ≥10 (%) 
8.2 12.6 0.380 
Current drinkers were defined as individuals who drank alcohol ≥2 times a week.  Heavy 
drinkers were defined as alcohol intake ≥ 69 grams/day. Exercise was defined as exercise ≥ 1 
hour a week. 
BP: blood pressure, LDL: low-density lipoprotein cholesterol, HDL: high-density lipoprotein 
cholesterol 
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Figure 4-1 Distribution of serum isoflavones among Japanese in Japan (nM) 
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 Table 4-3 Multivariable-adjusted odds ratio (95% CI) for the presence of coronary artery calcification 
according to tertiles of serum isoflavones among men in Japan (n=303) 
 Tertile 1 Tertile 2 Tertile 3 
Crude 1.0 1.54 (0.68, 3.49) 0.81 (0.32, 2.04) 
Model I 1.0 1.65 (0.68, 4.03) 0.85 (0.32, 2.26) 
Model II 1.0 1.56 (0.60, 4.04) 0.83 (0.28, 2.44) 
Model III 1.0 1.55 (0.60, 4.03) 0.83 (0.28, 2.43) 
Model I: Adjusted for age, exercise, education (years), smoking status, and alcohol intake 
Model II: Model I + Further adjusted for body-mass index, LDL-c, HDL-c, hypertension and 
diabetes 
Model III: Model II + Further adjusted for serum levels of omega-3 fatty acids 
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Table 4-4 Multivariable-adjusted odds ratio (95% CI) for the presence of coronary artery calcification (%) 
according to tertiles of serum isoflavones among men in Japan (n=272) 
 Tertile 1 Tertile 2 Tertile 3 
Crude 1.0 1.84 (0.69, 4.92) 0.96 (0.32, 2.84) 
Model I 1.0 2.23 (0.79, 6.28) 0.98 (0.32, 3.02) 
Model II 1.0 2.62 (0.83, 8.25) 1.32 (0.38, 4.56) 
Model III 1.0 2.69 (0.84, 8.58) 1.36 (0.39, 4.71) 
*Analysis was performed after removing heavy alcohol drinkers from the sample 
Model I: Adjusted for age, exercise, education (years), smoking status, and alcohol intake 
Model II: Model I + Further adjusted for body-mass index, LDL-c, HDL-c, hypertension and 
diabetes 
Model III: Model II + Further adjusted for serum levels of omega-3 fatty acids 
*After removing heavy alcohol drinkers (≥69 grams/day) 
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Figure 4-2 Distribution of serum equol among Japanese men in Japan (nM) 
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Figure 4-3 Distribution of serum equol among those with equol more than 1 nM and less than 100 nM 
(n=146) 
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Table 4-5 Characteristics of the participants by Equol producer status after excluding heavy alcohol drinkers 
(≥83 nmol/L) (n=272) 
Equol Producer 
(n=43) 
Equol non-producer 
(n=229) 
P-value 
Soy Isoflavones 803.7 (279.0, 1346.6) 445.5 (186.7, 1030.7) 0.014 
Age (years) 45.6 (2.6) 44.9 (2.8) 0.121 
Body-mass index (kg/m2) 23.8 (2.7) 23.6 (3.2) 0.820 
Systolic BP (mmHg) 123.1 (16.6) 124.6 (15.6) 0.635 
Diastolic BP (mmHg) 75.0 (11.7) 76.0 (11.8) 0.753 
Hypertension (%) 18.6 25.8 0.317 
Total cholesterol (mg/dl ) 218.6 (33.5) 217.3 (36.1) 0.833 
HDL-cholesterol (mg/dl ) 52.0 (10.3) 53.5 (13.8) 0.433 
LDL-cholesterol (mg/dl) 137.1 (33.3) 133.5 (35.3) 0.539 
Triglycerides (mg/dl) 128 (108, 161) 139 (103, 181) 0.359 
Glucose ( mg/dl ) 105.8 (7.4) 106.5 (19.1) 0.681 
Diabetes (%) 0.0 6.1 0.136 
Current smokers (%) 41.9 48.5 0.246 
Pack years of smoking 18.0 (3.0, 29.0) 18.0 (2.2, 28.0) 0.771 
Education 14.4 (2.3) 14.3 (2.0) 0.660 
Current drinkers (%) 72.1 62.0 0.207 
Medication for 
Hypertension (%) 2.3 4.8 0.698 
Lipids (%) 4.6 2.6 0.616 
Coronary calcium score 
(50th,  75th, 90th and 95th 
percentile) 
(0, 1.0, 4.6, 6.7) (0, 1.0, 13.1, 36.6) 0.707 
Prevalence of coronary 
calcium score ≥10 (%) 
2.3 10.9 0.092 
Current drinkers were defined as individuals who drank alcohol ≥2 times a week.  Heavy 
drinkers were defined as alcohol intake ≥ 69 grams/day. Exercise was defined as exercise ≥ 1 
hour a week. 
BP: blood pressure, LDL: low-density lipoprotein, HDL: high-density lipoprotein 
*After removing heavy alcohol drinkers (≥69 grams/day)
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* After removing heavy alcohol drinkers (≥69 gms/day) 
 
Figure 4-4 Prevalence of coronary calcification by Equol producer status (n=272)* 
  
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
12.00%
Equol producer (n=44) Equol non-producer (n=237)
2.33%
10.92%
CA
C 
Pr
ev
al
en
ce
 (%
)
Equol Producer status
CAC Prevalence
108 
Table 4-6 Multivariable-adjusted odds ratio of the presence of CAC by equol producing status in men in Japan 
(n=303) 
Odds Ratio P value 
Crude 0.62 (0.21, 1.83) 0.384 
Model I 0.50 (0.16, 1.62) 0.248 
Model II 0.46 (0.14, 1.55) 0.210 
Model III 0.44 (0.13, 1.53) 0.197 
Model IV 0.46 (0.13, 1.59) 0.220 
Model I:   Adjusted for age, body-mass index and alcohol intake 
Model II:  Model I + Further adjusted for hypertension, diabetes, LDL-c and HDL-c 
Model III: Model II + further adjusted for serum levels of soy isoflavones (log) 
Model IV: Model II + further adjusted for serum levels of omega-3 fatty acids 
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Table 4-7 Multivariable-adjusted odds ratio for the presence of CAC by equol producing status (≥83 nM) 
among men in Japan (n=272) 
 
  
 Odds Ratio P value 
Crude 0.19 (0.03, 1.47) 0.113 
Model I 0.16 (0.02, 1.23) 0.078 
Model II 0.14 (0.02, 1.17) 0.069 
Model III 0.10 (0.01, 0.94) 0.044* 
Model IV 0.10 (0.01, 0.96) 0.046* 
Model I:   Adjusted for factors significantly associated in the univariate model – age, BMI 
Model II:  Further adjusted for other traditional risk factors – hypertension, diabetes, LDL-
c and lipid medication 
Model III: Further adjusted for serum levels of soy isoflavones 
Model IV: Further adjusted for serum levels of omega-3 fatty acids 
*After removing heavy alcohol drinkers (≥69 grams/day) 
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Table 4-8 Multivariable-adjusted odds ratio for the presence of CAC by equol producing status (≥20 nM) 
among men in Japan (n=272) 
Odds Ratio P value 
Crude 1.09 (0.48, 2.47) 0.838 
Model I 1.02 (0.44, 2.36) 0.966 
Model II 1.06 (0.43, 2.59) 0.901 
Model III 0.99 (0.40, 2.46) 0.982 
Model IV 1.01 (0.40, 2.53) 0.978 
Model I:   Adjusted for factors significantly associated in the univariate model – age, BMI 
Model II:  Further adjusted for other traditional risk factors – hypertension, diabetes, LDL-
cholesterol and lipid medication 
Model III: Further adjusted for serum levels of soy isoflavones 
Model IV: Further adjusted for serum levels of omega-3 fatty acids 
*After removing heavy alcohol drinkers (≥69 grams/day)
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Table 4-9 Table. Multivariable-adjusted odds ratio for the presence of CAC by equol producing status (≥40 
nM) among men in Japan (n=272) 
Odds Ratio P value 
Crude 0.77 (0.28, 2.14) 0.618 
Model I 0.62 (0.22, 1.80) 0.382 
Model II 0.54 (0.18, 1.65) 0.280 
Model III 0.48 (0.15, 1.50) 0.209 
Model IV 0.49 (0.16, 1.54) 0.224 
Model I:   Adjusted for factors significantly associated in the univariate model – age, BMI 
Model II:  Further adjusted for other traditional risk factors – hypertension, diabetes, LDL-
cholesterol and lipid medication 
Model III: Further adjusted for serum levels of soy isoflavones 
Model IV: Further adjusted for serum levels of omega-3 fatty acids 
*After removing heavy alcohol drinkers (≥69 grams/day)
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5.0  DISCUSSION 
This manuscript examined several subclinical disease biomarkers and their risk factors in 
a population sample of apparently healthy middle-aged men drawn from three different countries 
i.e. the US, Japan and South Korea. It also compares the prevalence of subclinical cardiovascular 
disease by comparing presence of one of the biomarkers, i.e. carotid plaque, among these 
population samples. An effort is made to examine the risk factors associated with subclinical 
cardiovascular disease. Finally, among Japanese population, where the intake of soy and soy 
products is regular, this manuscript examines the association between serum levels of soy 
isoflavones, a measure of the dietary intake of soy isoflavones, and coronary atherosclerosis 
examined as coronary artery calcification. The major findings of this dissertation is that Japanese, 
and to some extent, South Koreans have lower subclinical atherosclerosis than US men, and that 
among Japanese, equol producer status is associated with lower subclinical atherosclerosis. 
Additionally, this dissertation work indicates that among apparently health men, brachial-ankle 
pulse wave velocity, a biomarker of arterial stiffness, is associated with coronary artery 
calcification (CAC). Given its non-invasive measurement and clinical applicability, brachial-ankle 
pulse wave velocity deserves thorough examination as a biomarker of arterial stiffness and a 
predictor of future cardiovascular disease in the US.  
This manuscript highlights several lessons that may be learned from Japan for further 
reducing the burden of CHD in the US. US have one of the highest rates of CHD among western 
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countries. In contrast, the CHD rates in Japan are one of the lowest is the world, in spite of high 
rates of smoking and higher blood pressure prevalent in Japan although the prevalence of obesity 
in much lower in Japan. Several studies have tried to examine the lower CHD in Japan, by 
comparing the CHD rates between Japanese in Japan, Japanese Americans living in the US and 
Whites living in the US. However, these previous studies were conducted when there was a 
significant difference in lifestyle between the US and Japan, i.e. the level of total cholesterol in the 
US was much higher than that in Japan. The present study is significant as it examines these 
populations in the 21st century and among men born after the World War II. With westernization 
of diet and lifestyle in Japan, these men have consumed increasingly western diet over their 
lifetime.  
Previous studies have examined the differences in CHD between the US and Japan by 
examining the rates of CHD events.100,103,108 This study examines these differences using newer 
technologies to evaluate the subclinical burden of atherosclerosis. This is especially important as 
increasing life expectancy is likely to increase the burden of atherosclerosis in the population. 
Also, with an ever-increasing availability of therapeutic options to prevent and delay the onset of 
CHD, identifying subclinical atherosclerosis informs is beneficial as it aids in the decision-making 
while instituting the therapy for CHD prevention. This study confirms the finding of lower 
atherosclerosis in Japan that was first reported by epidemiological studies in the 20th century. 
East Asian men, especially Japanese in Japan, have lower atherosclerosis than men in the 
US. In the present study carotid plaque was used to compare the burden of atherosclerosis between 
these populations, as it has emerged as a predictor of CHD risk. This study confirms the findings 
from previous reports of lower subclinical atherosclerosis among Japanese in Japan as compared 
to the US men. Also, similar to the US, the CHD rates in Japan are declining for the past several 
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decades. The “Japanese paradox” i.e. declining CHD rates in spite of increasing total cholesterol 
levels has been attributed to the decline in smoking rates and blood pressure achieved in Japan.255 
Nonetheless, the extremely low CHD rates among Japanese in Japan remain a subject of 
examination. 
This study also reports a relatively new biomarker of CVD i.e. brachial-ankle pulse wave 
velocity (baPWV). baPWV is a popular too for assessing CVD risk in east Asian countries 
including Japan. If the success of baPWV is replicated in the US, it may turn out to be a clinically 
convenient predictor of CVD and may aid the clinicians in decision-making. baPWV has a 
potential for wide clinical application. baPWV measurement is inexpensive, can be performed in 
a physician’s office, requires little operator’s expertise, and does not require exposure to the 
inguinal area. However, several concerns need to be addressed before it can be used as a clinical 
tool in the US, most important of which are determination of normal reference values and 
applicability among Western populations  
This study also reports that equol producers in Japan have lower coronary atherosclerosis 
than equol non-producers. Equol is producer by the action of intestinal bacteria on dietary 
isoflavone i.e. daidzein. Dietary intake of isoflavones is high in Japan, thus, it is likely that equol 
producers in Japan have had protective benefits from the anti-atherosclerotic properties of equol 
over the past several years. This is especially likely as equol producer status is stable in an 
individual. However, it is unlikely that at the current level of intake of isoflavones in the US, 
isoflavones or equol would have any protective effect. Thus, this hypothesis cannot be currently 
examined in the general population in the US. Nevertheless, as equol is now available as a dietary 
supplement in the US, anti-atherosclerotic properties of equol can be examined with a clinical trial 
in the US and elsewhere. 
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Strengths 
This work makes several contributions to the scientific literature. This study uses 
standardized approach to compare the prevalence of carotid plaque across several countries. This 
is also the first study to examine the usefulness of brachial-ankle pulse wave velocity among 
apparently healthy men in the US. Finally, it indicates that a dietary factor i.e. soy isoflavones may 
be protective against atherosclerosis.    
Several study strengths increase the impact and validity of these findings. All the data 
acquisition was done in a standardized manner under strict data quality control. Several established 
research laboratories in Pittsburgh, PA handled data acquisition and processing – (1) the 
Ultrasound Research lab at the University of Pittsburgh examined baPWV, and kept quality 
control check over carotid plaque assessments that were made at individual sites. The Ultrasound 
Research Lab has a track record of examination of subclinical disease markers esp. vascular 
markers such as intima-media thickness, carotid-femoral pulse wave velocity and flow-mediated 
dilatation for several large epidemiological studies in the US, including the Study of Women’s 
Health Across the Nation and the ERA JUMP study. It employs several trained full-time 
sonographers who are experts in assessing the subclinical markers under strict quality control. This 
lab has been one of the pioneers for establishing validity and reproducibility for some of these 
biomarkers. (2) The Cardiovascular Institute at the University of Pittsburgh Medical Center 
examined CAC after obtaining cardiac images from all the study sites. CAC assessment was 
performed by one trained technician with a low inter-scan variability for measurement. (3) The 
Heinz laboratory at the University of Pittsburgh examined the blood for all the serum markers used 
in this study including lipids, glucose, and dietary markers such as soy isoflavones and equol. The 
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Heinz lab, similar to the previous two labs has a long history of providing services to the research 
studies conducted at the University of Pittsburgh.  
This study examines the research questions is a population of apparently healthy middle-
aged men. These men were recruited directly from the population. Thus, the results of this study 
are applicable especially for middle-aged men, a section of the general population who is most 
likely to get potentially preventable coronary heart disease in the next 20 years. Studying this 
population provides the greatest opportunity to prevent any future reversal of declining trend of 
coronary heart disease in the population. In contrast, a study recruiting patients from the hospital, 
however clinically important, would not provide an insight into preclinical preventable phase of 
the disease.  
Although the study sample size is relatively modest, it is sufficiently large esp. given the 
breadth of self-reported and laboratory assessments included in the study and the strict quality 
control under which these assessments were made. In a part of the first aim (chapter 2) and the 
second aim (chapter 3), data from all the groups could be combined for the analysis, thus providing 
large sample size to enable statistically powerful analysis. However, for parts of these chapter 
where the population was stratified by the race-ethnicity, certain limitations were present with 
regards to statistical power.        
Limitations 
Results from this dissertation should be interpreted in light of the study limitations. Certain 
general limitations were common to all the aims – low generalizability, cross-sectional design, and 
lack of more sophisticated biomarkers to assess subclinical atherosclerosis.  
As the sample population in this study included only men that were 40-49 years of age, the 
study findings are not generalizable to other sections of the population. An important section of 
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the population that has gained importance in the recent scientific literature comprises of women 
transitioning through the menopause. Although slightly overlapping in age with the population of 
this study, the findings of this study should not be extrapolated to menopausal women. Further, 
number of chronic diseases such as hypertension and diabetes increase with age. These conditions 
when present in the same individual has a greater effect on the progression of atherosclerosis than 
that of the sum of their individual effects. Thus, our findings may not necessarily be extrapolated 
to older populations, both men and women. However, use of a wider age-range or both genders 
would have necessitated a much larger sample to be recruited into the study.  
The cross-sectional nature of these studies slightly limits the impact of these results. Hill’s 
criteria for assessing causal association puts emphasis on the temporality of association between a 
factor and a disease. Unfortunately, given its cross-sectional design, this dissertation research 
could not assess temporality which might be important for Aims 2 and 3. In the second aim of this 
manuscript, association between baPWV and CAC, both subclinical measures of cardiovascular 
disease, was examined. An assumption was made that baPWV would increase before appearance 
of CAC, and thus baPWV was used as a predictor variable in the models while CAC was kept as 
the outcome variable. However, this limitation should not significantly impact the validity of the 
findings as the aim was to only examine the association between the two biomarkers with no 
intention to prove a causal relationship between the two pathophysiological processes that these 
biomarkers assess. However, this study design may be more important while interpreting the 
results of the third aim. In this chapter, as assumption is made that the dietary practices of the 
population have been consistent for the past several years at least with regards to intake of soy and 
soy products. Given the generally unreliable nature of other dietary assessment techniques such as 
food frequency questionnaires, serum levels of dietary factors such as isoflavones provide a 
118 
relatively accurate measure of their current intake, but provide little information about the past 
dietary habits. 
Several studies have used more sophisticated cardiovascular disease biomarkers such as 
coronary angiography to examine coronary atherosclerosis and intravascular ultrasound to 
examine carotid atherosclerosis. Given the population-based design of this study, only non-
invasive measures such as electron-beam computed tomography and carotid B-mode ultrasound 
were used. Although these biomarkers have been examined thoroughly in several studies, 
including population-based studies, other studies have started to show that these biomarkers, 
although qualitatively valid, may not be accurate in assessing the quantity of atherosclerosis in the 
vascular beds. Thus, a need exists for incorporating more sophisticated but non-invasive 
techniques for quantifying atherosclerosis.    
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6.0  PUBLIC HEALTH SIGNIFICANCE AND FUTURE RESEARCH 
WHO describes public health as "all organized measures (whether public or private) to 
prevent disease, promote health, and prolong life among the population as a whole.” Various 
functions of public health are described as (i) assessment and monitoring of the health of 
communities and populations at risk to identify health problems and priorities, (ii) formulation of 
public policies designed to solve identified local and national health problems and priorities, and 
(iii) to assure that all populations have access to appropriate and cost-effective care, including 
health promotion and disease prevention services.256 To the extent of the abovementioned role of 
public health, this dissertation highlights several research areas that are of public health importance 
globally as well as in the US.  
The first aim of this dissertation reports on higher atherosclerosis – an underlying factor 
for coronary heart disease (CHD) – among US men than among east Asian men. As these 
differences were independent of other traditional cardiovascular risk factors, this finding suggests 
that some other factor(s) might be responsible for higher atherosclerosis in US or lower 
atherosclerosis among east Asian men. Identification of such factor(s) might lead the way to lower 
the rising global epidemic of cardiovascular disease. Thus, larger longitudinal studies are needed 
to systematically examine reasons for lower carotid atherosclerosis in Japan as compared to the 
US.   
Early identification of cardiovascular disease (CVD) using biomarkers is a well-established 
strategy to prevent the occurrence of clinical CVD. In this regards, several biomarkers have been 
examined extensively in the past few decades. Although some of these biomarkers have 
consistently been shown to be associated with future CVD, they have certain limitations such as 
side-effects, increased costs and generalizability. Thus, a search of an “ideal” CVD biomarker 
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continues. In this regard, brachial-ankle pulse wave velocity is a promising biomarker of CVD and 
needs to be thoroughly examined in the western populations.  
The third and final aim of this dissertation examines the effects of a dietary component i.e. 
soy isoflavones on coronary atherosclerosis. Although dietary isoflavones are not associated with 
lower coronary atherosclerosis, equol – a product of the action of intestinal bacteria on isoflavones 
– has shown some benefit over coronary atherosclerosis, examined in this aim with coronary artery 
calcification. Equol is available as a dietary supplement. Thus, if this finding is replicated in larger 
longitudinal studies and clinical trials in the US and other countries with a high burden of 
atherosclerosis and CVD, it may lead to reduction of the public health burden of the CHD.  
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APPENDIX A: STUDIES EXAMINING ASSOCIATION BETWEEN TRADITIONAL CVD RISK FACTORS AND CAROTID 
PLAQUE
Table A-1 Studies examining association between Traditional CVD Risk Factors and Carotid Plaque 
Author-Year Study Population Follow-Up Carotid plaque measurement 
Prevalence of carotid 
plaque 
Risk factors 
associated with 
carotid plaque 
Tell 1989 USA257 CV Diagnostic patients, 49.0% 
male, 90% White, 10% Blacks, in 
USA, Mean age: 63 years, Age 
range: 24-98 years  
Cross-sectional 
study 
Biosound compact 
scanner; plaque 
defined as thickening > 
1.0 mm; calculation of 
plaque score based on 
severity of plaques 
Not reported Age and cigarette 
smoking consistently 
associated with plaque 
thickness 
Handa 1990 Japan258 Japanese patients, 71% male, 59 
± 13 years, N=232 
-do- B-mode US, SSD-125 
Tokyo Japan, and 
EUB-450, Tokyo, 
Japan 
59% among CVD group and 
41% among non-CVD group 
Age, sex, 
hyperlipidemia, DM 
Prati 1992 Italy259 Population-based, 46.7% male, 
Age range: 18 to 99 years, 
N=1348 (San Daniele Project) 
-do- Duplex US; plaque 
defined as a distinct 
area with 
mineralization or 
protrusion into the 
lumen 
Men: 25.4%, Women: 26/4% Above 40 years only: 
Age, SBP, HDL-c, 
smoking (pack years), 
alcohol intake  
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Author-Year Study Population Follow-Up Carotid plaque measurement 
Prevalence of carotid 
plaque 
Risk factors 
associated with 
carotid plaque 
Salonen 1994 Finland260 Population-based, all men, Age 
range: 40-59 years, N=182 from 
Seven Countries Study 
FU: 30 years B-mode US scan; 
plaque categories: (1) 
smooth arterial wall 
surface, (2) uneven 
arterial wall surface, 
(3) protrusion into 
lumen, (4) Large 
(≥25%) protrusion 
45.1% had any plaque present TC, smoking 
Bonithon-Kopp 1996 
France261 
Population-based, 40.6% male, 
Age range: 59-71 years. The 
EVA Study  
Cross-sectional 
study 
B-mode US Aloka 
SSD-650; plaque 
defined as a localized 
structure that protruded 
into the lumen with 
IMT >1.0 mm 
Men: 25.59%, Women: 16.5% Age, hypertension, IMT 
Bonora 1997 Italy262 Population-based,  59±11 years. 
The Bruneck study 
FU: 5 years B-mode US, plaque 
not expressly defined 
42.5% had any plaque present Univariate: 2-hr glucose, 
2-hr insulin, SBP, DBP, 
hypertension, LDL-c, 
apoB, AT-III 
Ebrahim 1999 UK263 Population-based, 53.2% male, 
66 years. The British Regional 
Heart Study  
Cross-sectional 
study 
Advanced Tech. Lab. 
HDI 3000 triplex 
system. Plaque defined 
as localized IMT >1.2 
mm 
Me:57%, Women:58% Men: current smoking, 
HDL-c Fibrinogen, 
Factor VII(age adjusted) 
Women: current 
smoking, manual labor, 
SBP, TC (age adjusted) 
Spence 1999 Canada264 CVD patients, 
Atherosclerosis group: 51.4% 
male, 48.4±12.7 years, N=294; 
Control group: 55.2% male, 
50.4±10.8 years, N=351  
-do- B-mode US. Plaque 
defined with plaque 
area on US 
Mena plaque area: 0.55±0.83 
cm2 
Age, sex, smoking, 
medications for lipid, 
medications for BP 
Zureik 2000 France220 Population-based FU: 4 years B-mode US Aloka 
SSD-650; plaque 
defined as a localized 
structure that protruded 
into the lumen with 
IMT >1.0 mm 
Occurrence of new plaque: 
18.3% 
Univariate: 
Hypertension, TC 
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Author-Year Study Population Follow-Up Carotid plaque measurement 
Prevalence of carotid 
plaque 
Risk factors 
associated with 
carotid plaque 
Klein 2008 Canada35 CVD patients, 52.9% male, 
53.4±12.0 years, N=876 
Cross-sectional 
study 
ATL Mark 9, ATL 
HDI 2000. Plaque 
defined as % stenosis 
Carotid plaque area: 0.38 (0.11, 
0.96) cm2 
Age, sex, SBP, 
Smoking(pack years) 
medication for lipid, DM 
Wagenknecht 2009 
USA265 
Population-based  43% male, 
19% blacks, Mean age >70 years. 
The ARIC study 
FU: 18 years Contrast-enhanced 
MRI + 3D Angiogram; 
Plaque composition 
analysis done only 
among those with wall 
thickness ≥1.5 mm  
Lipid core observed in 42% 
(weighted) 
18 Year predictors of 
lipid core: age, LDL-c, 
TC 
Concurrent predictors: 
LDL-c, glucose, BMI  
Kelley 2011 USA266 Population-based, 42% male, 
31% Blacks, Age range: 29-51 
years, N=914. The Bogalusa 
heart Study 
Cross-sectional 
study 
Power vision Toshiba 
SSH-380, Carrollton, 
USA. Plaque defined 
as discrete, focal area 
50% greater than the 
surrounding wall, ≥1.5 
mm IMT 
White men: 14%, White women: 
8%, Black men: 9%, Black 
women: 9% 
Age, race, smoking, 
hypertension, DM 
Kuo 2012 USA36 Population-based, 40% male, 
61% Hispanics, 19% Blacks, 
17% white, Age: 69±9 years, 
N=1790. The NOMAS Study 
-do- Plaque defined as the 
total plaque area. 
Average plaque area: 1.45±1.38 
cm2 
Age, SBP, smoking, and 
DM 
Herder 2012 Norway38 Population-based, 47.6% male, 
Age ~ 56 years, N=2743. The 
Tromso study 
B-mode US Acuson 
Xp10 128 ART-
upgraded. Plaque 
defined as a localized 
protrusion ≥50% 
thicker than the 
adjacent IMT. Total 
plaque area. 
TPA: Men-7.42 mm2, Women- 
4.73 mm2 
TC, SBP, smoking 
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Author-Year Study Population Follow-Up Carotid plaque measurement 
Prevalence of carotid 
plaque 
Risk factors 
associated with 
carotid plaque 
van den Bouwhuijsen 
2012 Netherlands267 
Participants with carotid wall 
thickening (≥2.5mm) in a 
previous survey, 52% men, 
70.3±10.2 years, N=1006. The 
Rotterdam Study 
-do- 1.5 T MR scanner, GE 
Healthcare, 
Milwaukee, US: 2D 
images, and 3D 
angiogram. 
Composition of plaque 
assessed in all plaque 
with IMT > 2.0mm 
13.5% had more than 30% 
stenosis, intraplaque hemorrhage 
in 34.5%, and lipid core in 
25.5% of participants   
Hemorrhage: age, sex, 
hypertension, current 
smoking, IMT, carotid 
stenosis 
Lipid Core: Age, sex, 
dyslipidemia, IMT, 
carotid stenosis 
Calcification: age, 
hypertension, IMT, 
carotid stenosis 
Herder 2012 Norway38 Population-based, 47.6% male, 
Age ~56 years, N=2743 
FU: 13 years B-mode US Acuson 
Xp10 128, ART-
upgraded. Plaque 
defined as a localized 
protrusion ≥50% 
compared with 
adjacent IMT. The area 
of the plaques was 
outlined manually. 
Progression in plaque 
area calculated  
Progression: 
Men: 0.82 mm2/year 
Women: 0.56 mm2/year 
Age, sex, TC, SBP, 
smoking, medications for 
lipids, CVD 
Ijas 2013 Finland268 Population survey, 45.4% males, 
57.1±8.1 years, N=91 from 
Helsinki Carotid Endarterectomy 
study 
Cross-sectional 
study 
B-mode US 14.1% prevalence of plaque Age, haptoglobin-2 allele 
Khalil 2013 India269 Population-based, 60.3% male, 
Age ~36 years, N=600 
FU: 6.9±1.0 
years 
B-mode US GE 5X3, 
Barrington, USA. 
Plaque defined as IMT 
>1mm 
Men: 33.4%, Women: 25.6% Sex, metabolic 
syndrome, education, 
SES, exercise 
Blondon 2013 USA37 Population-based, 46.5% men, 
60.4±9.4 years, N=3246 The 
MESA study 
FU: 9.4 years B-mode US. Plaque 
defined as localized 
thickening of IMT > 
50% than the adjacent 
IMT. 
47% prevalence of plaque at 
baseline, and 40.6% at FU 
among those with no plaque at 
baseline 
PTH and Vit. D are not 
associated with/ predict 
plaque  
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Author-Year Study Population Follow-Up Carotid plaque measurement 
Prevalence of carotid 
plaque 
Risk factors 
associated with 
carotid plaque 
Sala Vila 2014 Spain270 High CVD risk participants, 
46.3% male, Age ~66 years, 
N=164Sub-cohort of a clinical 
Trial (PREDIMED trial)  
FU: 2.4 years B-mode US Sequoia 
Acuson, Enlargen, 
Germany. Plaque 
defined as focal 
protrusions ≥1.2 mm 
thick. 
76.8% prevalence of plaque at 
baseline. Mediterranean 
diet+nuts lead to delayed 
progression of mean plaque 
thickness.    
Mediterranean diet, nuts 
Hogberg 2014 Sweden271 Population-based, all men, 65 
years, N=4657 
Cross-sectional 
study 
Carotid US Sequoia, 
Mountain view, USA. 
Plaque defined as focal 
IMT ≥2 mm 
25.1% had plaque Univariate: Smoking, 
hypertension, CAD, 
hypercholesterolemia, 
claudication, COPD, 
DM, TIA/Stroke 
Sinning 2014 
Germany271 
Population-based, 50.8% male, 
55.5±10.9 years, N=5000. The 
Gutenberg health study 
-do- iE33 US system. 
Plaque defined as 
protrusions ≥1.5mm 
into the lumen. 
Plaque was present in 37.8% ? 
CVD = cardiovascular disease, DM= diabetes mellitus, US= ultrasound, TC= total cholesterol, IMT= intima-media thickness, FU = follow-up, SBP=systolic blood 
pressure, DBP = diastolic blood pressure, LDL-c = low-density lipoprotein cholesterol, HDL-c = high-density lipoprotein cholesterol, UK = United Kingdom, 
MESA= multi-ethnic study of atherosclerosis, TIA= transient ischemic attack, CAD= coronary artery disease, COPD = chronic obstructive pulmonary disease 
. 
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APPENDIX B: ASSOCIATION OF CAROTID PLAQUE WITH OTHER SUBCLINICAL AND CLINICAL DISEASE MARKERS
Table B-1 Association of Carotid plaque with other subclinical and clinical disease markers 
Author-Year Study Population Follow-Up Carotid plaque measurement 
Prevalence of carotid 
plaque 
Risk factors 
associated with 
carotid plaque 
Coronary Artery Calcification 
Oei 2002 The 
Netherlands272 
Population-based, 46.3% men, 
~71 years, N=2013. The 
Rotterdam Coronary 
Calcification Study 
-do- Carotid US Scan. 
Plaque defined as focal 
protrusion at least 50% 
thicker than the 
adjacent IMT 
Men: 78%, Women: 59% Carotid plaque 
significantly associated 
with CAC among men as 
well as women 
Polak 2013 USA273 Population-based, 42.3% men, 
63.6±10.4 years, N=2837. The 
MESA Study 
FU: 2.4 years B-mode US scan. Plaque was present in 45.6% Carotid plaque 
significantly predicted 
incidence of coronary 
calcification 
Lee 2012 USA274 Population-based, 47.8% men, 
62.15±10.2 years, N=6715. The 
MESA Study baseline data  
Cross-sectional 
study 
B-mode US scan, GE 
Logiq 700 US 
machine,. Peak-
systolic velocities of 
<150 cms, 150-250 
cm/s, and >250 cm/s 
were determined to 
correspond to <50%, 
50-75% and >75 
stenosis 
Prevalence of stenosis (≥25%) 
was 15% 
Carotid stenosis was 
associated with presence 
of CAC as well as CAC 
score 
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Author-Year Study Population Follow-Up Carotid plaque measurement 
Prevalence of carotid 
plaque 
Risk factors 
associated with 
carotid plaque 
Schroeder 2013 
Canada275 
Asymptomatic patients, 54% 
male, 53±10 years, N=50. 
-do- Carotid US scan, 
Siemens Antares. 
Carotid plaque defined 
as wall thickness that 
was increased as 
compared to the 
surrounding IMT 
Prevalence of plaque: 28% No association between 
US-assessed carotid  
plaque and presence of 
CAC 
Coronary Angiogram 
Morito 2008 Japan276 Suspected CAD patients, 58.6% 
male, 68.5 ± 10.8 years, N=116  
-do- B-mode Carotid US 
scan, Toshiba Power 
vision 8000. Carotid 
plaque was defined as 
focal IMT ≥ 1.1 mm. 
Mean number of plaque: 3 
among those with coronary 
artery stenosis, and 1 among 
those with no coronary artery 
stenosis 
Plaque score was 
associated with severity 
of coronary stenosis 
Chang 2013 Taiwan277 Suspected CAD patients, 79.2% 
male, 61±11 years, N=120 
-do- B-mode US scan iE33 
xMatrix, Philips, 
Andover, USA. Plaque 
defined as focal 
thickening that was at 
least 50% greater than 
the surrounding vessel 
wall, or a focal region 
with IMT ≥1.5 mm 
Carotid plaque were present in 
77.5% 
Carotid plaque was 
associated with CAD 
(defined as coronary 
luminal narrowing 
>50%) 
Intima-Media Thickness 
von Sarnowski 2010 
Germany278 
Population-based, 45-81 years, 
N=1922 
FU: 5 years Carotid US scan, 
Gateway VST, GE 
Diagnostics 
Carotid plaque prevalence at 
baseline: 67%. 
Among those with no 
carotid plaque at 
baseline, baseline IMT 
predicted the 
development of carotid 
plaque 
Pulse Wave Velocity 
Selwaness 2014 The 
Netherlands279 
Population-based, 43.4% men, 
67.0±8.6 years, N=6527. The 
Rotterdam Study 
FU: 10.9 years 
and 0.8 years 
Carotid US scan, ATL 
Ultra-Mark IV. Carotid 
MRI scan. Carotid wall 
thickening reported as 
IMT ≥2.5 mm. 
Prevalence of plaque: 39.6% Higher PWV was 
associated with carotid 
plaque, intraplaque 
hemorrhage, and 
intraplaque calcification. 
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Author-Year Study Population Follow-Up Carotid plaque measurement 
Prevalence of carotid 
plaque 
Risk factors 
associated with 
carotid plaque 
CAC= coronary artery calcification, MESA= multi-ethnic study of atherosclerosis, US= ultrasound,  CVD = cardiovascular disease, CAD= coronary artery 
disease, IMT= intima-media thickness, FU = follow-up, PWV = pulse wave velocity 
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APPENDIX C: PREVALENCE OF CAROTID PLAQUE AND ITS ASSOCIATION WITH CARDIOVASCULAR RISK FACTORS
Table C-1 Prevalence of Carotid plaque and its association with cardiovascular risk factors 
Author-Year Study Population Follow-Up Carotid plaque measurement Prevalence of carotid plaque 
Risk factors associated 
with carotid plaque 
Polak 1993 USA280 Population-based study, 43.2% 
men, ~73 years, N=5201 
Cross-sectional 
study 
Internal carotid artery  
US scan, SSA-270A 
Toshiba America 
Medical System, 
Tustin, USA. Carotid 
stenosis categorized as 
0%, 1-24%, 25-49%, 
50-74%, and >74% 
based on peak flow 
velocities on US   
Prevalence of plaque: 68.2% ICA stenosis was 
associated with Stroke as 
well as TIA 
Hollander, 2002, The 
Netherlands281 
Population-based, 39.9% male, 
68.8 years, N=4217. The 
Rotterdam study 
FU: 5.2 years B-mode US scan. 
Plaque defined as a 
focal widening of 
vessel wall >50% 
relative to the adjacent 
segments 
Prevalence of plaque: 60% Carotid plaque increased 
the risk of lacunar stroke 
as well as stroke in the 
anterior circulation, but 
not in the posterior 
circulation. 
Spence 2002 Canada282 Patients in the premature 
atherosclerosis clinic, ~55% 
male, N=1686 
FU: 5 years Carotid US scan. 
Plaque defined as local 
thickening of intima > 
1mm in thickness. 
Prevalence of plaque: 87.6% Carotid plaque 
progression was 
associated with higher 
risk of Stroke. 
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Author-Year Study Population Follow-Up Carotid plaque measurement Prevalence of carotid plaque 
Risk factors associated 
with carotid plaque 
Touboul 2005 France283 Brain infarct patients (n=510) and 
controls (n=510). The GENIC 
study  
Cross-sectional 
study 
Carotid US scan. 
Plaque defined as a 
localized protrusion 
into the lumen  > 1mm 
in thickness than 
surrounding IMT. 
Prevalence among Cases: 61.4%, 
controls: 35.2% 
Carotid plaque 
associated with Stroke 
risk 
Roman 2012 USA284 Population-based, 35% male, 
63±8 years, N=2441. The Strong 
Heart Study 
FU: 7.7 years Carotid US scan, 
Acuson 128 system. 
Plaque defined as focal 
thickness ≥ 50% 
thicker than the 
adjacent IMT  
Plaque prevalence: 63.6% Carotid plaque was 
associated with incident 
CVD. 
Polak, 2013, USA31 Population-based, 47.4% male, 
61.1±10.2 years, N=6562. The 
MESA Study 
FU:7.8 years Carotid US scan.  
Presence of carotid 
lesions graded as 0%,  
1-24%, 25-49%, and 
>49%. 
Plaque prevalence: 41.9% Carotid plaque at 
baseline was associated 
with CHD 
Ziegelbauer 2013 
Germany285 
Population-based, 48.7% male, 
49.9±13.0 years. N=4995. The 
Carotid Atherosclerosis 
Progression Study (CAPS) 
FU: 10 years Internal carotid artery 
US scan, P700SE, 
Philips Medical 
System. Plaque defined 
as a focal protrusion of 
at least 1.8 mm 
Prevalence of ICA plaque: 71% ICA predicted any stroke 
or death as the outcome 
over 10 years 
Wannarong 2013 
Canada286 
Stroke prevention clinic patients, 
baseline plaque area 40 to 600 
mm2, ~70 years of age. N=349 
FU: 1 year Philips duplex 
scanners ATL 5000 
HDI, ATL, Bothel, 
USA. Plaque measure 
as total plaque area and 
total plaque volume 
NA Progression of total 
plaque volume but not 
total plaque area 
predicted stroke among 
patients 
Park 2013 S Korea287 Consecutive patients with carotid 
US scan and coronary angiogram. 
54.5% male, 59.5±10.6 years, 
N=1390. 
Cross-sectional 
study 
Carotid US scan, HP 
Sonos-5500. Plaque 
defined as a focal 
protrusion >50 thicker 
than the surrounding 
intima-media or 
IMT>1.2 mm.  
Prevalence of plaque: 31%. Carotid plaque was 
associated with cardiac 
death and major adverse 
cardiovascular event 
131 
Table C-1 contd.
Author-Year Study Population Follow-Up Carotid plaque measurement Prevalence of carotid plaque 
Risk factors associated 
with carotid plaque 
Hald  2014 Norway288 Population-based study, 47.8% 
male,  59.9 ±10.3 years, N=6257. 
The Tromso Study 
FU:15.4 years B-mode US scan, 
Acuson Xp10 128 
ART scanner. Plaque 
defined as localized 
thickening more than 
50% thicker than the 
adjacent IMT 
Plaque prevalence at baseline: 
47.9% 
Carotid plaque area 
predicted MI but net 
VTE 
US= ultrasound, IMT= intima-media thickness, CHD= coronary heart disease, CVD = cardiovascular disease, FU = follow-up, ICA = internal carotid artery, 
TIA= transient ischemic attack, VTE = venous thromboembolism.  
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APPENDIX D: STUDIES EXAMINING ASSOCIATION BETWEEN baPWV AND SUBCLINICAL AND CLINICAL 
CARDIOVASCULAR DISEASE
Table D-1 Studies examining association between baPWV and subclinical and clinical cardiovascular disease 
Author-Year Population Follow-
Up 
baPWV 
Measurement 
/Distance 
Mean baPWV baPWV 
definition 
for 
model 
Outcome Confounders Results 
Coronary Artery Calcification 
Venkitachalam, 
2007 USA223 
Obese 
postmenopausal 
women, 57.0±2.9 
years  
N=441 (WOMAN 
Study) 
Cross-
sectional 
analysis 
Form ABI/PWV; 
Colin Co Ltd 
1434 ± 232 cm/s Quartiles of 
baPWV 
Presence (>0 
AU) and 
severity (>100 
AU) of CAC 
Age, SBP, WC, BMI, 
Smoking, HRT Use, 
race, glucose, insulin, 
TC, HDL-c, LDL-c, 
TG, and 
antihypertensive 
medications 
baPWV 
independently 
associated 
with presence 
and severity 
of CAC 
Lemos 2007 
Brazil289 
Pre-dialysis 
patients (59% 
male), 54.4±11.5 
years N=104  
-do- Complior SP 
apparatus Artech 
Medical, Panyin, 
France 
1220 ± 340 cm/s Continuous Presence of 
CAC 
None Higher 
baPWV 
among those 
with presence 
of CAC 
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Author-Year Population Follow-
Up 
baPWV 
Measurement 
/Distance 
Mean baPWV baPWV 
definition 
for 
model 
Outcome Confounders Results 
Seo 2010 S 
Korea229 
Suspected CAD 
(68% male), 63 ± 9 
years, N=174 
-do- Colin VP-2000; 
Komaki Japan 
1651± 354 cm/s Continuous CAC score Sex, age, BMI, BP, 
HR, TC, glucose 
baPWV 
correlated in 
unadjusted 
analysis but 
not after 
adjustment 
Liu 2011 
Taiwan227 
Health screening 
patients (45.3% 
male), 54.5±9.4 
years N=654 
-do- Form ABI/PWV; 
Colin Co Ltd 
Normal: 1439 ± 98 
cm/s; CAD: 
1594±307 cm/s 
Categorical: 
<1400, 
1400-1800, 
>1800 cm/s 
CAC score None Mean CAC 
score 
significantly 
increased 
with 
increasing 
categories of 
baPWV 
Nam 2012 S 
Korea228 
Health screening 
patients, (63.9% 
male), 53.7±9.2 
years, N=615 
-do- VP device; 
Omron, Japan 
1427±234 cm/s Continuous CAC score None baPWV 
significantly 
correlated 
with CAC 
score in an 
unadjusted 
analysis 
Sung 2013 S 
Korea290 
Health screening 
patients, 81.2% 
male, Age: 
41.0±6.2 in no 
CAC group & 
47.2±7.3 in the 
CAC group, 
N=6009 
-do- VP-1000 device; 
Omron, Japan 
No CAC group: 
1302.9±146.3 cm/s; 
CAC group: 
1379.9±174.8 cm/s 
Quartiles Presence of 
CAC (>0 AU) 
Sex, age, TG, HDL-c, 
LDL-c, glucose, SBP, 
alcohol (glass/day), 
Smoking (ever), 
physical activity (≥ 3 
times/week), waist 
circumference, fatty 
liver 
Odds for 
presence of 
CAC 
significantly 
higher in 4th 
vs. 1st quartile 
of baPWV 
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Author-Year Population Follow-
Up 
baPWV 
Measurement 
/Distance 
Mean baPWV baPWV 
definition 
for 
model 
Outcome Confounders Results 
Coronary Angiography 
Imanishi 2004 
Japan231 
CAD patients (?) 
(62.6% male) 
63.5±11.8 years, 
N=123 
Cross-
sectional 
study 
Form ABI/PWV; 
Colin Co Ltd 
Japan 
Males: No 
CAD=1529±50 
cm/s, 
CAD=1890±53 
cm/s; Females, No 
CAD=1680±69 
cm/s, 
CAD=1846±84 
cm/s 
Categorical: 
1044-1470 
cm/s, 
1471-1693 
cm/s, 
1694-1986 
cm/s, 
1987-2643 
cm/s 
CAD defined as 
greater than 
50% stenosis in 
each of three 
coronary 
arteries 
Age, hypertension, 
DM, hyperlipidemia, 
chest pain 
Odds for 
CAD 
significantly 
higher in 
highest vs. 
lowest 
category of 
baPWV 
Sakuragi 2005 
Japan291 
CAD patients, 
(73.3% male), 
Non-CAD: 63±8 
years, CAD: 67±9 
years; N=251   
-do- Form PWV/ABI, 
Nihon Colin, 
Japan  
Non-CAD: 
1623±395 cm/s, 
CAD: 1748± 389 
cm/s 
Continuous Presence of 
CAD; one-, 
two-, or three- 
vessel disease 
None baPWV is 
higher in the 
CAD group, 
but not 
different in 
patients  with 
one-, two-, or 
three- vessel 
disease 
Koji 2007 
Japan292 
CAD patients 
(77.0% male) 
63±11 years 
N=396 
-do- Form ABI/PWV; 
Colin Co Ltd 
Japan 
Not reported Not 
reported 
No. of diseased 
arteries with 
>50% stenosis 
Age, gender, smoking 
and hypercholester-
olemia  
baPWV 
significantly 
associated 
with number 
of diseased 
arteries. 
Kwon 2011 
Korea230 
CAD patients 
(67.7% male). 
Age: 
baPWV<1600 
cm/s: 56.2±10.3 
years, 
baPWV≥1600 
cm/s: 66.6±8.33 
years  
-do- Colin VP-1000; 
Komaki, Japan 
Not reported <1600 
cm/s, and 
≥1600 cm/s 
Diseased 
vessel: >50% 
stenosis 
None Higher 
baPWV 
(>1600 cm/s) 
was 
associated 
with longer 
lesions and 
smaller 
lumen area 
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Up 
baPWV 
Measurement 
/Distance 
Mean baPWV baPWV 
definition 
for 
model 
Outcome Confounders Results 
Xiong 2012 
China232 
Retrospective 
enrollment od 
CAD 
patients(61.1% 
male) . Age: 
baPWV=61.8±9.4 
years, baPWVmid= 
64.5±10.6 years, 
baPWV hig= 
67.6±10.6 years, 
N=321 
-do- VP device, 
Omron, Japan 
SYNTAXlow:1474.9 
±357.7, 
SYNTAXmid:1947.7 
±323.9, 
SYNTAXhig:2428.8 
±440.7 
baPWV 
tertiles 
SYNTAX score 
tertiles  
Age, sex, BMI, 
current smoking, 
family history of 
CAD, DM< 
hypertension, 
hyperlipidemia, 
antihypertensive 
medication use, 
statins, SBP, DBP, 
MBP, BUN, sr. 
creatinine, TG, LDL-
c, cysteine proteinase, 
LV ejection fraction 
Significantly 
higher odds 
for higher 
SYNTAX 
score with 
increasing 
tertile of 
baPWV 
Seo 2010 S 
Korea229 
Suspected CAD 
(68% male), 63 ± 9 
years, N=174 
-do- Colin VP-2000; 
Komaki Japan 
1651± 354 cm/s Continuous Modified 
Gensini score, 
luminal 
narrowing 
Sex, age, BMI, BP, 
HR, TC, glucose 
baPWV is not 
correlated 
with CAD 
severity 
Liu 2011 
Taiwan227 
Health screening 
patients (45.3% 
male), 54.5±9.4 
years N=654 
-do- Form ABI/PWV; 
Colin Co Ltd 
Normal: 1439 ± 98 
cm/s; CAD: 
1594±307 cm/s 
Categorical: 
<1400, 
1400-1800, 
>1800 cm/s 
Coronary 
stenosis 
None Prevalence of 
coronary 
stenosis 
significantly 
higher with 
increasing 
categories of 
baPWV 
Chae 2013 S 
Korea293 
Chest pain 
patients, 58.1% 
male, 61.5±9.9 
years, N=651 
-do- VP device, 
Omron, Japan 
1646.5±467.2 cm/s Continuous Significant 
CAD= >50% 
stenosis; 0,1,2,3 
group 
depending on 
the number of 
vessels 
involved 
Sex, age, BMI, 
hypertension, DM, 
smoking, 
dyslipidemia, anti-
hypertensive 
medication use, 
HDL-c, LDL-c, 
glucose, HbA1c, SBP 
baPWV 
associated 
with 
significant 
CAD but not 
number of 
vessels 
involved 
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Nam 2012 S 
Korea228 
Health screening 
patients, (63.9% 
male), 53.7±9.2 
years, N=615 
-do- VP device; 
Omron, Japan 
1427±234 cm/s Continuous Coronary 
stenosis >50% 
Sex, age, 
hypertension, DM, 
current smoking, 
dyslipidemia 
baPWV 
significantly 
associated 
with 
significant 
coronary 
stenosis after 
multivariable 
adjustment 
Other disease Outcomes 
Munakata 2005 
Japan294 
ESRD patients, 
67.6% male, 
59.6±1.6 years, 
N=68 
-do- AT-form 
PWV/ABI, 
Colin, Komaki, 
Japan 
1836±48 (?SE) 
cm/s 
Continuous IMT (max IMT, 
plaque score), 
Echo-
cardiography 
(LVMI) 
None baPWV 
significantly 
correlated 
with max 
IMT, plaque 
score but not 
LVMI 
Takaki 2008 
Japan295 
Patients with chest 
pain, 61.5% male, 
69±12 years, 
N=130 
-do- AT-form 
PWV/ABI, 
Colin, Komaki, 
Japan 
1676±389 cm/s Continuous IMT, Echo-
cardiography 
None baPWV 
significantly 
correlated 
with max-
IMT but not 
with EDCT 
Sakuragi 2005 
Japan291 
CAD patients, 
(73.3% male), 
Non-CAD: 63±8 
years, CAD: 67±9 
years; N=251   
-do- Form PWV/ABI, 
Nihon Colin, 
Japan  
Non-CAD: 
1623±395 cm/s, 
CAD: 1748± 389 
cm/s 
Continuous Echo-
cardiography 
(LVEF) 
Age, BMI, TC, TG, 
HbA1c, LAD, E 
wave velocity, Dct, 
Number of diseased 
vessels, PP, ABI 
baPWV is 
significantly 
inversely  
associated 
with LVEF 
Otsuka 2013 
Japan296 
Health screening 
patients,  all males, 
38±9 years, N=387 
-do- Form PWV/ABI, 
Colin, Komaki, 
Japan 
1277±181 cm/s Continuous Oscillometric 
measurement of 
brachial artery 
cross-sectional 
area (eA) 
Age, BMI, SBP, HR, 
LDL-c, TG, glucose, 
uric acid, volume 
elastic modulus 
baPWV is not 
associated 
with eA 
independent 
of 
confounders 
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Nakamura 
2003 Japan297 
ESRD or PAD 
patients, 55.7% 
male, 62.3±1.3 
years, N=97 
-do- Form PWV/ABI, 
Colin, Komaki, 
Japan 
Males: 2047±86 
cm/s, Females: 
1881±78 cm/s 
Continuous Aortic 
calcification 
Age, SBP Aortic 
calcification 
length 
significantly 
associated 
with baPWV 
Cardiovascular disease event (since publication of meta-analysis in 2012 67 
Kawai 2013 
Japan298 
Hospital-based 
cohort (NOAH 
study), 56.1% 
male, 61.0±0.6 
years, N=440 
FU: 12.7 
years 
FCP-4731, 
Fukuda Denshi, 
Japan 
1690±17 cm/s <1750 
cm/s, and 
≥1750 cm/s 
CVD, Stroke, 
and all-cause 
mortality 
Age, Sex, DM, 
dyslipidemia, current 
smoking, and anti-
hypertensive 
medications 
baPWV is an 
independent 
predictor of 
CVD+Stroke 
mortality 
Yoon 2013 S 
Korea299 
Health screening 
(?) patients,  54.4% 
male, 52.9±9.2 
years, N=241 
Retro-
spective 
FU 
VP-1000, Colin, 
Japan 
1461.0±263.4 cm/s Continuous CHD, 
cerebrovascular 
disease, PVD, 
arrhythmia, and 
HF 
Age, sex, baseline 
eGFR, eGFR change, 
smoking, DM, 
hypertension, statins, 
CVD, SBP, DBP, 
BMI, brachial artery 
PWV, hematocrit, 
glucose, albumin, 
calcium, phosphorus, 
TC, TG, LDL-c, 
CRP, albuminuria 
baPWV was 
independently 
associated 
with CVD 
events in 
group with 
low eGFR 
(<90) but not 
in eGFR ≥ 90 
group 
Huang 2013 
Taiwan299 
Hemodialysis 
patients 
4.4±1.5 
years 
Form PWV/ABI, 
Colin, Komaki, 
Japan 
FRS low risk: 
1758.2±490.2 cm/s, 
intermediate risk: 
2065.5±560.5 cm/s, 
high risk: 
2082.3±430.0 cm/s 
Continuous CV events, CV 
mortality, all-
cause mortality 
None Addition of 
baPWV and 
ABI to FRS 
model 
improves 
prediction of 
all-cause but 
not CV 
mortality 
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Ishisone 2013 
Japan300 
General 
population, 88.2% 
male, 59±11 years, 
N=973 
FU: 7.8 
years 
HEM-907, 
Omron, Japan 
Not reported Quartiles; 
>90th 
percentile; 
1SD 
CV events 
(stroke+ CHF+ 
MI+ CV death) 
Age (>65), sex, 
obesity, hypertension, 
DM, 
hypercholesterolemia, 
current smoking  
baPWV 
(>90th 
percentile and 
1 SD change 
significantly 
and 
independently 
predicts CV 
event) 
Ninomiya 2013 
Japan301 
Population-based, 
42.7% male, >40 
years, N=2916 
FU: 7.1 
years 
BP-203RPE II 
form PWV/ABI, 
Omron, Japan 
Not reported Quintiles  CHD (AMI, 
silent MI, SCD, 
CABG, 
angioplasty) 
Age, sex, 
hypertension, DM, 
TC, HDL-c, obesity, 
smoking, alcohol, 
exercise 
baPWV 
associated 
independently 
with CV risk  
Nagai 2013 
Japan302 
Geriatric patients, 
41.6% male, Age: 
with vascular 
event-74±12 years, 
w/o vascular 
event-71±12 years, 
N=274 
FU: 
41±28 
months 
Form PWV/ABI, 
Omron, Japan 
With vascular 
event-2250 ± 660 
cm/s, w/o vascular 
event-1970± 650 
cm/s 
Tertile Angina/MI, 
cerebral 
hemorrhage, 
subarachnoid 
hemorrhage, 
cerebral 
infarction, TIA, 
HF, renal 
failure, 
arteriosclerosis 
obliterans, 
aortic dissection 
Age, sex baPWV 
predicted 
event 
independent 
of age, sex 
Han 2013 S 
Korea303 
Consecutive 
patients with 
baPWV & 
echocardiography, 
56.2% male, 61,7 
± 11.6 years, 
N=185 
FU: 19.8 
months 
Form BP-
203RPE II, 
Colin, Komaki, 
Japan 
1724 ± 454 cm/s <1704 
cm/s, 
≥1704 cm/s 
CV event 
(ischaemic 
stroke, CAD, 
PAD, or AD) 
Sex, age, ABI (≤0.9), 
hypertension, DM  
baPWV 
predicted 
independently 
CV event 
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Kuwahara 
2014 Japan304 
Hemodialysis 
patients, 61.0% 
male, 61.0±9.6 
years, N=300 
FU: 7 
years 
Form BP-
203RPE II, 
Colin, Komaki, 
Japan 
1870 ± 488 cm/s / 100 cm/s  Cardiac, 
cerebrovascular, 
and PAD events 
Age, duration of 
hemodialysis, DM, 
ABI, rate of decrease 
in ABI, rate of 
increase in baPWV, 
LDL-c, BMP, LVEF, 
LVMI 
baPWV not 
associated 
with any 
outcome in 
multivariable 
analysis 
Takashima 
2014 Japan305 
Population-based 
cohort, 37.2% 
male, 58.9±13.0 
years, N=4164  
FU:6.5 
years 
Form BP-
203RPE II, 
Omron 
1548 ± 374 cm/s /200 cm/s; 
<1400 
cm/s, 1400-
1790 cm/s, 
≥ 1800 
cm/s 
CVD, Stroke, 
AMI 
Age, sex, smoking, 
drinking, BMI, HDL-
c, LDL-c, TG, 
HbA1c, HR, diabetes 
medication, anti-
hypertensive 
medication, MBP 
Higher 
baPWV (≥ 
1800 cm/s) 
significantly 
predicted 
CVD event 
Sugamata 2014 
Japan306 
Patients with stable 
CAD, 72% male, 
65 ± 12 years, 
N=923 
FU: 
64±30 
months 
VP-1000, Colin, 
Komaki, Japan 
1651± 381 cm/s Continuous; 
/ 1SD 
change 
Coronary event 
(cardiac death, 
non-fatal MI, 
refractory 
unstable angina 
pectoris) 
Age, DM, LDL-c, 
number of diseased 
vessel, maxIMT, 
FMD 
1 SD change 
in baPWV 
significantly 
predicted 
coronary 
event 
140 
Table D-1 contd.
BIBLIOGRAPHY 
1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update:
a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
2. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for
cardiovascular health promotion and disease reduction: the American Heart Association's
strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586-613.
3. American Heart Association Nutrition C, Lichtenstein AH, Appel LJ, et al. Diet and
lifestyle recommendations revision 2006: a scientific statement from the American Heart
Association Nutrition Committee. Circulation. 2006;114(1):82-96.
4. NHLBI. Risk Assessment Tool for Estimating Your 10-year Risk of Having a Heart Attack.
Clinical Practice Guidelines  http://cvdrisk.nhlbi.nih.gov/. Accessed 10/27/2014, 2014.
5. Lloyd-Jones DM. Cardiovascular Risk Prediction: Basic Concepts, Current Status, and
Future Directions. Circulation. 2010;121(15):1768-1777.
6. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and
intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions
of the Council on Arteriosclerosis, American Heart Association. Circulation.
1994;89(5):2462-2478.
7. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes.
Circulation. 2001;104(3):365-372.
8. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory
enlargement of human atherosclerotic coronary arteries. N Engl J Med.
1987;316(22):1371-1375.
9. Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein KP. Remodeling of coronary
arteries in human and nonhuman primates. JAMA. 1994;271(4):289-294.
10. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation.
2005;111(25):3481-3488.
11. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred
definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
12. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by
cardiac computed tomography: a scientific statement from the American Heart Association
Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular
Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical
Cardiology. Circulation. 2006;114(16):1761-1791.
13. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus
document on coronary artery calcium scoring by computed tomography in global
cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the
American College of Cardiology Foundation Clinical Expert Consensus Task Force
141 
(ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on 
Electron Beam Computed Tomography). Circulation. 2007;115(3):402-426. 
14. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of 
cardiovascular risk in asymptomatic adults: A report of the american college of cardiology 
foundation/american heart association task force on practice guidelines. Circulation. 
2010;122(25):e584-e636. 
15. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart 
disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task 
Force. Ann Intern Med. 2009;151(7):496-507. 
16. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in 
cardiovascular risk prediction. Circulation. 2011;123(5):551-565. 
17. Blaha MJ, Silverman MG, Budoff MJ. Is there a role for coronary artery calcium scoring 
for management of asymptomatic patients at risk for coronary artery disease?: clinical risk 
scores are not sufficient to define primary prevention treatment strategies among 
asymptomatic patients. Circulation. Cardiovascular imaging. 2014;7(2):398-408. 
18. Andersson C, Vasan RS. Is there a role for coronary artery calcium scoring for management 
of asymptomatic patients at risk for coronary artery disease?: clinical risk scores are 
sufficient to define primary prevention treatment strategies among asymptomatic patients. 
Circulation. Cardiovascular imaging. 2014;7(2):390-397. 
19. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events 
in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336-1345. 
20. Vliegenthart R, Oudkerk M, Hofman A, et al. Coronary calcification improves 
cardiovascular risk prediction in the elderly. Circulation. 2005;112(4):572-577. 
21. Bauer M, Mohlenkamp S, Lehmann N, et al. The effect of age and risk factors on coronary 
and carotid artery atherosclerotic burden in males-Results of the Heinz Nixdorf Recall 
Study. Atherosclerosis. 2009;205(2):595-602. 
22. Akram K, O'Donnell RE, King S, Superko HR, Agatston A, Voros S. Influence of 
symptomatic status on the prevalence of obstructive coronary artery disease in patients with 
zero calcium score. Atherosclerosis. 2009;203(2):533-537. 
23. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score 
combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 
2004;291(2):210-215. 
24. Taylor AJ, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O'Malley PG. Coronary calcium 
independently predicts incident premature coronary heart disease over measured 
cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary 
Calcium (PACC) project. J Am Coll Cardiol. 2005;46(5):807-814. 
25. Becker A, Leber A, Becker C, Knez A. Predictive value of coronary calcifications for 
future cardiac events in asymptomatic individuals. American Heart Journal. 
2008;155(1):154-160. 
26. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical 
cardiovascular events with carotid intima-media thickness: a systematic review and meta-
analysis. Circulation. 2007;115(4):459-467. 
27. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media 
thickness, more accurately predicts coronary artery disease events: a meta-analysis. 
Atherosclerosis. 2012;220(1):128-133. 
142 
28. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness 
measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012;308(8):796-
803. 
29. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment 
of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S49-
S73. 
30. Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thickness progression to 
predict cardiovascular events in the general population (the PROG-IMT collaborative 
project): a meta-analysis of individual participant data. Lancet. 2012;379(9831):2053-
2062. 
31. Polak JF, Szklo M, Kronmal RA, et al. The value of carotid artery plaque and intima-media 
thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J 
Am Heart Assoc. 2013;2(2):e000087. 
32. Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or 
absence of plaque improves prediction of coronary heart disease risk: the ARIC 
(Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010;55(15):1600-1607. 
33. Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino RB, Sr. Carotid-
wall intima-media thickness and cardiovascular events. N Engl J Med. 2011;365(3):213-
221. 
34. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. 
Predictive value of noninvasive measures of atherosclerosis for incident myocardial 
infarction: the Rotterdam Study. Circulation. 2004;109(9):1089-1094. 
35. Klein JH, Hegele RA, Hackam DG, Koschinsky ML, Huff MW, Spence JD. Lipoprotein(a) 
is associated differentially with carotid stenosis, occlusion, and total plaque area. 
Arteriosclerosis, Thrombosis & Vascular Biology. 2008;28(10):1851-1856. 
36. Kuo F, Gardener H, Dong C, et al. Traditional cardiovascular risk factors explain the 
minority of the variability in carotid plaque. Stroke. 2012;43(7):1755-1760. 
37. Blondon M, Sachs M, Hoofnagle AN, et al. 25-Hydroxyvitamin D and parathyroid 
hormone are not associated with carotid intima-media thickness or plaque in the multi-
ethnic study of atherosclerosis. Arteriosclerosis, Thrombosis & Vascular Biology. 
2013;33(11):2639-2645. 
38. Herder M, Johnsen SH, Arntzen KA, Mathiesen EB. Risk factors for progression of carotid 
intima-media thickness and total plaque area: A 13-year follow-up study: The Tromsø 
study. Stroke. 2012;43(7):1818-1823. 
39. Resnick HE, Foster GL. Prevalence of elevated ankle-brachial index in the United States 
1999 to 2002. Am J Med. 2005;118(6):676-679. 
40. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial 
disease and risk factors in persons aged 60 and older: data from the National Health and 
Nutrition Examination Survey 1999-2004. J Am Geriatr Soc. 2007;55(4):583-589. 
41. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients 
with peripheral arterial disease. N Engl J Med. 1992;326(6):381-386. 
42. Kuller LH, Shemanski L, Psaty BM, et al. Subclinical disease as an independent risk factor 
for cardiovascular disease. Circulation. 1995;92(4):720-726. 
143 
43. Allison MA, Hiatt WR, Hirsch AT, Coll JR, Criqui MH. A high ankle-brachial index is 
associated with increased cardiovascular disease morbidity and lower quality of life. J Am 
Coll Cardiol. 2008;51(13):1292-1298. 
44. Ankle Brachial Index C, Fowkes FG, Murray GD, et al. Ankle brachial index combined 
with Framingham Risk Score to predict cardiovascular events and mortality: a meta-
analysis. JAMA. 2008;300(2):197-208. 
45. Lin JS, Olson CM, Johnson ES, Whitlock EP. The ankle-brachial index for peripheral 
artery disease screening and cardiovascular disease prediction among asymptomatic adults: 
a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 
2013;159(5):333-341. 
46. Witte DR, Westerink J, de Koning EJ, van der Graaf Y, Grobbee DE, Bots ML. Is the 
association between flow-mediated dilation and cardiovascular risk limited to low-risk 
populations? J Am Coll Cardiol. 2005;45(12):1987-1993. 
47. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation 
predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. 
Circulation. 2007;115(18):2390-2397. 
48. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flow-mediated dilation 
and cardiac risk factors in post-menopausal women. J Am Coll Cardiol. 2008;51(10):997-
1002. 
49. Suzuki T, Hirata K, Elkind MS, et al. Metabolic syndrome, endothelial dysfunction, and 
risk of cardiovascular events: the Northern Manhattan Study (NOMAS). American Heart 
Journal. 2008;156(2):405-410. 
50. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of 
arterial stiffness. Arteriosclerosis, Thrombosis & Vascular Biology. 2005;25(5):932-943. 
51. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current 
understanding and future directions. J Am Coll Cardiol. 2011;57(14):1511-1522. 
52. Mahfouz Badran H, Elnoamany M. Impact of type 2 diabetes mellitus on aortic elastic 
properties in normotensive diabetes: Doppler tissue imaging study. Journal of the 
American Society of Echocardiography. 2006;19(12):1471-1481. 
53. Vitarelli A, Giordano M, Germano G, et al. Assessment of ascending aorta wall stiffness 
in hypertensive patients by tissue Doppler imaging and strain Doppler echocardiography. 
Heart. 2010;96(18):1469-1474. 
54. Lee AT, Cerami A. Role of glycation in aging. Ann N Y Acad Sci. 1992;663:63-70. 
55. Bailey AJ. Molecular mechanisms of ageing in connective tissues. Mech Ageing Dev. 
2001;122(7):735-755. 
56. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension. 
1986;8(7):553-559. 
57. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide 
produced by vascular endothelial cells. Nature. 1988;332(6163):411-415. 
58. Gurtner GH, Burke-Wolin T. Interactions of oxidant stress and vascular reactivity. Am J 
Physiol. 1991;260(4 Pt 1):L207-211. 
59. Gates PE, Tanaka H, Hiatt WR, Seals DR. Dietary sodium restriction rapidly improves 
large elastic artery compliance in older adults with systolic hypertension. Hypertension. 
2004;44(1):35-41. 
144 
60. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Non-insulin-dependent diabetes 
mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness 
indexes: The ARIC study. Circulation. 1995;91(5):1432-1443. 
61. Sutton-Tyrrell K, Newman A, Simonsick EM, et al. Aortic stiffness is associated with 
visceral adiposity in older adults enrolled in the Study of Health, Aging, and Body 
Composition. Hypertension. 2001;38(3):429-433. 
62. Chang FC, Chiang WC, Tsai MH, et al. Angiopoietin-2-induced arterial stiffness in CKD. 
J Am Soc Nephrol. 2014;25(6):1198-1209. 
63. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for 
cardiovascular disease: functional markers. Circulation. 2004;109(25 Suppl 1):IV31-46. 
64. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-
cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll 
Cardiol. 2010;55(13):1318-1327. 
65. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial 
stiffness: methodological issues and clinical applications. European Heart Journal. 
2006;27(21):2588-2605. 
66. Van Bortel LM, Duprez D, Starmans-Kool MJ, et al. Clinical applications of arterial 
stiffness, Task Force III: recommendations for user procedures. Am J Hypertens. 
2002;15(5):445-452. 
67. Vlachopoulos C, Aznaouridis K, Terentes-Printzios D, Ioakeimidis N, Stefanadis C. 
Prediction of cardiovascular events and all-cause mortality with brachial-ankle elasticity 
index: a systematic review and meta-analysis. Hypertension. 2012;60(2):556-562. 
68. Asmar R, Benetos A, Topouchian J, et al. Assessment of arterial distensibility by automatic 
pulse wave velocity measurement. Validation and clinical application studies. 
Hypertension. 1995;26(3):485-490. 
69. Kimoto E, Shoji T, Shinohara K, et al. Preferential stiffening of central over peripheral 
arteries in type 2 diabetes. Diabetes. 2003;52(2):448-452. 
70. Hatsuda S, Shoji T, Shinohara K, et al. Regional arterial stiffness associated with ischemic 
heart disease in type 2 diabetes mellitus. J Atheroscler Thromb. 2006;13(2):114-121. 
71. Kimoto E, Shoji T, Shinohara K, et al. Regional arterial stiffness in patients with type 2 
diabetes and chronic kidney disease. J Am Soc Nephrol. 2006;17(8):2245-2252. 
72. Rhee MY, Na SH, Kim YK, Lee MM, Kim HY. Acute effects of cigarette smoking on 
arterial stiffness and blood pressure in male smokers with hypertension. Am J Hypertens. 
2007;20(6):637-641. 
73. Choo J, Shin C, Barinas-Mitchell E, et al. Regional pulse wave velocities and their 
cardiovascular risk factors among healthy middle-aged men: a cross-sectional population-
based study. BMC Cardiovascular Disorders. 2014;14:5. 
74. Tsuchikura S, Shoji T, Kimoto E, et al. Central versus peripheral arterial stiffness in 
association with coronary, cerebral and peripheral arterial disease. Atherosclerosis. 
2010;211(2):480-485. 
75. Massoud MA, Mourad AK, El BA, El SM. Biochemical studies on different field strains 
of the pink bollworm Pectinophora gossypiella (Saund.) (Lepidoptera: Gelechiidae) in 
Egypt. Commun Agric Appl Biol Sci. 2006;71(2 Pt B):517-535. 
76. Jadhav UM, Kadam NN. Non-invasive assessment of arterial stiffness by pulse-wave 
velocity correlates with endothelial dysfunction. Indian Heart J. 2005;57(3):226-232. 
145 
77. Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with 
increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism. 
2005;54(3):345-350. 
78. Vishnu A, Choo J, Masaki KH, et al. Particle numbers of lipoprotein subclasses and arterial 
stiffness among middle-aged men from the ERA JUMP study. J Hum Hypertens. 
2014;28(2):111-117. 
79. Ito N, Ohishi M, Takagi T, et al. Clinical usefulness and limitations of brachial-ankle pulse 
wave velocity in the evaluation of cardiovascular complications in hypertensive patients. 
Hypertens Res. 2006;29(12):989-995. 
80. O'Rourke MF. Pressure and flow waves in systemic arteries and the anatomical design of 
the arterial system. J Appl Physiol. 1967;23(2):139-149. 
81. Karamanoglu M, Gallagher DE, Avolio AP, O'Rourke MF. Pressure wave propagation in 
a multibranched model of the human upper limb. Am J Physiol. 1995;269(4 Pt 2):H1363-
1369. 
82. Franklin SS, Gustin Wt, Wong ND, et al. Hemodynamic patterns of age-related changes in 
blood pressure. The Framingham Heart Study. Circulation. 1997;96(1):308-315. 
83. Beltran A, McVeigh G, Morgan D, et al. Arterial compliance abnormalities in isolated 
systolic hypertension. Am J Hypertens. 2001;14(10):1007-1011. 
84. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction 
and heart failure in the elderly. J Am Coll Cardiol. 2000;36(1):130-138. 
85. Vaccarino V, Berger AK, Abramson J, et al. Pulse pressure and risk of cardiovascular 
events in the systolic hypertension in the elderly program. American Journal of 
Cardiology. 2001;88(9):980-986. 
86. Mitchell GF, Moye LA, Braunwald E, et al. Sphygmomanometrically determined pulse 
pressure is a powerful independent predictor of recurrent events after myocardial infarction 
in patients with impaired left ventricular function. SAVE investigators. Survival and 
Ventricular Enlargement. Circulation. 1997;96(12):4254-4260. 
87. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-
cause and cardiovascular mortality in hypertensive patients. Hypertension. 
2001;37(5):1236-1241. 
88. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse 
wave velocity as index of arterial stiffness in the general population. Circulation. 
2006;113(5):664-670. 
89. Mattace-Raso FUS, Van Der Cammen TJM, Hofman A, et al. Arterial stiffness and risk of 
coronary heart disease and stroke: The Rotterdam Study. Circulation. 2006;113(5):657-
663. 
90. Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al. Elevated aortic pulse wave velocity, a 
marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. 
Circulation. 2005;111(25):3384-3390. 
91. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the 
Framingham Heart Study. Circulation. 2010;121(4):505-511. 
92. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: 
a report from the American Heart Association. Circulation. 2013;127(1):e6-e245. 
93. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary 
disease, 1980-2000. N Engl J Med. 2007;356(23):2388-2398. 
146 
94. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal Trends in Coronary Heart 
Disease Mortality and Sudden Cardiac Death From 1950 to 1999: The Framingham Heart 
Study. Circulation. 2004;110(5):522-527. 
95. Goraya TY, Jacobsen SJ, Kottke TE, Frye RL, Weston SA, Roger VL. Coronary heart 
disease death and sudden cardiac death: a 20-year population-based study. Am J Epidemiol. 
2003;157(9):763-770. 
96. Kuller LH, Traven ND, Rutan GH, Perper JA, Ives DG. Marked decline of coronary heart 
disease mortality in 35-44-year-old white men in Allegheny County, Pennsylvania. 
Circulation. 1989;80(2):261-266. 
97. Chambless L, Keil U, Dobson A, et al. Population versus clinical view of case fatality from 
acute coronary heart disease: results from the WHO MONICA Project 1985-1990. 
Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. 
Circulation. 1997;96(11):3849-3859. 
98. Nichol G, Rumsfeld J, Eigel B, et al. Essential Features of Designating Out-of-Hospital 
Cardiac Arrest as a Reportable Event: A Scientific Statement From the American Heart 
Association Emergency Cardiovascular Care Committee; Council on Cardiopulmonary, 
Perioperative, and Critical Care; Council on Cardiovascular Nursing; Council on Clinical 
Cardiology; and Quality of Care and Outcomes Research Interdisciplinary Working Group. 
Circulation. 2008;117(17):2299-2308. 
99. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular 
disease in the United States: a policy statement from the American Heart Association. 
Circulation. 2011;123(8):933-944. 
100. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term 
coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the 
seven countries study. JAMA. 1995;274(2):131-136. 
101. Kagan A, Harris BR, Winkelstein W, Jr., et al. Epidemiologic studies of coronary heart 
disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, 
physical, dietary and biochemical characteristics. J Chronic Dis. 1974;27(7-8):345-364. 
102. Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum 
total cholesterol since 1980: systematic analysis of health examination surveys and 
epidemiological studies with 321 country-years and 3·0 million participants. The Lancet. 
2011;377(9765):578-586. 
103. Okayama A, Ueshima H, Marmot M, Elliott P, Choudhury SR, Kita Y. Generational and 
Regional Differences in Trends of Mortality from Ischemic Heart Disease in Japan from 
1969 to 1992. Am. J. Epidemiol. 2001;153(12):1191-1198. 
104. Sekikawa A, Willcox B, Usui T, et al. Do differences in risk factors explain the lower rates 
of coronary heart disease in Japanese versus U.S. women? (In Press). J Womens Health 
(Larchmt). 2013. 
105. Syme SL, Marmot MG, Kagan A, Kato H, Rhoads G. Epidemiologic studies of coronary 
heart disease and stroke in Japanese men living in Japan, Hawaii and California: 
introduction. Am J Epidemiol. 1975;102(6):477-480. 
106. Worth RM, Kato H, Rhoads GG, Kagan K, Syme SL. Epidemiologic studies of coronary 
heart disease and stroke in Japanese men living in Japan, Hawaii and California: mortality. 
Am J Epidemiol. 1975;102(6):481-490. 
147 
107. Nichaman MZ, Hamilton HB, Kagan A, Grier T, Sacks T, Syme SL. Epidemiologic studies 
of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and 
California: distribution of biochemical risk factors. Am J Epidemiol. 1975;102(6):491-501. 
108. Marmot MG, Syme SL, Kagan A, Kato H, Cohen JB, Belsky J. Epidemiologic studies of 
coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: 
prevalence of coronary and hypertensive heart disease and associated risk factors. Am J 
Epidemiol. 1975;102(6):514-525. 
109. Takeya Y, Popper JS, Shimizu Y, Kato H, Rhoads GG, Kagan A. Epidemiologic studies 
of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and 
California: Incidence of stroke in Japan and Hawaii. Stroke. 1984;15(1):15-23. 
110. Reed D, McGee D, Cohen J, Yano K, Syme SL, Feinleib M. Acculturation and coronary 
heart disease among Japanese men in Hawaii. Am J Epidemiol. 1982;115(6):894-905. 
111. Huang B, Rodriguez BL, Burchfiel CM, Chyou PH, Curb JD, Yano K. Acculturation and 
prevalence of diabetes among Japanese-American men in Hawaii. Am J Epidemiol. 
1996;144(7):674-681. 
112. Schakel SF, Dennis BH, Wold AC, et al. Enhancing data on nutrient composition of foods 
eaten by participants in the INTERMAP study in China, Japan, the United Kingdom, and 
the United States. Journal of Food Composition and Analysis. 2003;16(3):395-408. 
113. Stamler J, Elliott P, Dennis B, et al. INTERMAP: background, aims, design, methods, and 
descriptive statistics (nondietary). J Hum Hypertens. 2003;17(9):591-608. 
114. Ueshima H, Stamler J, Elliott P, et al. Food omega-3 fatty acid intake of individuals (total, 
linolenic acid, long-chain) and their blood pressure: INTERMAP study. Hypertension. 
2007;50(2):313-319. 
115. Elliott P, Stamler J, Dyer AR, et al. Association between protein intake and blood pressure: 
the INTERMAP Study. Arch Intern Med. 2006;166(1):79-87. 
116. Sakurai M, Stamler J, Miura K, et al. Relationship of dietary cholesterol to blood pressure: 
the INTERMAP study. Journal of Hypertension. 2011;29(2):222-228. 
117. Okuda N, Ueshima H, Okayama A, et al. Relation of long chain n-3 polyunsaturated fatty 
acid intake to serum high density lipoprotein cholesterol among Japanese men in Japan and 
Japanese-American men in Hawaii: the INTERLIPID study. Atherosclerosis. 
2005;178(2):371-379. 
118. Sekikawa A, Ueshima H, Kadowaki T, et al. Less subclinical atherosclerosis in Japanese 
men in Japan than in white men in the United States in the post-world war II birth cohort. 
Am J Epidemiol. 2007;165(6):617-624. 
119. Sekikawa A, Ueshima H, Zaky WR, et al. Much lower prevalence of coronary calcium 
detected by electron-beam computed tomography among men aged 40-49 in Japan than in 
the US, despite a less favorable profile of major risk factors. Int J Epidemiol. 
2005;34(1):173-179. 
120. Sekikawa A, Curb JD, Ueshima H, et al. Marine-derived n-3 fatty acids and atherosclerosis 
in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll 
Cardiol. 2008;52(6):417-424. 
121. Sekikawa A, Miura K, Lee S, et al. Long chain n-3 polyunsaturated fatty acids and 
incidence rate of coronary artery calcification in Japanese men in Japan and white men in 
the USA: Population based prospective cohort study. Heart. 2014;100(7):569-573. 
148 
122. Dolecek TA. Epidemiological evidence of relationships between dietary polyunsaturated 
fatty acids and mortality in the multiple risk factor intervention trial. Proc Soc Exp Biol 
Med. 1992;200(2):177-182. 
123. Morris MC, Manson JE, Rosner B, Buring JE, Willett WC, Hennekens CH. Fish 
consumption and cardiovascular disease in the physicians' health study: a prospective 
study. Am J Epidemiol. 1995;142(2):166-175. 
124. Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of 
long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 
1995;274(17):1363-1367. 
125. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and 
the risk of sudden death. N Engl J Med. 2002;346(15):1113-1118. 
126. Mozaffarian D, Lemaitre RN, Kuller LH, et al. Cardiac benefits of fish consumption may 
depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation. 
2003;107(10):1372-1377. 
127. Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE. Fish and long-chain omega-3 fatty 
acid intake and risk of coronary heart disease and total mortality in diabetic women. 
Circulation. 2003;107(14):1852-1857. 
128. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence 
supporting a causal link between dietary factors and coronary heart disease. Arch Intern 
Med. 2009;169(7):659-669. 
129. Stamler J, Elliott P, Chan Q. INTERMAP Appendix Tables, Tables of Contents (Tables 
A). J Hum Hypertens. 2003;17(9):665-758. 
130. Hodis HN, Mack WJ, Kono N, et al. Isoflavone Soy Protein Supplementation and 
Atherosclerosis Progression in Healthy Postmenopausal Women A Randomized 
Controlled Trial. Stroke. 2011;42(11):3168-3175. 
131. Kokubo Y, Iso H, Ishihara J, et al. Association of dietary intake of soy, beans, and 
isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the 
Japan Public Health Center-based (JPHC) study cohort I. Circulation. 2007;116(22):2553-
2562. 
132. van der Schouw YT, Kreijkamp-Kaspers S, Peeters PH, Keinan-Boker L, Rimm EB, 
Grobbee DE. Prospective study on usual dietary phytoestrogen intake and cardiovascular 
disease risk in Western women. Circulation. 2005;111(4):465-471. 
133. Zhang X, Shu XO, Gao YT, et al. Soy food consumption is associated with lower risk of 
coronary heart disease in Chinese women. J Nutr. 2003;133(9):2874-2878. 
134. File SE, Hartley DE, Elsabagh S, Duffy R, Wiseman H. Cognitive improvement after 6 
weeks of soy supplements in postmenopausal women is limited to frontal lobe function. 
Menopause. 2005;12(2):193-201. 
135. Shimazu T, Inoue M, Sasazuki S, et al. Plasma isoflavones and the risk of lung cancer in 
women: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev. 
2011;20(3):419-427. 
136. Messina M, Ho S, Alekel DL. Skeletal benefits of soy isoflavones: a review of the clinical 
trial and epidemiologic data. Curr Opin Clin Nutr Metab Care. 2004;7(6):649-658. 
137. Aso T, Uchiyama S, Matsumura Y, et al. A natural S-equol supplement alleviates hot 
flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese 
women. J Womens Health (Larchmt). 2012;21(1):92-100. 
149 
138. Nestel P. Isoflavones: their effects on cardiovascular risk and functions. Curr Opin Lipidol. 
2003;14(1):3-8. 
139. Rimbach G, Boesch-Saadatmandi C, Frank J, et al. Dietary isoflavones in the prevention 
of cardiovascular disease--a molecular perspective. Food Chem Toxicol. 2008;46(4):1308-
1319. 
140. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis 
progression: a comparison of the effects of conjugated equine estrogens and soy 
phytoestrogens. J Clin Endocrinol Metab. 2001;86(1):41-47. 
141. Gencel VB, Benjamin MM, Bahou SN, Khalil RA. Vascular effects of phytoestrogens and 
alternative menopausal hormone therapy in cardiovascular disease. Mini Rev Med Chem. 
2012;12(2):149-174. 
142. Makela S, Savolainen H, Aavik E, et al. Differentiation between vasculoprotective and 
uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha 
and beta. Proc Natl Acad Sci U S A. 1999;96(12):7077-7082. 
143. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity 
and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 
1997;138(3):863-870. 
144. Salzman AL, Preiser JC, Setchell KD, Szabo C. Isoflavone-mediated inhibition of tyrosine 
kinase: a novel antiinflammatory approach. J Med Food. 1999;2(3-4):179-181. 
145. Klein MA, Nahin RL, Messina MJ, et al. Guidance from an NIH workshop on designing, 
implementing, and reporting clinical studies of soy interventions. J Nutr. 
2010;140(6):1192S-1204S. 
146. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. 
Nutr Cancer. 2006;55(1):1-12. 
147. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and 
phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139(10):4252-4263. 
148. Anthony MS, Clarkson TB, Bullock BC, Wagner JD. Soy Protein Versus Soy 
Phytoestrogens in the Prevention of Diet-Induced Coronary Artery Atherosclerosis of Male 
Cynomolgus Monkeys. Arteriosclerosis, Thrombosis & Vascular Biology. 
1997;17(11):2524-2531. 
149. Honoré EK, Williams JK, Anthony MS, Clarkson TB. Soy isoflavones enhance coronary 
vascular reactivity in atherosclerotic female macaques. Fertility and Sterility. 
1997;67(1):148-154. 
150. Anthony MS, Clarkson TB, Hughes Jr CL, Morgan TM, Burke GL. Soybean isoflavones 
improve cardiovascular risk factors without affecting the reproductive system of 
peripubertal rhesus monkeys. J Nutr. 1996;126(1):43-50. 
151. Rayner K, Sun J, Chen YX, et al. Heat shock protein 27 protects against atherogenesis via 
an estrogen-dependent mechanism: role of selective estrogen receptor beta modulation. 
Arteriosclerosis, Thrombosis & Vascular Biology. 2009;29(11):1751-1756. 
152. Nilsson S, Gustafsson JA. Estrogen receptors: therapies targeted to receptor subtypes. Clin 
Pharmacol Ther. 2011;89(1):44-55. 
153. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human 
health. J Nutr. 1999;129(3):758S-767S. 
154. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in 
Japanese men. Lancet. 1993;342(8881):1209-1210. 
150 
155. Marrian GF, Haslewood GAD. Equol, a new inactive phenol isolated from the 
ketohydroxyoestrin fraction of mares' urine. Biochemical Journal. 1932;26(4):1227. 
156. Setchell KDR, Borriello SP, Hulme P. Nonsteroidal estrogens of dietary origin: Possible 
roles in hormone-dependent disease. Am J Clin Nutr. 1984;40(3):569-578. 
157. Setchell KD, Clerici C. Equol: pharmacokinetics and biological actions. J Nutr. 
2010;140(7):1363S-1368S. 
158. Setchell KD, Faughnan MS, Avades T, et al. Comparing the pharmacokinetics of daidzein 
and genistein with the use of 13C-labeled tracers in premenopausal women. Am J Clin 
Nutr. 2003;77(2):411-419. 
159. Lamberton JA, Suares H, Watson K. Catalytic hydrogenation of isoflavones. The 
preparation of (±)-equol and related isoflavans. Australian Journal of Chemistry. 
1978;31(2):455-457. 
160. Setchell KDR, Sorokin VD. Method for enantioselective hydrogenation of chromenes. 
Google Patents; 2011. 
161. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite 
equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002;132(12):3577-
3584. 
162. Nagel SC, Vom Saal FS, Welshons WV. The effective free fraction of estradiol and 
xenoestrogens in human serum measured by whole cell uptake assays: Physiology of 
delivery modifies estrogenic activity. Proceedings of the Society for Experimental Biology 
and Medicine. 1998;217(3):300-309. 
163. Setchell KD, Zhao X, Jha P, Heubi JE, Brown NM. The pharmacokinetic behavior of the 
soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults 
determined by using stable-isotope-labeled tracers. Am J Clin Nutr. 2009;90(4):1029-1037. 
164. Setchell KD, Zhao X, Shoaf SE, Ragland K. The pharmacokinetics of S-(-)equol 
administered as SE5-OH tablets to healthy postmenopausal women. J Nutr. 
2009;139(11):2037-2043. 
165. Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors 
alpha and beta. Biol Pharm Bull. 2001;24(4):351-356. 
166. Cheng C, Wang X, Weakley SM, et al. The soybean isoflavonoid equol blocks ritonavir-
induced endothelial dysfunction in porcine pulmonary arteries and human pulmonary 
artery endothelial cells. J Nutr. 2010;140(1):12-17. 
167. Hwang J, Wang J, Morazzoni P, Hodis HN, Sevanian A. The phytoestrogen equol increases 
nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for 
cell-mediated LDL modification. Free Radic Biol Med. 2003;34(10):1271-1282. 
168. Jackman KA, Woodman OL, Chrissobolis S, Sobey CG. Vasorelaxant and antioxidant 
activity of the isoflavone metabolite equol in carotid and cerebral arteries. Brain Res. 
2007;1141:99-107. 
169. Joy S, Siow RC, Rowlands DJ, et al. The isoflavone Equol mediates rapid vascular 
relaxation: Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 
involving ERK1/2 and Akt phosphorylation in human endothelial cells. J Biol Chem. 
2006;281(37):27335-27345. 
170. Akaza H, Miyanaga N, Takashima N, et al. Comparisons of percent equol producers 
between prostate cancer patients and controls: case-controlled studies of isoflavones in 
Japanese, Korean and American residents. Jpn J Clin Oncol. 2004;34(2):86-89. 
151 
171. Arai Y, Uehara M, Sato Y, et al. Comparison of isoflavones among dietary intake, plasma 
concentration and urinary excretion for accurate estimation of phytoestrogen intake. J 
Epidemiol. 2000;10(2):127-135. 
172. Fujimoto K, Tanaka M, Hirao Y, et al. Age-stratified serum levels of isoflavones and 
proportion of equol producers in Japanese and Korean healthy men. Prostate Cancer 
Prostatic Dis. 2008;11(3):252-257. 
173. Nagata C, Ueno T, Uchiyama S, et al. Dietary and lifestyle correlates of urinary excretion 
status of equol in Japanese women. Nutr Cancer. 2008;60(1):49-54. 
174. Setchell KD, Clerici C. Equol: history, chemistry, and formation. J Nutr. 
2010;140(7):1355S-1362S. 
175. Maskarinec G, Yamakawa R, Hebshi S, Franke AA. Urinary isoflavonoid excretion and 
soy consumption in three generations of Japanese women in Hawaii. Eur J Clin Nutr. 
2007;61(2):255-261. 
176. Lampe JW, Skor HE, Li S, Wähälä K, Howald WN, Chen C. Wheat bran and soy protein 
feeding do not alter urinary excretion of the isoflavan equol in premenopausal women. 
Journal of Nutrition. 2001;131(3):740-744. 
177. Setchell KD, Brown NM, Summer S, et al. Dietary factors influence production of the soy 
isoflavone metabolite s-(-)equol in healthy adults. J Nutr. 2013;143(12):1950-1958. 
178. Usui T, Tochiya M, Sasaki Y, et al. Effects of natural S-equol supplements on overweight 
or obesity and metabolic syndrome in the Japanese, based on sex and equol status. Clin 
Endocrinol (Oxf). 2013;78(3):365-372. 
179. Setchell KDR, Cole SJ. Method of defining equol-producer status and its frequency among 
vegetarians. Journal of Nutrition. 2006;136(8):2188-2193. 
180. Vedrine N, Mathey J, Morand C, et al. One-month exposure to soy isoflavones did not 
induce the ability to produce equol in postmenopausal women. Eur J Clin Nutr. 
2006;60(9):1039-1045. 
181. Setchell KDR, Zimmer-Nechemias L, Cai J, Heubi JE. Exposure of infants to phyto-
oestrogens from soy-based infant formula. Lancet. 1997;350(9070):23-27. 
182. Watanabe S, Yamaguchi M, Sobue T, et al. Pharmacokinetics of soybean isoflavones in 
plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J 
Nutr. 1998;128(10):1710-1715. 
183. Rowland IR, Wiseman H, Sanders TAB, Adlercreutz H, Bowey EA. Interindividual 
variation in metabolism of soy isoflavones and lignans: Influence of habitual diet on equol 
production by the gut microflora. Nutr Cancer. 2000;36(1):27-32. 
184. Wiseman H, Casey K, Bowey EA, et al. Influence of 10 wk of soy consumption on plasma 
concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy 
adults. Am J Clin Nutr. 2004;80(3):692-699. 
185. Atkinson C, Newton KM, Aiello Bowles EJ, Yong M, Lampe JW. Demographic, 
anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-
metabolizing phenotypes among premenopausal women in the United States. Am J Clin 
Nutr. 2008;87(3):679-687. 
186. Thorp AA, Howe PRC, Mori TA, et al. Soy food consumption does not lower LDL 
cholesterol in either equol or nonequol producers. Am J Clin Nutr. 2008;88(2):298-304. 
187. Sen C, Morimoto Y, Heak S, Cooney RV, Franke AA, Maskarinec G. Soy foods and 
urinary isoprostanes: Results from a randomized study in premenopausal women. Food 
and Function. 2012;3(5):517-521. 
152 
188. Wong JM, Kendall CW, Marchie A, et al. Equol status and blood lipid profile in 
hyperlipidemia after consumption of diets containing soy foods. Am J Clin Nutr. 
2012;95(3):564-571. 
189. Tseng M, Byrne C, Kurzer MS, Fang CY. Equol-producing status, isoflavone intake, and 
breast density in a sample of U.S. Chinese women. Cancer Epidemiol Biomarkers Prev. 
2013;22(11):1975-1983. 
190. van der Velpen V, Geelen A, Hollman PC, Schouten EG, van 't Veer P, Afman LA. 
Isoflavone supplement composition and equol producer status affect gene expression in 
adipose tissue: a double-blind, randomized, placebo-controlled crossover trial in 
postmenopausal women. Am J Clin Nutr. 2014;100(5):1269-1277. 
191. Nakatsu CH, Armstrong A, Clavijo AP, Martin BR, Barnes S, Weaver CM. Fecal bacterial 
community changes associated with isoflavone metabolites in postmenopausal women 
after soy bar consumption. PLoS ONE [Electronic Resource]. 2014;9(10):e108924. 
192. Hwang CS, Kwak HS, Lim HJ, et al. Isoflavone metabolites and their in vitro dual 
functions: they can act as an estrogenic agonist or antagonist depending on the estrogen 
concentration. J Steroid Biochem Mol Biol. 2006;101(4-5):246-253. 
193. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall 
stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 
2006;13(2):101-107. 
194. Zhang X, Gao YT, Yang G, et al. Urinary isoflavonoids and risk of coronary heart disease. 
Int J Epidemiol. 2012;41(5):1367-1375. 
195. Johnsen SH, Mathiesen EB. Carotid plaque compared with intima-media thickness as a 
predictor of coronary and cerebrovascular disease. Current Cardiology Reports. 
2009;11(1):21-27. 
196. Ranjit N, Diez-Roux AV, Chambless L, Jacobs DR, Jr., Nieto FJ, Szklo M. Socioeconomic 
differences in progression of carotid intima-media thickness in the Atherosclerosis Risk in 
Communities study. Arteriosclerosis, Thrombosis & Vascular Biology. 2006;26(2):411-
416. 
197. Carson AP, Rose KM, Catellier DJ, et al. Cumulative socioeconomic status across the life 
course and subclinical atherosclerosis. Ann Epidemiol. 2007;17(4):296-303. 
198. Touboul PJ, Hernandez-Hernandez R, Kucukoglu S, et al. Carotid artery intima media 
thickness, plaque and Framingham cardiovascular score in Asia, Africa/Middle East and 
Latin America: the PARC-AALA study. The International Journal of Cardiovascular 
Imaging. 2007;23(5):557-567. 
199. Lutsey PL, Diez Roux AV, Jacobs DR, Jr., et al. Associations of acculturation and 
socioeconomic status with subclinical cardiovascular disease in the multi-ethnic study of 
atherosclerosis. Am J Public Health. 2008;98(11):1963-1970. 
200. Thompson T, Sutton-Tyrrell K, Wildman R. Continuous quality assessment programs can 
improve carotid duplex scan quality. Journal of Vascular Technology. 2001;25(1):33-39. 
201. Choo J, Ueshima H, Curb JD, et al. Serum n-6 fatty acids and lipoprotein subclasses in 
middle-aged men: the population-based cross-sectional ERA-JUMP study. Am J Clin Nutr. 
2010;91(5):1195-1203. 
202. Fujiyoshi A, Sekikawa A, Shin C, et al. A cross-sectional association of obesity with 
coronary calcium among Japanese, Koreans, Japanese Americans, and U.S. whites. Eur 
Heart J Cardiovasc Imaging. 2013;14(9):921-927. 
153 
203. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management 
of hypertension in the community a statement by the american society of hypertension and 
the international society of hypertension. Journal of Hypertension. 2014;32(1):3-15. 
204. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National 
Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate 
and precise lipid measurements. Clin Lab Med. 1989;9(1):105-135. 
205. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment 
of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report 
of the American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines. Circulation. 2013. 
206. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 
Suppl 1:S81-90. 
207. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and 
differences. Am J Epidemiol. 2005;162(3):199-200. 
208. Li R, Duncan BB, Metcalf PA, et al. B-mode-detected carotid artery plaque in a general 
population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke. 
1994;25(12):2377-2383. 
209. Lee YH, Kweon SS, Choi BY, et al. Self-reported snoring and carotid atherosclerosis in 
middle-aged and older adults: the Korean Multi-Rural Communities Cohort Study. J 
Epidemiol. 2014;24(4):281-286. 
210. Kweon SS, Shin MH, Park KS, et al. Distribution of the ankle-brachial index and 
associated cardiovascular risk factors in a population of middle-aged and elderly koreans. 
J Korean Med Sci. 2005;20(3):373-378. 
211. Choo J, Ueshima H, Jang Y, et al. Difference in carotid intima-media thickness between 
Korean and Japanese men. Ann Epidemiol. 2008;18(4):310-315. 
212. Sekikawa A, Kuller LH, Ueshima H, et al. Coronary heart disease mortality trends in men 
in the post World War II birth cohorts aged 35-44 in Japan, South Korea and Taiwan 
compared with the United States. Int J Epidemiol. 1999;28(6):1044-1049. 
213. Ishihara J, Iso H, Inoue M, et al. Intake of folate, vitamin B6 and vitamin B12 and the risk 
of CHD: the Japan Public Health Center-Based Prospective Study Cohort I. J Am Coll 
Nutr. 2008;27(1):127-136. 
214. Ueshima H, Okayama A, Saitoh S, et al. Differences in cardiovascular disease risk factors 
between Japanese in Japan and Japanese-Americans in Hawaii: the INTERLIPID study. J 
Hum Hypertens. 2003;17(9):631-639. 
215. Eshak ES, Iso H, Yamagishi K, et al. Modification of the excess risk of coronary heart 
disease due to smoking by seafood/fish intake. Am J Epidemiol. 2014;179(10):1173-1181. 
216. Nakamura T, Azuma A, Kuribayashi T, Sugihara H, Okuda S, Nakagawa M. Serum fatty 
acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: 
the Kumihama study. Br J Nutr. 2003;89(2):267-272. 
217. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major 
coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, 
blinded endpoint analysis. Lancet. 2007;369(9567):1090-1098. 
218. Najjar SS, Scuteri A, Lakatta EG. Arterial aging: is it an immutable cardiovascular risk 
factor? Hypertension. 2005;46(3):454-462. 
154 
219. Wasserman BA, Sharrett AR, Lai S, et al. Risk factor associations with the presence of a 
lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI: the 
multi-ethnic study of atherosclerosis (MESA). Stroke. 2008;39(2):329-335. 
220. Zureik M, Ducimetiere P, Touboul PJ, et al. Common carotid intima-media thickness 
predicts occurrence of carotid atherosclerotic plaques: longitudinal results from the Aging 
Vascular Study (EVA) study. Arteriosclerosis, Thrombosis & Vascular Biology. 
2000;20(6):1622-1629. 
221. Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical 
significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens 
Res. 2002;25(3):359-364. 
222. Brunner-La Rocca HP. Towards applicability of measures of arterial stiffness in clinical 
routine. European Heart Journal. 2010;31(19):2320-2322. 
223. Venkitachalam L, Mackey RH, Sutton-Tyrrell K, et al. Elevated pulse wave velocity 
increases the odds of coronary calcification in overweight postmenopausal women. Am J 
Hypertens. 2007;20(5):469-475. 
224. Li S, Chen W, Srinivasan SR, Berenson GS. Influence of metabolic syndrome on arterial 
stiffness and its age-related change in young adults: The Bogalusa Heart study. 
Atherosclerosis. 2005;180(2):349-354. 
225. Loehr LR, Snyder M, Selvin E, et al. Abstract P336: Diabetes and Impaired Fasting 
Glucose are Associated with Pulse Wave Velocity in Older Adults: the ARIC Study. 
Circulation. 2014;129(Suppl 1):AP336. 
226. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R. 
Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll 
Cardiol. 1990;15(4):827-832. 
227. Liu CS, Li CI, Shih CM, et al. Arterial stiffness measured as pulse wave velocity is highly 
correlated with coronary atherosclerosis in asymptomatic patients. J Atheroscler Thromb. 
2011;18(8):652-658. 
228. Nam HJ, Jung IH, Kim J, et al. Association between brachial-ankle pulse wave velocity 
and occult coronary artery disease detected by multi-detector computed tomography. 
International Journal of Cardiology. 2012;157(2):227-232. 
229. Seo WW, Chang HJ, Cho I, et al. The value of brachial-ankle pulse wave velocity as a 
predictor of coronary artery disease in high-risk patients. Korean Circ J. 2010;40(5):224-
229. 
230. Kwon JE, Mintz GS, Kim SW, et al. Relationship between coronary artery plaque 
composition by virtual histology intravascular ultrasound analysis and brachial-ankle pulse 
wave velocity in patients with coronary artery disease. Coron Artery Dis. 2011;22(8):565-
569. 
231. Imanishi R, Seto S, Toda G, et al. High brachial-ankle pulse wave velocity is an 
independent predictor of the presence of coronary artery disease in men. Hypertension 
Research. 2004;27(2):71-78. 
232. Xiong Z, Zhu C, Zheng Z, et al. Relationship between arterial stiffness assessed by 
brachial-ankle pulse wave velocity and coronary artery disease severity assessed by the 
SYNTAX score. J Atheroscler Thromb. 2012;19(11):970-976. 
233. Sugawara J, Hayashi K, Yokoi T, et al. Brachial-ankle pulse wave velocity: an index of 
central arterial stiffness? J Hum Hypertens. 2005;19(5):401-406. 
155 
234. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive 
protein is associated with arterial stiffness in apparently healthy individuals. 
Arteriosclerosis, Thrombosis & Vascular Biology. 2004;24(5):969-974. 
235. Hall JE, Kuo JJ, da Silva AA, de Paula RB, Liu J, Tallam L. Obesity-associated 
hypertension and kidney disease. Curr Opin Nephrol Hypertens. 2003;12(2):195-200. 
236. Safar M, O'Rourke MF. Arterial stiffness in hypertension. Vol 23: Elsevier Health 
Sciences; 2006. 
237. London GM, Guerin AP. Influence of arterial pulse and reflected waves on blood pressure 
and cardiac function. American Heart Journal. 1999;138(3 Pt 2):220-224. 
238. Blaha M, Budoff MJ, Shaw LJ, et al. Absence of coronary artery calcification and all-cause 
mortality. Jacc: Cardiovascular Imaging. 2009;2(6):692-700. 
239. Mozaffarian D, Appel LJ, Van Horn L. Components of a Cardioprotective Diet. 
Circulation. 2011;123(24):2870-2891. 
240. Sekikawa A, Willcox BJ, Usui T, et al. Do differences in risk factors explain the lower 
rates of coronary heart disease in Japanese versus U.S. women? J Womens Health 
(Larchmt). 2013;22(11):966-977. 
241. Wagner JD, Cefalu WT, Anthony MS, Litwak KN, Zhang L, Clarkson TB. Dietary soy 
protein and estrogen replacement therapy improve cardiovascular risk factors and decrease 
aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism. 
1997;46(6):698-705. 
242. Zhang X, Shu XO, Gao Y-T, et al. Soy Food Consumption Is Associated with Lower Risk 
of Coronary Heart Disease in Chinese Women. J. Nutr. 2003;133(9):2874-2878. 
243. Clarkson TB, Utian WH, Barnes S, et al. The role of soy isoflavones in menopausal health: 
Report of the North American Menopause Society/Wulf H. Utian Translational Science 
Symposium in Chicago, IL (October 2010). Menopause. 2011;18(7):732-753. 
244. Shimada Y, Takahashi M, Miyazawa N, Abiru Y, Uchiyama S, Hishigaki H. Identification 
of a novel dihydrodaidzein racemase essential for biosynthesis of equol from daidzein in 
Lactococcus sp. strain 20-92. Appl Environ Microbiol. 2012;78(14):4902-4907. 
245. Yamamoto S, Sobue T, Sasaki S, et al. Validity and reproducibility of a self-administered 
food-frequency questionnaire to assess isoflavone intake in a japanese population in 
comparison with dietary records and blood and urine isoflavones. J Nutr. 
2001;131(10):2741-2747. 
246. Pumford SL, Morton MM, Turkes A, Griffiths K. Determination of the isoflavonoids 
genistein and daidzein in biological samples by gas chromatography-mass spectrometry. 
Ann Clin Biochem. 2002;39(Pt 3):281-292. 
247. Okamura T, Kadowaki T, Sekikawa A, et al. Alcohol Consumption and Coronary Artery 
Calcium in Middle-Aged Japanese Men. American Journal of Cardiology. 
2006;98(2):141-144. 
248. Balk E, Chung M, Chew P, et al. Effects of Soy on Health Outcomes. Evidence 
Report/Technology Assessment No. 126. Vol No. 126. Rockville, MD: Agency for 
Healthcare Research and Quality; 2005. 
249. Liu XX, Li SH, Chen JZ, et al. Effect of soy isoflavones on blood pressure: a meta-analysis 
of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2012;22(6):463-470. 
250. Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum 
total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. 
Am J Clin Nutr. 2007;85(4):1148-1156. 
156 
251. Ricci E, Cipriani S, Chiaffarino F, Malvezzi M, Parazzini F. Effects of soy isoflavones and 
genistein on glucose metabolism in perimenopausal and postmenopausal non-Asian 
women: a meta-analysis of randomized controlled trials. Menopause. 2010;17(5):1080-
1086. 
252. Chan YH, Lau KK, Yiu KH, et al. Isoflavone intake in persons at high risk of 
cardiovascular events: implications for vascular endothelial function and the carotid 
atherosclerotic burden. Am J Clin Nutr. 2007;86(4):938-945. 
253. Curtis PJ, Potter J, Kroon PA, et al. Vascular function and atherosclerosis progression after 
1 y of flavonoid intake in statin-treated postmenopausal women with type 2 diabetes: a 
double-blind randomized controlled trial. Am J Clin Nutr. 2013;97(5):936-942. 
254. Liu ZM, Ho SC, Chen YM, et al. Whole soy, but not purified daidzein, had a favorable 
effect on improvement of cardiovascular risks: a 6-month randomized, double-blind, and 
placebo-controlled trial in equol-producing postmenopausal women. Mol Nutr Food Res. 
2014;58(4):709-717. 
255. Ueshima H. Explanation for the Japanese paradox: prevention of increase in coronary heart 
disease and reduction in stroke. J Atheroscler Thromb. 2007;14(6):278-286. 
256. WHO. Public Health. Trade, foreign policy, diplomacy and health 2014; 
http://www.who.int/trade/glossary/story076/en/. Accessed 29th November, 2014. 
257. Tell GS, Howard G, McKinney WM. Risk factors for site specific extracranial carotid 
artery plaque distribution as measured by B-mode ultrasound. J Clin Epidemiol. 
1989;42(6):551-559. 
258. Handa N, Matsumoto M, Maeda H, et al. Ultrasonic evaluation of early carotid 
atherosclerosis. Stroke. 1990;21(11):1567-1572. 
259. Prati P, Vanuzzo D, Casaroli M, et al. Prevalence and determinants of carotid 
atherosclerosis in a general population. Stroke. 1992;23(12):1705-1711. 
260. Salonen R, Tervahauta M, Salonen JT, Pekkanen J, Nissinen A, Karvonen MJ. 
Ultrasonographic manifestations of common carotid atherosclerosis in elderly eastern 
Finnish men. Prevalence and associations with cardiovascular diseases and risk factors. 
Arterioscler Thromb. 1994;14(10):1631-1640. 
261. Bonithon-Kopp C, Touboul PJ, Berr C, et al. Relation of intima-media thickness to 
atherosclerotic plaques in carotid arteries. The Vascular Aging (EVA) Study. 
Arteriosclerosis, Thrombosis & Vascular Biology. 1996;16(2):310-316. 
262. Bonora E, Willeit J, Kiechl S, et al. Relationship between insulin and carotid 
atherosclerosis in the general population. The Bruneck Study. Stroke. 1997;28(6):1147-
1152. 
263. Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima media thickness, 
cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the 
British Regional Heart Study. Stroke. 1999;30(4):841-850. 
264. Spence JD, Barnett PA, Bulman DE, Hegele RA. An approach to ascertain probands with 
a non-traditional risk factor for carotid atherosclerosis. Atherosclerosis. 1999;144(2):429-
434. 
265. Wagenknecht L, Wasserman B, Chambless L, et al. Correlates of carotid plaque presence 
and composition as measured by MRI: the Atherosclerosis Risk in Communities Study. 
Circulation. Cardiovascular imaging. 2009;2(4):314-322. 
157 
266. Kelley RE, Dasmahapatra P, Wang J, et al. Prevalence of atherosclerotic plaque in young 
and middle-aged asymptomatic individuals: the Bogalusa heart study. South Med J. 
2011;104(12):803-808. 
267. van den Bouwhuijsen QJ, Vernooij MW, Hofman A, Krestin GP, van der Lugt A, 
Witteman JC. Determinants of magnetic resonance imaging detected carotid plaque 
components: the Rotterdam Study. European Heart Journal. 2012;33(2):221-229. 
268. Ijas P, Saksi J, Soinne L, et al. Haptoglobin 2 allele associates with unstable carotid plaque 
and major cardiovascular events. Atherosclerosis. 2013;230(2):228-234. 
269. Khalil A, Huffman MD, Prabhakaran D, et al. Predictors of carotid intima-media thickness 
and carotid plaque in young Indian adults: the New Delhi birth cohort. International 
Journal of Cardiology. 2013;167(4):1322-1328. 
270. Sala-Vila A, Romero-Mamani ES, Gilabert R, et al. Changes in ultrasound-assessed carotid 
intima-media thickness and plaque with a Mediterranean diet: a substudy of the 
PREDIMED trial. Arteriosclerosis, Thrombosis & Vascular Biology. 2014;34(2):439-445. 
271. Sinning C, Kieback A, Wild PS, et al. Association of multiple biomarkers and classical risk 
factors with early carotid atherosclerosis: results from the Gutenberg Health Study. Clin 
Res Cardiol. 2014;103(6):477-485. 
272. Oei HH, Vliegenthart R, Hak AE, et al. The association between coronary calcification 
assessed by electron beam computed tomography and measures of extracoronary 
atherosclerosis: the Rotterdam Coronary Calcification Study. J Am Coll Cardiol. 
2002;39(11):1745-1751. 
273. Polak JF, Tracy R, Harrington A, Zavodni AE, O'Leary DH. Carotid artery plaque and 
progression of coronary artery calcium: the multi-ethnic study of atherosclerosis. Journal 
of the American Society of Echocardiography. 2013;26(5):548-555. 
274. Lee KB, Budoff MJ, Zavodni A, et al. Coronary artery calcium is associated with degree 
of stenosis and surface irregularity of carotid artery. Atherosclerosis. 2012;223(1):160-165. 
275. Schroeder B, Francis G, Leipsic J, Heilbron B, John Mancini GB, Taylor CM. Early 
atherosclerosis detection in asymptomatic patients: a comparison of carotid ultrasound, 
coronary artery calcium score, and coronary computed tomography angiography. Can J 
Cardiol. 2013;29(12):1687-1694. 
276. Morito N, Inoue Y, Urata M, et al. Increased carotid artery plaque score is an independent 
predictor of the presence and severity of coronary artery disease. J Cardiol. 2008;51(1):25-
32. 
277. Chang CC, Chang ML, Huang CH, Chou PC, Ong ET, Chin CH. Carotid intima-media 
thickness and plaque occurrence in predicting stable angiographic coronary artery disease. 
Clinical Interventions in Aging. 2013;8:1283-1288. 
278. von Sarnowski B, Ludemann J, Volzke H, Dorr M, Kessler C, Schminke U. Common 
carotid intima-media thickness and framingham risk score predict incident carotid 
atherosclerotic plaque formation: longitudinal results from the study of health in 
Pomerania. Stroke. 2010;41(10):2375-2377. 
279. Selwaness M, van den Bouwhuijsen Q, Mattace-Raso FU, et al. Arterial stiffness is 
associated with carotid intraplaque hemorrhage in the general population: the Rotterdam 
study. Arteriosclerosis, Thrombosis & Vascular Biology. 2014;34(4):927-932. 
280. Polak JF, O'Leary DH, Kronmal RA, et al. Sonographic evaluation of carotid artery 
atherosclerosis in the elderly: relationship of disease severity to stroke and transient 
ischemic attack. Radiology. 1993;188(2):363-370. 
158 
281. Hollander M, Bots ML, Del Sol AI, et al. Carotid plaques increase the risk of stroke and 
subtypes of cerebral infarction in asymptomatic elderly: the Rotterdam study. Circulation. 
2002;105(24):2872-2877. 
282. Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid plaque 
area: a tool for targeting and evaluating vascular preventive therapy. Stroke. 
2002;33(12):2916-2922. 
283. Touboul PJ, Labreuche J, Vicaut E, Amarenco P, Investigators G. Carotid intima-media 
thickness, plaques, and Framingham risk score as independent determinants of stroke risk. 
Stroke. 2005;36(8):1741-1745. 
284. Roman MJ, Kizer JR, Best LG, et al. Vascular biomarkers in the prediction of clinical 
cardiovascular disease: the Strong Heart Study. Hypertension. 2012;59(1):29-35. 
285. Ziegelbauer K, Schaefer C, Steinmetz H, Sitzer M, Lorenz MW. Clinical usefulness of 
carotid ultrasound to improve stroke risk assessment: ten-year results from the Carotid 
Atherosclerosis Progression Study (CAPS). Eur J Prev Cardiol. 2013;20(5):837-843. 
286. Wannarong T, Parraga G, Buchanan D, et al. Progression of carotid plaque volume predicts 
cardiovascular events. Stroke. 2013;44(7):1859-1865. 
287. Park HW, Kim WH, Kim KH, et al. Carotid plaque is associated with increased cardiac 
mortality in patients with coronary artery disease. International Journal of Cardiology. 
2013;166(3):658-663. 
288. Hald EM, Lijfering WM, Mathiesen EB, et al. Carotid atherosclerosis predicts future 
myocardial infarction but not venous thromboembolism: the Tromso study. 
Arteriosclerosis, Thrombosis & Vascular Biology. 2014;34(1):226-230. 
289. Lemos MM, Jancikic AD, Sanches FM, et al. Pulse wave velocity--a useful tool for 
cardiovascular surveillance in pre-dialysis patients. Nephrol Dial Transplant. 
2007;22(12):3527-3532. 
290. Sung KC, Lim YH, Park S, et al. Arterial stiffness, fatty liver and the presence of coronary 
artery calcium in a large population cohort. Cardiovasc Diabetol. 2013;12(1):162. 
291. Sakuragi S, Iwasaki J, Tokunaga N, Hiramatsu S, Ohe T. Aortic stiffness is an independent 
predictor of left ventricular function in patients with coronary heart disease. Cardiology. 
2005;103(2):107-112. 
292. Koji Y, Tomiyama H, Yamada J, et al. Relationship between arterial stiffness and the risk 
of coronary artery disease in subjects with and without metabolic syndrome. Hypertens 
Res. 2007;30(3):243-247. 
293. Chae MJ, Jung IH, Jang DH, et al. The Brachial Ankle Pulse Wave Velocity is Associated 
with the Presence of Significant Coronary Artery Disease but Not the Extent. Korean Circ 
J. 2013;43(4):239-245. 
294. Munakata M, Sakuraba J, Tayama J, et al. Higher brachial-ankle pulse wave velocity is 
associated with more advanced carotid atherosclerosis in end-stage renal disease. 
Hypertens Res. 2005;28(1):9-14. 
295. Takaki A, Ogawa H, Wakeyama T, et al. Cardio-ankle vascular index is superior to 
brachial-ankle pulse wave velocity as an index of arterial stiffness. Hypertens Res. 
2008;31(7):1347-1355. 
296. Otsuka T, Munakata R, Kato K, et al. Oscillometric measurement of brachial artery cross-
sectional area and its relationship with cardiovascular risk factors and arterial stiffness in a 
middle-aged male population. Hypertens Res. 2013;36(10):910-915. 
159 
297. Nakamura U, Iwase M, Nohara S, Kanal H, Ichikawa K, Iida M. Usefulness of branchial-
ankle pulse wave velocity measurement: Correlation with abdominal aortic calcification. 
Hypertension Research. 2003;26(2):163-167. 
298. Kawai T, Ohishi M, Onishi M, et al. Cut-off value of brachial-ankle pulse wave velocity 
to predict cardiovascular disease in hypertensive patients: a cohort study. J Atheroscler 
Thromb. 2013;20(4):391-400. 
299. Huang JC, Chen SC, Su HM, Chang JM, Hwang SJ, Chen HC. Performance of the 
Framingham Risk Score in patients receiving hemodialysis. Nephrology. 2013;18(7):510-
515. 
300. Ishisone T, Koeda Y, Tanaka F, Sato K, Nagano M, Nakamura M. Comparison of utility 
of arterial stiffness parameters for predicting cardiovascular events in the general 
population. Int Heart J. 2013;54(3):160-165. 
301. Ninomiya T, Kojima I, Doi Y, et al. Brachial-ankle pulse wave velocity predicts the 
development of cardiovascular disease in a general Japanese population: The Hisayama 
study. Journal of Hypertension. 2013;31(3):477-483. 
302. Nagai K, Shibata S, Akishita M, et al. Efficacy of combined use of three non-invasive 
atherosclerosis tests to predict vascular events in the elderly; carotid intima-media 
thickness, flow-mediated dilation of brachial artery and pulse wave velocity. 
Atherosclerosis. 2013;231(2):365-370. 
303. Han JY, Choi DH, Choi SW, et al. Predictive value of brachial-ankle pulse wave velocity 
for cardiovascular events. Am J Med Sci. 2013;346(2):92-97. 
304. Kuwahara M, Hasumi S, Mandai S, et al. Rate of ankle-brachial index decline predicts 
cardiovascular mortality in hemodialysis patients. Therapeutic Apheresis and Dialysis. 
2014;18(1):9-18. 
305. Takashima N, Turin TC, Matsui K, et al. The relationship of brachial-ankle pulse wave 
velocity to future cardiovascular disease events in the general Japanese population: the 
Takashima Study. J Hum Hypertens. 2014;28(5):323-327. 
306. Sugamata W, Nakamura T, Uematsu M, et al. The combined assessment of flow-mediated 
dilation of the brachial artery and brachial-ankle pulse wave velocity improves the 
prediction of future coronary events in patients with chronic coronary artery disease. 
Journal of Cardiology. 2014. 
 
160 
